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ZUSAMMENFASSUNG 
 
Die Tyrosinphosphorylierung ist ein wichtiger Signalmechanismus in eukaryotischen 
Zellen. Sie wird durch die gegensätzliche Aktivität von Protein-Tyrosinkinasen (PTK) 
und Protein-Tyrosinphosphatasen (PTP) gesteuert. Im Rahmen dieser Arbeit wurde die 
funktionelle Rolle der PTP mit dem Namen „density-enhanced phosphatase-1“ (DEP-1) 
in Kolonepithelzellen untersucht. DEP-1 (auch als PTPRJ, PTPη, oder CD 148 
bezeichnet) ist eine ubiquitär exprimierte Transmembran-PTP. Sie zeichnet sich 
strukturell durch 8 Fibronektin-ähnliche Repeats in der extrazellulären Domäne und eine 
einzelne katalytische Domäne auf der zytoplasmatischen Seite der Membran aus. DEP-1 
wurde als Tumorsuppressor für verschiedene epitheliale Tumoren vorgeschlagen, 
darunter Mammakarzinom, Schilddrüsen-Karzinom, Gliom und Pankreas-Karzinom. Der 
in Mäusen identifizierte „colon cancer susceptibility locus- 1“ (Scc 1) enthält das DEP-1-
kodierende Gen Ptprj. Die physiologische Rolle von DEP-1 in Kolonepithelzellen ist 
jedoch bisher unbekannt. 
 
Die Analyse der endogenen Expression des DEP-1 Proteins in einer Serie von 
Kolonepithel-Zelllinien zeigte, dass die Expressionsspiegel sehr unterschiedlich waren. 
Hohe Spiegel wurden in der Adenom-Zelllinie LT97 und der Karzinom-Zelllinien HT29 
gefunden, während die Karzinom-Zelllinie SW480 keine endogene Proteinexpression 
aufwies. SW480 Zellen wurde deshalb ausgewählt, um humane aktive DEP-1 (Wildtyp, 
WT) und die katalytisch inaktive Version mit der Mutation C1239S konditionell zu re-
exprimieren. Die Expression von DEP-1 WT hemmte die Proliferation der Zellen, 
wohingegen die katalytisch inaktive Mutante keinen Einfluss darauf hatte. Die 
Unterdrückung der Expression von DEP-1 in HT29 Zellen förderte die Proliferation 
dieser Zellen, was die anti-proliferative Aktivität von DEP-1 bestätigte. Wenn SW480 
Zellen mit Hepatozyten-Wachstumsfaktor (HGF) stimuliert wurden, führte die Re-
Expression von DEP-1 WT zu einer starken Reduktion der Phosphorylierung des HGF-
Rezeptors und der durch HGF aktivierten Kinase Erk. Wie bei den genannten 
Proliferations-Assays, hängt dieser Effekt von der Phosphatase-Aktivität von DEP-1 ab 
und wurde in Zellen, welche die katalytisch inaktive DEP-1 C1239S Variante 
exprimierten nicht beaobachtet. Die negative Regulation dieses Signalweges könnte 
teilweise an der anti-proliferativen Aktivität von DEP-1 beteiligt sein. 
 
Re-Expression von DEP-1 hemmte auch die Zellmigration und induzierte starke 
Änderungen des Zytoskeletts. DEP-1 WT exprimierende Zellen waren abgeflacht und 
zeigten eine andere Verteilung des filamentösen Aktins, typischerweise charakterisiert 
durch kortikale Aktinbündel unterhalb der Zellperipherie. Die Zytoskelett-Veränderungen 
kamen auch in einer veränderten Verteilung von Paxillin, Phospho-Paxillin und Vinculin 
in der Zellperipherie zum Ausdruck. Die DEP-1 Expression induzierte eine erhöhte 
Phosphorylierung von Paxillin und der Fokalen Adhäsions-Kinase (FAK).  
 
Die Re-Expression von DEP-1 machte die Zellen sensitiver gegen die Induktion von 
Apoptose, was sich auch in verringerten Spiegeln der phosphorylierten Akt-Kinase 
ausdrückte. Ein komplementierender Befund war die erhöhte Phosphorylierung von Akt 
in Zellen mit unterdrückter DEP-1 Expression. Diese Daten legen nahe, dass die 
Regulation der Phosphorylierung von Akt eine der physiologischen Funktionen von DEP-
1 darstellt. Die relevanten Targets von DEP-1 „stromaufwärts“ von Akt sind noch nicht 
bekannt. Die Analyse der Effekte der DEP-1 Expression auf 42 verschiedene 
Rezeptortyrosinkinasen (RTK) in einem Antikörper-Array ergab keine wesentlichen 
Unterschiede in der Phosphorylierung dieser Kinasen. Dieser Befund legt nahe, dass die 
relevanten Targets von DEP-1 in den untersuchten Zellen nicht unter diesen Kinasen zu 
finden sind.   
 
Eine Anzahl von Nahrungsinhaltsstoffen und ihren Metaboliten wirken wahrscheinlich 
protektiv bezüglich der Entwicklung von Kolonkarzinomen. Wenn Kolonepithelzellen 
mit solchen Nahrungskomponenten (Apfel-Polyphenolextrakt, Butyrat, Extrakt aus 
Grünem Tee) behandelt wurden, erhöhte sich die Expression des DEP-1 Proteins. Damit 
wurde erstmals die Induktion eines Tumorsuppressors durch protektive 
Nahrungsbestandteile nachgewiesen. Die Daten legen nahe, dass die Induktion von DEP-
1 einen bisher unerkannten Mechanismus der Chemoprävention durch 
Nahrungsinhaltsstoffe darstellen könnte. 
Functional Analysis of DEP-1 Protein Tyrosine Phosphatase  
in Colon Epithelial Cells 
 
 
 
Thesis 
 
 
For acquiring the academic degree 
Doctor rerum naturalium 
 
 
 
Presented to the Faculty of Biology and Pharmacy 
Friedrich Schiller University, Jena 
 
 
 
 
By Kamal Kumar Balavenkatraman, M.Sc., 
from Musiri / India 
SUMMARY 
 
Tyrosine phosphorylation is an important signaling mechanism in eukaryotic cells. It is 
governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs). Here we have analysed the functional role of a protein tyrosine 
phosphatase called Density Enhanced Phosphatase-1 (DEP-1) in colon epithelial cells. 
DEP-1 (also referred to as PTPRJ, Ptpη or CD 148) is a ubiquitously expressed 
transmembrane protein-tyrosine phosphatase. It has eight fibronectin repeats on the 
extracellular side and a single catalytical domain on the cytoplasmic side. Its expression 
is increased upon high cell density in a number of cell lines. It has been proposed as a 
tumor suppressor in several epithelial cancers such as mammary carcinoma, thyroid 
carcinoma, glioma and pancreatic carcinomas. Furthermore, the colon cancer 
susceptibility locus (Scc 1) in mice harbors the Ptprj gene but its physiological role in 
colon cells is not known. 
 
Analysis of the endogenous level of DEP-1 expression in a set of colon epithelial cell 
lines revealed its expression to be quite heterogeneous; higher levels were found in the 
adenoma cell line LT 97 and the carcinoma cell line HT 29 whereas there was no 
detectable expression in the cell line SW 480. We conditionally re-expressed either the 
wild type human DEP-1 or the catalytically inactive C1239S mutant into the DEP-1-
negative cell line SW 480. The re-expression of DEP-1 WT impaired proliferation, 
whereas the catalytically inactive mutant had no effect on it. Moreover, suppression of 
DEP-1 in the HT 29 cell line, using shRNA (short hairpin RNA), enhanced the 
proliferation of these cells, confirming the anti-proliferative effect of DEP-1. When 
stimulated with hepatocyte growth factor (HGF), re-expression of DEP-1 leads to hypo-
phosphorylation of HGFR and Erk. Similar to the proliferation assays mentioned above 
these effects depend on the PTP activity of DEP-1 as they were not observed with cells 
expressing the catalytically inactive DEP-1 C1239S variant. Negative regulation of this 
pathway may partially be responsible for the anti-proliferative activity of DEP-1. 
 
Re-expression of DEP-1 also inhibited cell migration and induced severe cytoskeletal 
changes. DEP-1 WT expressing cells were flattened and exhibited a different distribution 
of filamentous actin, typically characterized by cortical actin bundles close to the cell 
periphery. These cytoskeletal changes were further emphasized by a differential pattern 
of distribution of paxillin, phospho-paxillin and vinculin in the cell periphery. DEP-1 
expression induces hyper-phosphorylation of paxillin and Focal Adhesion Kinase (FAK). 
 
The re-expression of DEP-1 sensitized the cells towards apoptosis which is also mirrored 
by the reduction of phospho-Akt levels. Complementing this finding, DEP-1 suppressed 
cell lines showed enhanced Akt phosphorylation. This emphasizes that the physiological 
regulation of Akt phosphorylation depends on DEP-1 expression. The relevant targets of 
DEP-1 “upstream” of Akt were yet unknown. Analysis of the effects of DEP-1 
expression on 42 different receptor tyrosine kinases (RTKs) did not reveal any significant 
differences on their phosphorylation status. This suggests that these RTKs may not be the 
prime targets of DEP-1 in the cell lines investigated. 
 
A number of food ingredients and their metabolites were proposed to be protective 
against colon cancer development. When colon epithelial cell lines were treated with 
such nutrient components (apple polyphenol extract, butyrate and green tea extract), the 
expression of DEP-1 was found to be upregulated. This is the first report where the 
effects of protective nutrients are attributed to the upregulation of a tumor suppressor. 
These data suggest that an upregulation of DEP-1 as a previously unrecognized aspect of 
chemoprevention by dietary compounds. 
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1. Introduction 
1.1. Cell Signaling 
Cell signaling is a part of complex system of communication that governs basic cellular 
activities and coordinates cell’s actions. A cell’s ability to respond to its various 
extracellular stimuli results in a complex and highly organized series of intracellular 
events. In general, cellular signaling is initiated with the binding of the extracellular 
stimuli (growth factors, cytokines, hormones, neuro-transmitters etc.) to their cognate 
receptors. These receptors then amplify and transmit the signals intracellularly (usually 
involving protein phosphorylation) culminating with changes in the gene expression, 
thereby altering the biological properties of the cells such as proliferation, migration and 
differentiation. (Tischer and Bastiens 2003) 
1.2. Protein Tyrosine Kinases 
Protein kinases are important regulators of intracellular signal-transduction pathways 
mediating development and multicellular communication in metazoans (Blume-Jensen 
and Hunter 2001). The human genome has been found to contain 518 putative protein 
kinase genes. 478 of them fall under eukarytotic protein kinases (ePK) whereas 40 belong 
to atypical protein kinases (aPK) because they lack sequence similarity to the ePK 
domain. The kinase genome can also be classified into nine broad groups, 134 families 
and 201 sub-families including 106 pseudogenes (Manning, Whyte et al. 2002). 
 
Phosphorylation of proteins on tyrosine residues acts as a reversible and specific 
switching mechanism which is controlled through the coordinated actions of protein 
tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). There are 90 known 
protein tyrosine kinase genes (PTKs) in the human genome of which 58 encode for 
receptor protein tyrosine kinases (RTKs) that span the cell membrane (distributed into 20 
subfamilies) and 32 encode for cytoplasmic, non-receptor PTKs (Blume-Jensen and 
Hunter 2001). RTKs are activated by an intermolecular mechanism whereas the 
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cytoplasmic tyrosine kinases are activated by both intra- and intermolecular mechanisms. 
(Weiss and Schlessinger 1998). RTKs are composed of an extracellular ligand binding 
domain which is usually glycosylated, a single transmembrane domain which spans the 
membrane and an intracellular kinase domain that contains key phospho-tyrosine 
residues. Ligand binding induces dimerization of these receptors resulting in 
autophosphorylation of their cytoplasmic domains (Heldin 1995). This activates the 
kinase, creating docking sites for other proteins which will then transmit the signals to the 
interior of the cell, usually the nucleus. Some of the important RTK family members 
which are extensively studied and have also been implicated in disease and cancer are 
Epidermal Growth Factor Receptor (EGFR), Hepatocyte Growth Factor Receptor 
(HGFR), Insulin Receptor (IR), and Platelet Derived Growth Factor Receptor (PDGFR). 
Among the cytoplasmic PTKs Src, Abl, Focal Adhesion Kinase (FAK) and Janus Kinase 
(JAK) were extensively studied. Fig. 1.1a and Fig. 1.1b refer to the broad classification of 
RTKs and cytoplasmic PTKs, respectively. 
 
 
Fig. 1.1a The prototypic receptor for each family is indicated above the receptor, and the 
known members are listed below. The symbols alpha and beta denote distinct RTK 
subunits. RTK members in bold and italic type are implicated in human malignancies. An 
asterisk indicates that the member is devoid of intrinsic kinase activity [taken from 
(Blume-Jensen and Hunter 2001)]. 
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Fig. 1.1b The family members are indicated to the right and the family name to the left of 
each PTK. The PTK members in bold and italic type are implicated in human 
malignancies [taken from (Blume-Jensen and Hunter 2001)]. 
1.3. Serine / Threonine Phosphatases 
Ser/Thr phosphatases represent a diverse family and are expressed in many cell types and 
different cellular compartments. They are regulated by several mechanisms and can be 
broadly classified into “PPP” and “PPM” families defined by amino acid sequence and 3-
dimensional structure. The PPP family members are composed of catalytic and regulatory 
subunits, with each subunit being expressed in several isoforms by distinct 
genes/alternative splicing. On the contrary the PPM family members exist as a monomer 
devoid of regulatory subunits. The regulatory subunits of PPP family members have 
multiple functions including the control of catalytic activity, subcellular localization and 
substrate specificity of the phosphatase. Some of the members depend on specific 
bivalent cations for their activity. For instance, PP2B requires Ca2+ and calmodulin for 
full activity whereas PP2C needs either Mg2+ or Mn2+ (Gee and Mansuy 2005). The 
following table (Table 1.1) gives an overview of different Ser/Thr phosphatases. 
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Table 1.1: Classification of Ser/Thr phosphatases [adapted from (Gallego and Virshup 
2005)]. 
1.4. Protein Tyrosine Phosphatases 
Protein tyrosine phosphatases (PTPs) act by dephosphorylating tyrosine residues and 
hence antagonizing the actions of tyrosine kinases. They can antagonize both ligand-
independent and ligand-activated RTK signaling (Ostman and Bohmer 2001). The first 
PTP to be purified was PTP 1B from human placenta in 1988 (Tonks, Diltz et al. 1988). 
Till date, 107 PTPs were found to be encoded by the human genome, and they fall into 
four major classes (Alonso, Sasin et al. 2004). 
1.4.1. Classification of Protein Tyrosine Phosphatases 
Based on the amino acid sequences of their catalytic domains, the PTPs can be grouped 
into four separate families (Fig. 1.2). Class I cysteine based PTPs constitute the largest 
family comprising 38 classical PTPs which are strictly tyrosine specific whereas the 61 
dual specific phosphatases can dephosphorylate both phospho Ser/Thr and phospho Tyr 
Family Subfamily Genes Catalytic subunits 
Regulatory 
subunits 
Subunit 
composition Selected inhibitors 
PPP PP1 (PPP1) 3 α, β, γ1, γ2 >50 
Heterodimer 
and higher 
order 
Inhibitor-1, inhibitor-
2, microcystin (MC), 
okadaic acid, 
calyculin A (Cal A) 
 PP2A (PPP2) 2 α, β 
PPP2R1–3 
PPP2R5 
Heterodimer 
and higher 
order 
Fostriecin, okadaic 
acid, MC, Cal A, 
nodularin 
 PP4 (PPP4) (PP2A-like) 1 1 
IGBP1, 
PR4R1, 
PPP4R2, c-Re1
Monomer and 
higher order 
Fostriecin, okadaic 
acid, MC, Cal A, 
nodularin 
 PP6 (PPP6) (PP2A-like) 1 1 IGBP1 
Monomer and 
higher order not known 
 PP2B (PPP3) 3 3 
Calcineurin B, 
AKAPs, 
calmodulin 
Heterodimer 
and higher 
order 
not known 
 PP5 (PPP5) 1 1 PP2A, A and B subunits 
Monomer and 
higher order 
Okadaic acid, MC, 
Cal A, nodularin 
 PP7 (PPP7) 2 2 not known Monomer not known 
PPM PP2C 6 10 not known Monomer not known 
FCP FCP1 1 4 not known Monomer not known 
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residues. Some members of this sub-family are also lipid phosphatases such as PTEN 
which can dephosphorylate both lipids as well as proteins. 
 
 
Fig. 1.2 Classification and substrate specificities of PTPs [taken from (Alonso, Sasin et 
al. 2004)]. 
 
The PTPs are characterized by the presence of conserved stretches of 240-250 amino 
acids (PTP domains) including the signature motif (VHCSXGXGR[T/S]G) which is 
essential for their action (Andersen, Mortensen et al. 2001). During PTP catalysis, the 
cysteinyl residue executes a nucleophilic attack (enhanced by the arginine residue in the 
signature motif) upon the oncoming phosphate moiety of the substrate, leading to 
formation of a thiophosphate intermediate. The depth of the cleft is set by an invariant 
tyrosyl residue thus allowing entry of only the longer phospho-tyrosine and not the 
shorter phospho-serine or phospho-threonine moieties. For efficient thiophosphate 
intermediate formation, the phenolic oxygen of the tyrosyl leaving group must be 
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protonated and a conserved aspartate residue (Asp 181 in PTP 1B) donates this proton 
thus serving as a general acid. Mutation of either the catalytic cysteine residue (into 
serine) or of the conserved aspartate residue (into alanine) completely abolishes the 
activity of the PTPs but still retains their ability to bind to substrates. Such PTP mutants 
are therefore helpful in identifying substrates by the so called  “trapping” approach (Neel 
and Tonks 1997; Tonks and Neel 2001). 
 
 
 Fig. 1.3 Schematic representation of PTP family members [taken from (Andersen, 
Mortensen et al. 2001)]. 
 
These 38 “classical PTPs” are further divided into transmembrane, receptor like PTPs 
(RPTPs) and the intracellular, non-receptor PTPs (NRPTPs). RPTPs can be further 
subdivided into five types (Type I – V) based upon common features in their extracellular 
domains. Most RPTPs contain two PTP domains and usually the membrane proximal 
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(amino-terminal) of these two domains (D1) has significant enzymatic activity. The distal 
one (D2) has less if any activity and may aid in protein-protein interactions or in 
regulating the activity of D1. Intracellular non-transmembrane PTPs (NRPTPs) possess a 
single catalytic domain with flanking regions. They often contain protein-protein 
interaction domains that direct the enzyme towards specific intracellular locations or 
towards substrates (Li and Dixon 2000). 
 
VH1-like DSPs are classified into MAP Kinase Phosphatases (MKPs) which are 
characterized by the presence of dual phospho-threonine and phospho-tyrosine 
specificity. The second group called “Atypical DSPs” are much smaller enzymes and 
have functions unrelated to MAP kinases. One outstanding example is PIR (DUSP11) 
which can dephosphorylate mRNA. The third group, “slingshots” is involved in the 
dephosphorylation and inactivation of Cyclin Dependent Kinases (Cdks). The last two 
subgroups, PTENs and myotubularins dephosphorylate phosphatidyl inositol 
phospholipids (Alonso, Sasin et al. 2004). 
 
The class II PTP family is represented by a single gene in the human genome ACP1 
which codes for 18 kDa Low Molecular phosphatase (LMPTP). However, related class II 
enzymes are widely present in prokaryotes. Class III PTPs comprise three cell cycle 
regulators, Cdc25A, Cdc25B, and Cdc25C which dephosphorylate Cdks at their 
inhibitory dually phosphorylated Thr-Tyr motifs, thereby activating them and driving the 
cells through cell cycle. Class IV Asp-based PTPs are represented by four “eyes absent” 
(Eya) genes. These PTPs are unique as they do not use catalytic cysteine as a nucleophile 
but an aspartic acid, in a metal dependent fashion. Eya PTPs are transcription factors and 
have phosphatase activity against both tyrosine and serine residues (Rayapureddi, 
Kattamuri et al. 2003). The members of the PTP family with their diverse structure are 
involved in the regulation of different processes ranging from development, axonal 
guidance, cell cycle, growth factor signaling, hematopoiesis, as well as liver and pituitary 
development (Van Vactor, O'Reilly et al. 1998). However due to constraint of space, 
emphasis will be laid here only on the functions of classical PTPs. 
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1.4.2. Regulation of PTP Activity 
The activity of PTPs can be regulated by several mechanisms – autoinhibiton, ligand 
binding, phosphorylation, oxidation and dimerization. 
1.4.2.1. Ligand binding 
The extracellular domains of RPTPs suggest that they may participate in ligand mediated 
interactions. Homophilic interactions for some RPTPs (PTPμ, PTPκ) have also been 
reported (Brady-Kalnay, Flint et al. 1993; Sap, Jiang et al. 1994). The surface protein 
contactin has been shown to interact with PTPα and PTPβ/ζ (Peles, Nativ et al. 1995) and 
the extracellular matrix proteins tenascin and laminin-nidogen complex binds to PTPβ/ζ 
and LAR respectively (O'Grady, Thai et al. 1998). There are two reports showing 
modulation of PTP activity due to ligand binding. Inactivation of PTPβ/ζ by pleiotrophin 
and activation of DEP-1 by an unknown component of matrigel have been reported 
(Meng, Rodriguez-Pena et al. 2000; Sorby, Sandstrom et al. 2001). 
1.4.2.2. Phosphorylation 
Tyrosine phosphorylation of PTPs has been described for SHP1, SHP2, PTP1B, LM-PTP 
among others (Chiarugi, Taddei et al. 2005). SHP2 contains two C-terminal tyrosine 
residues (Tyr542, Tyr580). An in vitro study in which these phospho-tyrosines were 
replaced by non-hydrolysable analogs showed that phosphorylation at each of these 
position stimulates catalysis by three folds and even the double phosphorylation 
increased the activity to nine folds (Lu, Shen et al. 2003). SHP2 has also been shown to 
undergo tyrosyl phosphorylation following growth factor stimulation (Araki, Nawa et al. 
2003). In the case of PTP 1B, the role of tyrosyl phosphorylation is controversial. Some 
studies showed an increase in the phosphatase activity following tyrosyl phosphorylation, 
(Dadke, Kusari et al. 2001) whereas a mouse model showed an opposing effect (Tao, 
Malbon et al. 2001). Phosphorylation of Tyr131 in LM-PTP by Src kinase has also been 
reported to increase its enzymatic activity (Chiarugi, Taddei et al. 2005). 
1.4.2.3. Oxidation 
Reactive Oxygen Species (ROS) are mainly produced by mitochondria and NADPH 
oxidases under different circumstances including as a consequence of various growth 
factor stimulation (Chiarugi and Cirri 2003). The cysteine residue in the signature motif 
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of the phosphatase displays an unusually low pKα which makes it susceptible to 
oxidation. Oxidation of this active site cysteine is coupled to its inactivation due to the 
formation of sulphenic acid (-SOH) derivative. This can be further oxidized to sulphinic 
acid (-SO2H) and sulphonic acid (-SO3H) forms which are usually irreversible (Tonks 
2005). Structural analysis of PTP 1B revealed that the generation of sulphenic acid (-
SOH) is followed by the formation of a cyclic sulphenylamide intermediate (a 5-atom 
ring structure in which a covalent bond is formed between the sulfur atom of the cysteine 
and the main chain nitrogen of the adjacent serine residue). This sulphenyl amide 
intermediate can be easily reduced by some cellular reducing agents such as GSH 
regenerating the active enzyme. Thus a transient inhibition of PTPs through the reversible 
oxidation of their catalytic cysteine can enhance the outcome of the signal (usually by 
hyper-phosphorylation of the RTK) (Salmeen, Andersen et al. 2003). Such a reversible 
oxidation mechanism has been demonstrated for PTP 1B during EGF and insulin 
signaling and for LM-PTP and SHP2 during PDGF signaling (Meng, Fukada et al. 2002; 
Meng, Buckley et al. 2004). Reversible oxidation has also been shown for DSPs such as 
Cdc25 and PTEN. In these cases, upon oxidation, the active site cysteine forms a 
disulfide bond with another vicinal cysteine leading to its inhibition (Lee, Yang et al. 
2002). 
1.4.2.4. Dimerization 
Dimerization induced inactivation of PTPs has been shown for CD 45 and PTPα. The 
inhibitory dimerization involved D1-D1 interactions at least in the case of PTPα (Jiang, 
den Hertog et al. 1999). However crystal studies on CD 45 implicated that in this PTP 
D1-D1 interactions are not possible due to the spatial arrangement of D1 and D2 
domains. Moreover structural analysis of transmembrane phosphatases of the LAR 
family has also emphasized that dimerizations induced inactivation is not an universal 
mechanism for the regulation of transmembrane phosphatases (Jiang, den Hertog et al. 
1999; Nam, Poy et al. 1999). 
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1.4.3. Protein Tyrosine Phosphatases in Disease and Cancer 
Studies using transgenic and knock out mice have revealed the involvement of PTPs in 
various kinds of physiological regulation and diseases. A few of them are discussed here. 
1.4.3.1. PTPs in metabolism, development and immune system 
PTP1B: PTP1B-/- mice showed reduced plasma glucose and insulin levels, obesity 
resistance and hyperphosphorylation of the insulin receptor. PTP 1B is therefore widely 
recognized as a candidate drug target. Metabolic regulation by PTP 1B does not only 
occur by its action on the insulin receptor (direct dephosphorylation). It also inhibits 
LeptinR signaling (Jak-2 dephosphorylation) thereby regulating lipid metabolism and 
energy expenditure (Elchebly, Payette et al. 1999; Cook and Unger 2002). 
 
CD 45: Knock out mice show a variety of lymphocyte abnormalities including block in 
maturation of thymocytes and poor proliferative responses of peripheral T cells to TCR 
cross-linking. CD 45 is also necessary for normal antigen receptor signaling in both B 
and T cells and is potentially a good target for immunosuppressors (Byth, Conroy et al. 
1996; Li and Dixon 2000; Hooft van Huijsduijnen, Walchli et al. 2002). 
 
VE-PTP (Vascular-Endothelial PTP): VE-PTP is also referred to as PTPβ (see Fig. 1.3). 
It can dephosphorylate Tie-2 RTK, which responds to its ligand angiopoietin-1 
(Fachinger, Deutsch et al. 1999). Signaling through this receptor antagonizes blood vessel 
leakage (anti-inflammatory). Hence VE-PTP could be exploited as a target in 
inflammation since its inhibition should block neutrophil and macrophage extravasations 
(van Huijsduijnen, Bombrun et al. 2002). 
 
LAR: LAR-/- females are incapable of delivering milk and have significantly lower 
plasma levels of insulin and glucose, suggesting elevated insulin sensitivity (Schaapveld, 
Schepens et al. 1997; Ren, Li et al. 1998). Another LAR family member is PTPσ (see 
Fig. 1.3). Targeted deletion of PTPσ causes stunted growth, developmental delays and 
severe neurological disorders (Elchebly, Wagner et al. 1999). The third member of the 
LAR family is PTPδ (see Fig. 1.3). Deletion of PTPδ causes growth retardation, 
abnormal positioning of hind limbs and abnormal limb flexing (Uetani, Kato et al. 2000). 
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1.4.3.2. PTPs in cancer 
Oncogenic signaling due to hyperactivation of tyrosine kinases is already well 
established. PTPs functions both as positive and negative mediators of signaling triggered 
by RTKs, integrins and cell-adhesion molecules indicating that they may either act as 
tumor suppressors or as oncoproteins. Some examples of tumor suppressive PTPs are 
DEP-1, SHP1 and GLEPP1 whereas oncogenic activity has been characterized for the 
mutational activation of SHP2. 
PTPs as tumor suppressors 
SHP1 (SH2 domain PTP): SHP1 is an antagonist of growth-factor signaling in epithelial 
and haemotopoietic cells. Motheaten (me/me) and motheaten viable (mev/mev) mice 
which either have no SHP1 protein or SHP1 protein with little catalytic activity exhibit 
hyperproliferation of hematopoietic cell lineages. Inactivation of SHP1 expression by 
promoter hypermethylation has been described in T-cell lymphoma, large cell lymphoma 
as well as in myeloma (Fig. 1.4(c)). SHP1 re-expression causes decreased 
phosphorylation of JAK3 and STAT3 (Chim, Fung et al. 2004; Ostman, Hellberg et al. 
2006). 
 
GLEPP1 (Glomerular Epithelial Protein-1): GLEPP1, encoded by the gene PTPRO, has 
a single intracellular catalytic domain and several extracellular fibronectin type III 
repeats (see Fig. 1.3). PTPRO promoter hypermethylation has been described in about 
50% of human lung cancer and microsatellite-instability-associated colon cancers. Over-
expression of GLEPP1 leads to reduced anchorage independent growth, proliferation and 
resistance to apoptosis (Motiwala, Kutay et al. 2004). Another important tyrosine 
phosphatase, DEP-1, which is structurally similar to GLEPP1 also plays an important role 
as a tumor suppressor and its role will be described in later sections. 
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Fig. 1.4 Mechanisms of inactivation of PTPs with tumor suppressive activity. a) Point 
mutations in the coding region of PTPRT, which encodes the receptor-like PTP PTPρ. 
Several of these mutations have been predicted or shown to affect PTP-mediated cell–cell 
adhesion, or inhibition of cell proliferation. b) Allelic loss, but no point mutations, was 
found for PTPRJ, which encodes the receptor-like PTP DEP-1 in different types of 
carcinoma. c) Promoter silencing of the SHP1-encoding gene, PTPN6, by methylation 
occurs frequently in lymphoma and leukemia. In the figure, the promoter region and 
coding region of genes are indicated in yellow and blue, respectively. mRNA is 
symbolized in pink. At the PTP protein level, active states are in dark green and inactive 
states are in red [taken from (Ostman, Hellberg et al. 2006)]. 
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PTEN (phosphatase and tensin homology deleted on chromosome ten): PTEN, has dual 
specificities as it can dephosphorylate both lipids (3-phosphoinositides) as well as 
proteins. Initially, based on the sequence homology it has been assigned as a protein 
tyrosine phosphatase, but later on it has been found that its primary substrate is a 
phosphorylated lipid – it catalyses the dephosphorylation of phosphatidylinositol-(3,4,5)-
triphosphate (PIP3) to phosphatidylinositol-(4,5)-diphosphate (PIP2). As a 
PIP3-phosphatase, PTEN has emerged as a principal antagonist of PI3K signaling. 
Germline mutations of PTEN lead to Cowden Syndrome which is associated with the 
development of malignant tumors. Somatic mutations of PTEN were also documented in 
a variety of malignant tumors at both advanced and early stages (Sulis and Parsons 2003). 
Moreover Pten+/- mice have also been shown to develop colonic adenomas and lymph 
node hyperplasia at a higher frequency because of haploinsufficiency (Podsypanina, 
Ellenson et al. 1999). Even though its function as a lipid phosphatase is well established, 
there are also reports showing that PTEN can dephosphorylate Focal Adhesion Kinase 
(FAK) and Shc, thereby regulating cellular motility and directionality (Wishart and 
Dixon 2002). 
PTPs as oncoproteins 
SHP2: SHP2 transduces mitogenic and promigratory signals from various types of 
receptors. In the absence of upstream stimulation, SHP2 is in an inactive state by 
interaction of its N-terminal SH2 domain with the catalytic PTP domain. Activation of 
surface receptors and subsequent phosphorylation, creates SHP2 binding sites in RTKs or 
in scaffolding adaptor proteins such as GAB2 (Grb2 associated binder 2) leading to SHP2 
recruitment. Activated SHP2 enhances signaling pathways leading to enhanced Erk1/2, 
Akt or STAT5 activation. It has been shown that SHP2 dephosphorylates a GAB1 YXXP 
motif which is a binding site for Ras-GTPase activating protein (RASGAP) thereby 
preventing its action (Montagner, Yart et al. 2005). It has also been shown to 
dephosphorylate the docking site of Csk in a transmembrane glycoprotein; PAG/Cbp. 
Csk is a negative regulator of Src Family Kinases (SFKs) by phosphorylating them at 
their terminal inhibitory domain. Thus by dephosphorylating PAG, SHP2 displaces Csk, 
allowing an enhanced SFK activation leading to sustained Erk activation (Zhang, Yang et 
al. 2004). 
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SHP2 mutations are found in 50% of Noonan syndromes (dominant, hereditary) and 30% 
of juvenile myelomonocytic leukemia (JMML) as well as in some somatic cases of Acute 
Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) (Tartaglia, 
Mehler et al. 2001). It has also been detected at low frequency in solid tumors such as 
lung, colon carcinoma and melanoma (Bentires-Alj, Paez et al. 2004). These mutants 
possess increased sensitivity for the corresponding ligands of upstream receptors. 
Activation of downstream signaling events occurs by similar mechanisms as that of wild 
type SHP2 but to supraphysiological levels and in a more sustained manner. Altered 
signaling may also be a result of the modified substrate selectivity of SHP2 mutants 
(Keilhack, David et al. 2005). 
 
Cdc25: Cdc25s comprise three PTPs (see Fig. 1.2) that activate cyclin dependent kinases. 
Among these, Cdc25B is over-expressed in approximately 30% of breast cancers and is 
being explored as a drug target (Hooft van Huijsduijnen, Walchli et al. 2002). 
 
Prl-3: Prl-3 is a dual specificity protein tyrosine phosphatase and specifically amplified 
and over expressed only in metastases but not in their originating tumors. Its level is 
significantly lower in normal, and in adenomas or primary cancerous tissue suggesting 
that it is necessary only for the metastasis and could be exploited as a drug target (Saha, 
Bardelli et al. 2001). 
 
Some other PTPs such as PTPα, PTPε can activate Src family kinases (SFKs). Based on 
the data from some mouse models and some over expression studies in certain human 
tumors, they have also been proposed to promote cancers. 
1.5. Cancer 
Cancer arises owing to the accumulation of mutations in critical genes. It is characterized 
by the uncontrolled division of cells that leads to the formation of tumorous tissue. 
Genomic instability is one of the hallmarks of cancer. The mutations that are involved 
can be broadly classified into two major groups - gain of function mutations in 
proto-oncogenes and loss of function mutations in tumor suppressor genes. Progressive 
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mutations lead to the acquisition of several features - uncontrolled proliferation (requires 
exit from senescence or cell cycle arrest), resistance to apoptosis (programmed cell death) 
and also invasion of other tissues. This latter phenomenon is referred to as metastasis and 
involves the migration of tumor cells from their initial site to a distant site where they 
adhere and initiate a new tumor. Hence, several properties of the cell determine the 
cancer phenotype - altered proliferation, apoptosis, migration and adhesion (Hanahan and 
Weinberg 2000). 
1.5.1. Proliferation 
Various mitogenic factors including growth factors and cytokines can stimulate the 
proliferation of cells. Usually proliferation is initiated by the binding of the growth factor 
to its receptor, leading to receptor dimerization, activation and phosphorylation of 
downstream targets. One of the essential signaling pathways is the MAP kinase pathway. 
It comprises RTK signaling to the adaptor protein Growth Factor Receptor Bound 2 
(Grb2), which then signals to Son of Sevenless (SOS). SOS, being a Ras Guanine 
nucleotide Exchange Factor (GEF), activates Ras, which leads to the activation of Raf, 
MEK (MAP/Erk Kinase) and Erk1/2. The latter enters the nucleus activating a set of 
transcription factors triggering proliferation (Hunter 2000). Activating mutations in any 
of the genes in this pathway leading to hyperactivation can cause cancer (Blume-Jensen 
and Hunter 2001). Therefore these genes are referred to as proto-oncogenes. To date, 
several genes in this pathway have been reported to play a role in cancer. 
They can be broadly divided into  
(a) Genes encoding secreted growth factors which act as ligands for RTKs. Examples 
of this class are Platelet Derived Growth Factor-beta (PDGF-B), Fibroblast 
Growth Factor (FGF) and Wingless (wnt-1). 
(b) Mutation or hyperactivation of transmembrane growth factor receptors (RTKs). 
Few examples include Epidermal Growth Factor Receptor (EGFR), Fms like 
tyrosine kinase-3 (Flt-3) and c-Kit. 
(c) Mutation or hyperactivation of cytoplasmic signaling molecules. Typical 
examples are members of the Ras GTPase family, c-Src and B-Raf.  
(d) Hyperactivation by over expression of nuclear proteins such as c-myc and 
members of Signal Transducer and Activators of Transcription (STAT) family. 
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1.5.2. Apoptosis 
It is also referred to as “programmed cell death” and helps to eliminate the unwanted or 
damaged cells in the organism. When a cell is under stress conditions such as starvation, 
UV-irradiation, DNA damaging events, apoptosis can be induced. There are several 
mechanisms of triggering apoptosis. It can be initiated by either ligand mediated (Fas L) 
or ligand independent pathways. In the latter case, mitochondria play a crucial role by 
releasing cytochrome C into cytoplasm. All pathways activate a group of proteases called 
caspases (Reed 1999). Apoptosis also affects the nuclear enzyme poly (ADP-ribose) 
polymerase-1 (PARP-1). Upon induction of apoptosis, the 116 kDa PARP-1 is cleaved 
into an 89 kDa and a 24 kDa fragment and acts as a marker for the detection of apoptosis. 
(Soldani and Scovassi 2002). Many tumor suppressor genes promote apoptosis. Mutation 
or inactivation of these genes makes the cells resistant to apoptosis, thus favoring 
tumorigenesis. 
 
However there are other sets of genes promoting cell survival, important of them is 
Protein Kinase B (PKB) also referred to as Akt. Activation of RTKs by ligands creates 
docking sites for a set of proteins leading to their recruitment. Phosphoinositide-3-kinase 
(PI3K) is one among them and recruited via binding of the SH2 domains of its regulatory 
subunit (p85) resulting in its activation. 3′-phosphoinositides generated by activated PI3K 
mediate the membrane recruitment of PKB/Akt from the cytosol via its PH domains 
changing the kinase from an inactive to an active state. PKB/Akt is then dually 
phosphorylated on Thr308 (by PDK1)and Ser473 (by an unidentified Ser473 kinase) (Brazil 
and Hemmings 2001). Activated PKB/Akt then phosphorylates a set of proteins 
promoting cell survival. PKB/Akt phosphorylates the pro-apoptotic protein BAD as well 
as caspase-9 thereby directly blocking apoptosis. It was also shown to phosphorylate 
I Kappa Kinase  β (IKK β - negative regulator of NFκB), Mdm2 (ubiquitin ligase for the 
tumor suppressor p53), Forkhead family of transcription factors, CREB (cyclic AMP 
response element binding proteins), YAP (Yes associated protein) bringing a change in 
the cell survival (Song, Ouyang et al. 2005). Phosphatases such as PP2A can 
dephosphorylate PKB/Akt and can antagonize its functions. 
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1.5.3. Migration and Adhesion 
Cell migration and adhesion are two tightly coupled processes which are critical for 
normal development, physiology and also cancer progression (particulary metastasis). 
They are in turn regulated by phosphorylation. Two types of adhesion can be 
distinguished: adhesion of cells to the underlying extracellular matrix, and adhesion 
between adjacent cells (Sallee, Wittchen et al. 2006). Adhesion of the cells to the 
underlying matrix is mediated by integrins and is usually initiated by the formation of 
focal complex at the cell periphery. Focal complexes are short lived and turn into focal 
adhesions which can be classified either into “classical” focal adhesions (located at cell 
periphery with high level of phospho-tyrosine proteins) or “fibrillar” focal adhesions 
(located at central positions with little or no phospho-tyrosine) (Zaidel-Bar, Ballestrem et 
al. 2003). Cell-cell junctions are usually classified into tight junctions (zonula occludens), 
adherens junctions (zonula adherens - formed by cadherins, catenins and linked to actin 
cytoskeleton) and desmosomes (macula adherens) (Cavallaro and Christofori 2004). 
 
Cell migration requires a series of repetitive, integrated processes to produce coordinated 
cellular movements. It can be briefed in five steps. The first step is the protrusion of the 
cell. The cell extension can either be a lamellipodium (broad and thin mediated by Rac 
GTPase (Guanosine triphosphatase)) or a filopodium (smaller and finger-like sharp 
protrusions mediated by Cdc 42). The second step is the attachment of these protrusions 
to the extracellular matrix (ECM) by the formation of focal complexes, which turn into 
focal adhesions thus enabling integrins to connect the actin cytoskeleton to the ECM. The 
next event in the migratory process is the cell-body translocation which is brought about 
by actomyosin contraction. The last two phases in cell migration are the release of cell 
contacts at the rear of the cell and recycling of membrane receptors to the front (Larsen, 
Tremblay et al. 2003). Thus migration of cells requires a constant turnover of focal 
adhesions. The molecular events in this process can be briefed as follows (see Fig. 1.5): 
following integrin engagement to the ECM, Focal Adhesion Kinase (FAK) is recruited 
and is activated through autophosphorylation at Tyr397. FAK then phosphorylates the 
adaptor protein paxillin at Tyr118. The PTK Src is also recruited and activated by 
dephosphorylation at Tyr529 (initiated by a PTP such as PTPα or PTP1B) (Freiss and 
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Vignon 2004). Autophosphorylation of Src at Tyr418 activates it and leads to 
phosphorylation of other tyrosine residues in FAK. This results in docking sites for 
proteins like p130cas and Grb2. p130cas activates Rac through the adaptor protein Crk 
and the Rac GEF Dock 180 leading to lamellipodia formation. Grb2 leads to activation of 
Erk and Myosin Light Chain Kinase (MLCK) which is necessary for cell body 
translocation (Webb, Donais et al. 2004; Nishiya, Kiosses et al. 2005). Some PTPs can 
oppose Rac activation (PTP-PEST, PTEN). The formation/turnover of focal adhesions is 
regulated by PP2A, SAP1, PTP-PEST and MLCP which generally act to inhibit 
migration, whereas phosphatases such as PTP1B, SHP2 and PTPφ enhance migration 
(Larsen, Tremblay et al. 2003). 
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Fig. 1.5 FAK-dependent signaling pathways. a) Status of FAK in cells kept in suspension. 
b) Binding of the cell to extracellular matrix proteins (ECM) induces phosphorylation 
and activation of FAK. c-Src is then activated and can bind the phosphorylated Y397 on 
FAK. c) Activated c-Src phosphorylates FAK and increases its catalytic activity. It also 
bridges p130cas and FAK, allowing signaling downstream of the adaptor protein. 
Activated FAK also associates with the paxillin through a LD domain [taken from 
(Angers-Loustau, Cote et al. 1999)]. 
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1.5.4. Angiogenesis 
Angiogenesis is defined as the process of the growth of new blood vessels. It is very 
essential during organogenesis as the oxygen and nutrients supplied by the vasculature 
are crucial for cellular function and survival. It has also been implicated in tumorigenesis 
since vascularization of tumors is required to nourish the hyperproliferating cells. In 
general, there are both positive and negative mediators of angiogenesis. Important are 
Vascular Endothelial Growth Factor (VEGF) and basic fibroblast growth factor (bFGF), 
which act positively whereas thrombospondin-1 or β-interferon act in a negative manner. 
Also, the transition from quiescent to sprouting capillaries is often accompanied by a 
change in the class of integrin expressed (Hanahan and Weinberg 2000). Generally the 
hyperproliferating cells in a tumor have a hypoxic environment. Such cells usually induce 
hypoxia-inducible factor-1α (HIF-1α), a key transcription factor that promotes 
angiogenesis (Harris 2002). Attempts are already underway in curtailing cancerous 
growth by targeting different angiogenic factors such as HIF-1α or VEGF (Semenza 
2003). Avastin, a monoclonal antibody targeting VEGF is already on the market for the 
treatment of colon cancers. 
1.6. Colon Cancer 
Colorectal cancer is one of the common cancers and stands fourth in occurrence 
including both men and women accounting for 655,000 deaths annually worldwide 
(www.who.int). The incidence is generally higher in the developed countries than in the 
developing countries. Both environmental and hereditary factors contribute to the 
development of colorectal tumors (Rupnarain, Dlamini et al. 2004). The different stages 
of cancer progression were best studied with colon cancer (Fig. 1.6). Initially the 
hyperplastic epithelium appears normal, advancing to adenomatous polyps at different 
stages of dysplasia (by acquiring mutations in critical genes), later to a non-invasive, and 
finally to an invasive carcinomatous phenotype (Weinberg 1991). 
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Fig. 1.6 Schematic representation of the genetic changes involved in colon cancer 
development. DCC: deleted in colorectal cancer, K-ras: Kirsten-ras [from (Rupnarain, 
Dlamini et al. 2004)]. 
1.6.1. Critical Genes and Pathways in Colon Cancer 
Genes that are critical and frequently found to be mutated in colon cancer are the K-ras, 
Adenomatous Polyposis Coli (APC), β-catenin, p53 and MMR (responsible for DNA 
mismatch repair). B-Raf point mutations have also been recently reported in a subset of 
colon cancers (Davies, Bignell et al. 2002). The major pathways that are altered in 
relation to colon cancer and drive its progression are: Erk pathway (enhances 
proliferation), Wnt signaling pathway (stabilization of β-catenin and activation of TCF-
LEF driven genes), increased survival signal/resistance to apoptosis (due to mutations in 
p53, Rb, PTEN), JAK-STAT pathway (generally activated by cytokine receptors and 
hyperactivation of STAT 3), TGF β (Transforming Growth Factor beta)-SMAD pathway. 
However, other genes including that of Cyclo-Oxygenase 2 (COX-2), Matrix 
Metalloproteinases (MMPs), Hypoxia Inducible Factor 1 alpha (HIF 1α), Deleted in 
Colorectal Cancer (DCC) and Mutated in Colorectal Cancer (MCC) are also relevant in 
the progression of colorectal cancer. 
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1.6.2. Therapy and Treatments 
Current treatments of colon cancer are the surgical removal in early cases, chemotherapy 
and radiation therapy. Chemotherapy is based on the action of chemicals particularly 
affecting DNA replication. Some of them are 5-fluorouracil, raltitrexed (inhibits 
thymidylate synthase), irinotecan (topoisomerase I poison) and oxaliplatin (bifunctional 
platinum alkylator of DNA) (Tebbutt, Cattell et al. 2002). Recently, targeted therapies 
using monoclonal antibodies have also been developed. Two of them were already 
approved for the treatment of colorectal cancer in 2004 by the Food and Drug 
Administration (FDA). Bevacizumab (Avastin) targets the Vascular Endothelial Growth 
Factor (VEGF) blocking angiogenesis thereby starving the tumor. Cetuximab (Erbitux), a 
monoclonal antibody against the EGF receptor inhibits signals emanating from EGFR 
(Adams and Weiner 2005). 
1.6.3. The Role of Diet in Colon Cancer 
The high incidence of colon cancer in the developed and western countries is sometimes 
correlated with the food habits. Studies have shown that diet rich in refined grain and red 
meat significantly increased the risk of colorectal cancer (Levi, Pasche et al. 1999) 
whereas, a diet rich in vegetables, fruits and whole grain consumption decreased the risk 
of polyp formation. These potential protective effects may result from the high levels of 
dietary fibre, antioxidants (beta-carotene, vitamin C and polyphenols) or other anti-
carcinogenic constituents (protease inhibitors and phytoestrogens) (Witte, Longnecker et 
al. 1996). 
1.6.3.1. Polyphenols 
Polyphenols are the most abundant antioxidants in our diets. The main classes of 
polyphenols are phenolic acids (mainly caffeic acid which occurs in foods mainly as an 
ester with quinic acid called chlorogenic acid) and flavonoids. Flavonoids are sub-divided 
into several classes: flavonoles (myricetin, fisetin, quercetin, kaempferol – abundant in 
normal diet and present in onions), isoflavones (daidzein, genistein – soy and dry beans), 
flavonols (catechins – present in tea also as their galloylated derivatives), flavanones 
(taxifolin, naringenin and hesperitin – citrus fruits) and flavones (luteolin, wogonin and 
apigenin - present in sweet red pepper and celery) (Fig. 1.7). In addition, other classes 
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such as anthocyanins (pigments of red fruits and present in red wines), proanthocyanidins 
and stilbenes (reservatrol – present in wine and has anticarcinogenic properties) also 
belong to the group of flavonoids (Tapiero, Tew et al. 2002). 
 
Several studies have emphasized the protective effects of various flavonoids in relation to 
colon cancer. The core structure of flavone (2-phenyl-4H-1-benzopyran-4-one) alone has 
been shown to affect proliferation, differentiation and apoptosis differently between 
transformed colon cancer cell line (HT 29) and non-transformed colon cells. These 
effects were also correlated to a change in the mRNA levels of cell cycle and apoptosis 
related genes including cyclo-oxygenase 2 (COX-2), NF κB and bcl-XL (Wenzel, Kuntz 
et al. 2000). Different flavonoids can also inhibit the expression of COX-2 (usually 
upregulated in colon cancer) to different extents, depending on their chemical structure 
(Mutoh, Takahashi et al. 2000). Flavonoids such as epigallocatechin gallate (EGCG), 
piceatannol (natural analog of reservatrol) have also been shown to inhibit cell cycle 
progression in CaCo-2 cells, a colon cancer cell line (Salucci, Stivala et al. 2002; Wolter, 
Clausnitzer et al. 2002). 
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Fig. 1.7 Major subclasses of flavonoids, their structure and food sources [taken from 
(Ross and Kasum 2002)]. 
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1.6.3.2. Apples 
Apple is one of the common fruits. It is rich in polyphenols including epicatechin, caffeic 
acid, phloretin-2’-glucoside (phloridzin), phloretin-2’-xyloglucoside, 3-hydroxy-
phloridzin, quercetin-3-arabinoside, quercetin-3-xyloside, quercetin-3-galactoside, 
quercetin-3-glucoside (isoquercetin) and quercetin-3-rhamnoside (Lu and Foo 1997). 
Apple contains significant amounts of anti-oxidants which have the capacity to scavenge 
radicals (Lu and Foo 2000). Recently it has been shown that an apple polyphenol extract 
(AE) contains inhibitors of EGFR. Cell treatments with AE reduced EGF induced Erk 
activity and inhibited proliferation (Kern, Tjaden et al. 2005). AE has also been shown to 
reduce oxidative damage in human colon cells (Schaefer, Baum et al. 2006; Schaefer, 
Baum et al. 2006). Another study has shown that AE inhibits the growth of HT 29 colon 
cancer cells. Furthermore, using a cDNA microarray based mRNA expression analysis, it 
has also been shown that AE can upregulate several genes (GSTP1, GSSTT2, MGST2, 
CYCP4F3, CHST5, CHST6 and CHST7) involved in detoxification (Veeriah, 
Kautenburger et al. 2006). Interestingly, the beneficial effects of AE with respect to colon 
cancer development were shown by three independent groups in vivo in rats. AE 
prevented both oxidative-induced damage in gastric epithelial cells, MKN 28 (ex vivo) as 
well as indomethacin induced injury in rats (in vivo) (Graziani, D'Argenio et al. 2005). In 
another study, the chemopreventive effects of AE were assessed. Rats were 
intraperitoneally injected with the carcinogen 1,2-dimethylhydrazine (DMH), and were 
given either water or apple juices for 7 weeks starting one week before DMH treatment. 
Apple juice drinking rats showed a reduction of genotoxic damage in mucosa cells, crypt 
cell proliferation as well as reduction in the number of aberrant crypt foci (ACF) (Barth, 
Fahndrich et al. 2005). 
 
1.6.3.3. Butyrate and Green tea 
Another interesting compound of dietary origin is butyrate. Butyrate is produced in the 
colon as a fermentation product from various precursors (Beyer-Sehlmeyer, Glei et al. 
2003). It is known for its antiproliferative activity on colon cancer cells in which it also 
induces apoptosis and promotes differentiation. It also acts as a survival factor (Hague, 
Singh et al. 1997) and a nutrient for non-transformed cells (Hague, Butt et al. 1996). 
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Differential patterns of gene expression were also reported for human colon cells treated 
with butyrate. Some of them are the enhanced expression of different isoenzymes of 
Glutathione-S-Transferases (GSTs), which may enhance cellular chemoprotection (Pool-
Zobel, Selvaraju et al. 2005). Also epigallocatechine-3-gallate (EGCG), a major 
component of green tea and related constituents has various anticancer effects, including 
inhibition of proliferation of human colon cancer cells (Shimizu, Deguchi et al. 2005; 
Shimizu, Deguchi et al. 2005). 
1.7. Colon Cancer and Tyrosine Phosphatases 
Since mutations of genes encoding proteins that regulate tyrosine phosphorylation can 
contribute to cancer, the tyrosine phosphatase gene superfamily was analysed for 
mutations in human cancers. This study revealed 83 somatic mutations in six different 
PTPs (PTPRF, PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14) affecting 26% of 
colorectal cancers. A number of these mutations were also found in a smaller fraction of 
lung, breast and gastric cancers. Some of the mutations resulted in truncated proteins 
lacking phosphatase activity. One of these PTPs, PTPRT was studied in detail. 
Biochemical studies revealed that all the five identified missense mutations of PTPRT 
resulted in reduced phosphatase activity. The authors of this study further showed that 
over expression of this PTPRT inhibited cell growth in colony assays. Based on these 
findings, it was proposed that the mutated PTPs may aid in tumor suppression (Wang, 
Shen et al. 2004). 
1.7.1. Protein Tyrosine Phosphatase DEP-1 and Cancer 
Density Enhanced Phosphatase-1 (DEP-1) was initially cloned independently by two 
different groups and also referred to as PTPRJ, PTP-η, CD 148 (Honda, Inazawa et al. 
1994; Ostman, Yang et al. 1994). As the name indicates, its expression is increased upon 
high cell density in a number of cell lines. DEP-1 is a glycosylated, transmembrane 
protein with a molecular weight of 180-220 KDa (1337 aminoacids). It has eight 
fibronectin repeats on the extracellular side (940 aa), a transmembrane region and a 
single catalytical domain (341 aa) on the intracellular side which harbors the phosphatase 
activity. Sequence analysis of the catalytic domains revealed that the closest relationships 
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are to the other members of class III RPTPs particularly PTPβ and SAP-1 (see Fig. 1.3). 
The chromosomal location is at 11p11.2. DEP-1 is a ubiquitously expressed protein 
ranging from lymphoid organs (B cells, T cells, granulocytes, macrophages, dendritic 
cells and thymocytes) to non-lymphoid organs (epithelial cells, fibrocytes, melanocytes 
and schwann cells). Its expression is absent in muscular tissue, adipose tissue, axons and 
ganglions of peripheral nervous system, neurons and microglia of the central nervous 
system (Autschbach, Palou et al. 1999). Several lines of evidences suggest DEP-1 as a 
tumor suppressor protein. 
 
Crossing of the mouse strains STS/A (colon cancer susceptible) with BALB/cHeA (colon 
cancer resistant) revealed the association of two loci namely Scc1 and Scc2 with colon 
cancer susceptibility (Moen, Groot et al. 1996). Further mapping and cloning of this 
quantitative trait locus Scc1 identified the phosphatase Ptprj as the underlying gene. 
PTPRJ is also frequently found to be lost in human cancers of lung, colon and breast. 
(Ruivenkamp, van Wezel et al. 2002). Another recent study about loss of heterozygosity 
(LOH) in human aberrant crypt foci (ACF) has revealed that a LOH is an early event 
(even before APC or β-catenin mutations). In a majority of cases a LOH was found at the 
chromosomal location 11p11, the chromosomal region containing PTPRJ (Luo, Shen et 
al. 2006). 
1.7.1.1. DEP-1 in other cellular models 
Breast 
Constitutive over-expression of DEP-1 in breast cancer cell lines reduced the colony 
formation by 3-5 folds; whereas upon induction with an inducible metallothionin 
promoter, cell growth was greatly inhibited (5-10 fold). DEP-1 was also found to be 
induced in breast carcinoma cells (SKBr-3) undergoing differentiation upon treatment 
with sodium butyrate (Keane, Lowrey et al. 1996). 
Thyroid 
In the case of thyroid carcinomas, the DEP-1 protein levels are shown to be drastically 
reduced in tumor samples when compared to that of normal thyroid tissues. Also the 
expression of the rat variant DEP-1 (rPTPη) in transformed cell lines induced 
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morphological reversion, upregulation of differentiation markers and a significant 
reduction in proliferation. These effects were attributed to increased p27kip1 protein 
levels. (Trapasso, Iuliano et al. 2000). Furthermore, the growth of xenograft tumors in 
athymic mice from anaplastic thyroid carcinoma cells transduced with the Ad-r-PTPη 
virus were drastically reduced (Iuliano, Trapasso et al. 2003). Recently it has also been 
shown that DEP-1 co-immunoprecipitates with the kinae Rearranged during Transfection 
(RET, an RTK implicated in thyroid tumors), dephosphorylates its autophosphorylation 
sites and thereby antagonizes RET signaling (Iervolino, Iuliano et al. 2006). 
Endothelium 
In the case of endothelial cells, DEP-1 is found in the complex of VE-Cadherin-β-catenin 
where it can dephosphorylate VEGFR-2, thus reducing proliferation and potentially 
mediating contact inhibited cell growth (Lampugnani, Zanetti et al. 2003). Recently it has 
been shown that a bivalent form of a DEP-1 activating monoclonal antibody against the 
extracellular domain blocks angiogenesis in mouse cornea by mediating G0/G1 mediated 
cell cycle arrest. An activation mechanism involving ectodomain induced oligomerisation 
of DEP-1 has been proposed (Takahashi, Takahashi et al. 2006). Thus DEP-1 is shown to 
play a pivotal role in endothelial cells related to angiogenesis and vasculogenesis 
(Argraves and Drake 2005). 
Glioma cells 
In glioma cells, the anti-proliferative effect of somatostatin appears to be mediated 
through the expression as well as the activity of DEP-1 by antagonizing Erk½ activation 
(Massa, Barbieri et al. 2004). 
Pancreas 
In pancreatic cancer cells, restoration of DEP-1 expression inhibits their proliferation. 
Cell cycle analysis revealed a substantial population of DEP-1 expressing cells in sub-G1 
phase indicating the apoptotic potential of DEP-1 (Trapasso, Yendamuri et al. 2004). 
Fibroblasts 
Controversial results have been obtained in the case of fibroblasts. Previous data from our 
group showed that inducible over expression of DEP-1 inhibits migration, enhances cell-
matrix adhesion and plays no role in proliferation. These effects were mediated by 
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antagonizing Ras-MAPK pathway as well as PLCγ- and Src-activation (Jandt, Denner et 
al. 2003). However, another group has shown that inducible over expression of DEP-1 
inhibits proliferation and migration. Moreover, in these experiments cell-matrix adhesion 
was reduced upon DEP-1 expression due to defective turnover of focal contacts; whereas 
cell-cell adhesion was enhanced and associated with re-distribution of cadherin and 
catenin junctions (Kellie, Craggs et al. 2004). 
T cells 
In the case of T cells, DEP-1 over-expression inhibited activation of the “Nuclear Factor 
of Activated T cells” (NFAT) following T cell receptor stimulation. A mechanism 
involving the dephosphorylation of phospholipase Cγ1 (PLCγ1) and Linker for 
Activation of T cells (LAT) has been proposed (Baker, Majeti et al. 2001). Another study 
has proposed a mechanism in which CD 148 (i.e., DEP-1), due to its large extracellular 
domain is excluded from the immunologic synapse [T cell receptor (TCR) of T cells with 
Antigen Presenting Cells] thereby blocking access to the substrate TCR. Upon T cell-
antigen presenting cell disengagement, CD 148 can then access and dephosphorylate 
TCR leading to down-regulation of signaling (Lin and Weiss 2003). 
1.7.1.2. Substrates 
Several studies involving over-expression have indicated some potential substrates of 
DEP-1. Site selective dephosphorylation of PDGFR-β has been shown in Porcine Aortic 
Endothelial (PAE) cells (Kovalenko, Denner et al. 2000). pTyr1021, a PLCγ binding site is 
preferred rather than pTyr857 (kinase domain) or pTyr562 (Persson, Engstrom et al. 2002). 
Studies with DEP-1 “trapping” (DA) mutants have revealed HGFR (Met) as another 
possible substrate. Again site selective dephosphorylation is emphasized. DEP-1 
preferentially dephosphorylated the Gab1 binding site (pTyr1349) and a C-terminal site 
(pTyr1365) rather than the activation loop / kinase domain (pTyr1230/1234/1235) hence 
presumably serving as a specific modulator rather than a simple on-off switch for the 
RTK. A genetic study in C.elegans has shown that the C.elegans homolog of DEP-1 can 
negatively regulate LET-23 EGFR signaling in the developing vulva (Berset, Hoier et al. 
2005). In the case of endothelial cells, DEP-1 has been shown to be present in a complex 
of VE-cadherin and β-catenin where DEP-1 dephosphorylates VEGFR-2. In glioma cells, 
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DEP-1 has been shown to antagonize activation of Erk1/2.  It has also been proposed that 
DEP-1 can directly interact and dephoshorylate Erk1/2 in vitro. Another study has 
suggested that DEP-1 can interact with c-Src and can dephosphorylate its inhibitory 
C-terminal (pTyr529) site. This leads to the activation of c-Src which enhances adhesion 
and causes hyperphosphorylation of focal adhesion proteins such as FAK and paxillin 
(Pera, Iuliano et al. 2005). DEP-1 has also been shown to interact with p120catenin, a 
component of adherens junctions (in A431 cells) thereby presumably playing a role in the 
regulation of cell-cell contact (Holsinger, Ward et al. 2002). A validated ligand for DEP-
1 is yet to be identified, but an unknown component of the matrigel has been shown to 
increase its intrinsic activity (Sorby, Sandstrom et al. 2001). 
1.7.1.3. Polymorphism 
Analysis of the PTPRJ status in human tumors has shown that a LOH occurs in several 
tumors of breast, colon, thyroid and lung (Ruivenkamp, van Wezel et al. 2002; 
Ruivenkamp, Hermsen et al. 2003; Iuliano, Le Pera et al. 2004). The authors have 
suggested that the loss of one allele in the absence of any acquired mutation in the 
remaining allele can predispose to cancer, indicating PTPRJ haploinsufficiency as a 
transforming mechanism in humans. Different allelic variants of human PTPRJ have 
been reported and linked to different levels of cancer susceptibility. Usually these are 
polymorphisms affecting single aminoacids which are distributed in the extracellular 
fibronectin-like domains. One such polymorphism is Q276P. Tumor analyses of 
heterozygous patients with colon cancer indicated the preferential loss of the Q276 
(resistance) allele and that the P276 allele is favored during cancer progression 
(Ruivenkamp, van Wezel et al. 2002). A similar analysis of thyroid tumors revealed an 
imbalance in another polymorphism, D872E (Iuliano, Le Pera et al. 2004). Recently, a 
similar study in breast cancer patients failed to identify imbalances on either of these 
polymorphisms but identified another single nucleotide polymorphism (SNP), in which 
the corresponding haplotype showed a weak but significant association with cancer 
progression (Lesueur, Pharoah et al. 2005). 
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1.7.1.4. Knock Out (KO) mice 
An initial report showed that the homozygous knock out of DEP-1 is embryonically 
lethal. The authors of this study found structural abnormalities as early as embryonic day 
8.25 (E8.25) and the embryos died at mid-gestation around E11.5. Death of the embryos 
was linked to vascularization defects as there was enhanced endothelial cell proliferation 
and enlargement of primitive vessels. However in this case, DEP-1 was replaced by a 
mutant allele CD148ΔCyGFP (cDNA encoding DEP1-GFP fusion which lacks phosphatase 
activity) by in-frame replacement of cytoplasmic sequences with a green fluorescent 
protein (GFP) (Takahashi, Takahashi et al. 2003). In contrast, it has been shown recently 
that Ptprj-deficient mice are viable, fertile and show no gross anatomical alterations. 
Furthermore, neither changes in life span nor spontaneous tumor appearance were 
observed in Ptprj null mice indicating that DEP-1 may be dispensable for normal growth 
and development of mice (Trapasso, Drusco et al. 2006). 
1.8 Aims 
Density Enhanced Phosphatase-1 (DEP-1) is proposed as a tumor suppressor in a number 
of epithelial cancers, including that of breast, lung, thyroid and pancreatic carcinomas. It 
has also been mapped down to the colon cancer susceptibility locus (Scc 1) in mice. 
Nevertheless, its physiological role in colon epithelial cells is not known. 
 
The aim of this thesis was to elucidate functional roles of DEP-1 in colon epithelial cells. 
To achieve this aim, two approaches should be used 
¾ inducible re-expression of DEP-1 in a colon cancer cell line, which is devoid of 
endogenous DEP-1 protein. 
¾ suppression of DEP-1 in a colon epithelial cell line normal endogenous levels 
using the si/shRNA approach. 
 
Possible biological phenotypes related to transformation should be analyzed, including 
potential effects of changed DEP-1 levels on cell proliferation, migration, cell-matrix 
adhesion and apoptosis. Further, possible signaling mechanisms that might be altered due 
to re-expression or suppression of DEP-1 should be analyzed. 
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2. Materials & Methods 
2.1. Materials 
2.1.1. Chemicals 
All general chemicals were purchased either from Carl Roth GmbH & Co (Karlsruhe, 
Germany) or Sigma-Aldrich Chemie GmbH (Deisenhofen, Germany), and all molecular 
biology enzymes were purchased from New England Biolabs (Frankfurt, Germany) 
unless otherwise stated. 
Compound / Substance Company Cat. No. 
Epidermal Growth Factor 
(EGF) 
Peprotech EC, Tebu bio, 
Frankfurt, Germany 100-15 
Hepatocyte Growth Factor 
(HGF) 
Peprotech EC, Tebu bio, 
Frankfurt, Germany 100-39 
Lysophosphatidic acid 
(LPA) 
Sigma Aldrich, Diesenhofen, 
Germany L7260 
Staurosporine (STS) Alexis Biochemicals, Axxora, Grünberg, Germany. Alx-380-014-C100 
Anhydrotetracycline (Atc) ACROS Organics, Fischer Scientific, Nidderav, Germany. 233131000 
Immumount Thermostandon, Pittsburgh, USA 9990402 
DePeX Serva Electrophoresis, Heidelberg, Germany 18243 
Stromal Cell Derived Factor 
1 alpha (SDF 1α) 
Prospec-Tany Technogene Ltd, 
Israel CHM 262B 
Sphingosine 1 phosphate 
(S1P) 
Calbiochem, Schwalbach, 
Germany 567727 
2.1.2. Reagents and Buffers 
Lysis buffers: 
(A) 50 mM HEPES pH 7.5 
150 mM NaCl 
1.5 mM MgCl2 
1 mM EDTA 
1% Triton X 100 
1% Sodium desoxycholate 
0.1% SDS 
10% Glycerol 
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(B) 50 mM HEPES pH 7.5 
150 mM NaCl 
1 mM EDTA 
2 mM EGTA 
1% NP 40 
10% Glycerol 
 
(C) 50 mM Tris pH 7.5 
 150 mM NaCl 
 5 mM MgCl2 
 1 mM EGTA 
 1% NP-40 
 
Initial experiments were carried out with the lysis buffer “A”. However later on it was 
replaced with the lysis buffer “B” without much discrepancy. For making the pull downs 
of active GTPases, lysis buffer “C” was used. 
Added freshly before use: 
1mM Dithiothreitol (DTT), Inhibitors (1 µg/ml Leupeptin, 1µg/ml Pepstatin A, 200 
KIE/ml Aprotinin, 1 mM PMSF, 1 mM Benzamidine, 0.1 mg/ml Pefablock, 1mM 
sodium orthovanadate). 
HNGT buffer (for washing Immunoprecipitates): 
20 mM HEPES pH 7.5 
150 mM NaCl 
10% Glycerol 
0.1% Triton X 100 
NET-G-T: 
50 mM Tris-HCl pH 7.5 
150 mM NaCl 
5 mM EDTA 
0.04% Gelatine 
0.05% Tween 20 
6 x Sample buffer: 
30% β-Mercaptoethanol 
40% Glycerol 
6% SDS 
Bromophenol blue 
Strip-buffer: 
62.5 mM Tris-HCl pH 6.7 
100 mM β-Mercaptoethanol 
2% SDS 
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Transfer Buffer: 
39 mM Glycine 
48 mM Tris-HCl pH 9.0 
20% Methanol 
0.037% SDS 
Coomassie staining: 
2 g/l Coomassie R250 
10% Acetic acid 
50% Ethanol 
Destaining: 
10% Acetic acid 
30% Ethanol 
TSB (for the preparation of competent cells - E.Coli XL1Blue): 
1 x Luria Broth medium 
5 % DMSO 
10 mM MgCl2 
10 mM MgSO4 
10 % PEG 4000 
KCM buffer (for transformation): 
0.5 M KCl 
0.15 M CaCl2 
0.25 M MgCl2 
Luria Broth: 
 10 g - Bactotryptone 
 5 g - yeast extract 
 10 g - Sodium chloride 
 1.0 lit. - Water 
 pH adjusted to 7.0 – 7.4 
BBS buffer (for calcium phosphate mediated transfections): 
50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4.2H2O 
pH adjusted to 6.96. 
pNpp buffer (for phosphatase assay): 
100 mM HEPES (pH 7.4) 
150 mM NaCl 
1 mM EDTA 
5 mM DTT (freshly added) 
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MACS buffer: 
0.5 % BSA, 2 mM EDTA in PBS (pH 7.2). Degassed before use. 
TBN 150: 
 25 mM Tris pH 7.5 
 150 mM NaCl 
 10 mM β-mercaptoethanol 
Inhibitors (freshly added before use) - final concentrations: 
10 mM β-Glycerol phosphate, 1 µg/ml Leupeptin, 1µg/ml Pepstatin A, 200 KIE/ml 
Aprotinin, 1 mM PMSF, 0.1 mg/ml Pefablock, 2 mM EGTA, 0.2mM EDTA 
EQM buffer (equilibration buffer): 
50 mM Tris-Cl pH 8.0 
100 mM NaCl 
10 mM DTT (freshly added) 
EQL buffer (elution buffer): 
EQM buffer + 10 mM Glutathione 
Dialysis buffer: 
100 mM NaCl 
20 mM NaH2PO4.H2O 
80 mM Na2HPO4.2H2O 
pH 7.5 
 
2.1.3. Antibodies 
Primary antibodies 
 
Antigen Type of Antibody 
Dilution 
used in 
immuno-
blotting 
Company Cat. No. 
anti-β-actin Mouse monoclonal 1:5000 
Sigma Aldrich, 
Deisenhofen, 
Germany 
A5441 
anti-pan Akt Rabbit polyclonal 1:2000 
Cell Signaling, NEB, 
Frankfurt, Germany. 9272 
anti-phospho Akt 
(ser473) 
Rabbit 
monoclonal 1:2000 
Cell Signaling, NEB, 
Frankfurt, Germany. 4058 
anti-DEP-1 (143.41) Mouse monoclonal 1:5000 
Biosource Europe, 
Solingen, Germany. AHT 4802 
anti-pan Erk Mouse monoclonal 1:2000 
BD Biosciences, 
Heidelberg, Germany 610123 
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anti-phospho-p44/42 
Erk [pT202Y204] 
Mouse 
monoclonal 1:2000 
Cell Signaling, NEB, 
Frankfurt, Germany 9106 
anti-FAK Rabbit polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 3285 
anti-FAK [pY397] Rabbit polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-631 
anti-FAK [pY407] Rabbit polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-631 
anti-FAK [pY576] Rabbit polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-631 
anti-FAK [pY577] Rabbit polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-631 
anti-FAK [pY861] Rabbit polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-631 
anti-phospho FAK 
[pY925] 
Rabbit 
polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 3284 
anti-Met (C-28) Rabbit polyclonal 1:200 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
sc-161 
anti-phospho Met 
[pYpYpY1230/1234/1235] 
Rabbit 
polyclonal 1:1000 
Biosource Europe, 
Solingen, Germany 44-888G 
anti-PARP Rabbit polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 9542 
anti-paxillin Rabbit polyclonal 1:1000 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
sc-5574 
anti-phospho paxillin 
[pY118] 
Rabbit 
polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 2541 
anti-PLC γ1 Rabbit polyclonal 1:2000 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
sc-426 
anti-phospho PLC γ1 
[pY783] 
Rabbit 
polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 2821 
anti-phospho tyrosine 
[4G10] 
Mouse 
monoclonal 1:5000 Home made  
anti-Rac-1 Mouse monoclonal 1:1000 
BD Biosciences, 
Heidelberg, Germany 610650 
anti-Rho Mouse monoclonal 1:1000 
BD Biosciences, 
Heidelberg, Germany R-73920 
anti-pan Src Rabbit polyclonal 1:2000 
Biosource Europe, 
Solingen, Germany 44-656G 
anti-c-Src (SRC 2) Rabbit polyclonal 1:2000 
Santa Cruz 
Biotechnology, 
Heidelberg, Germany 
sc - 18 
anti-phospho Src 
[pY529] 
Rabbit 
polyclonal 1:1000 
Cell Signaling, NEB, 
Frankfurt, Germany 2105 
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anti-phospho Src 
[pY418] 
Rabbit 
polyclonal 1:2000 
Biosource Europe, 
Solingen, Germany 44-660 
anti-vinculin Mouse monoclonal 1:5000 
Biozol Diagnostica 
Vertrieb GmbH, 
Eching, Germany 
BZL03106 
All primary antibodies were either incubated with the immunoblots overnight at 4oC or at 
RT for one hour except for the anti-DEP-1 blot which was always performed overnight at 
4oC. 
Secondary antibodies / Modified antibodies 
Antigen 
Source & 
Labelled / 
coupled with 
Dilution used 
in immuno-
blotting or 
labelling 
Company Cat. No. 
anti-mouse IgG Goat / Peroxidase 1:10,000 
KPL, Medac, 
Wedel, Germany 074-1806 
anti-rabbit IgG Goat / Peroxidase 1:10,000 
KPL, Medac, 
Wedel, Germany 074-1506 
anti-mouse IgG microbeads 1:5 (20 µl / 10
7 
cells) 
Miltenyi Biotech, 
Bergisch Gladbach, 
Germany 
130-048-401 
anti-mouse IgG Cy 3 1:600 
Jackson 
Immunoresearch, 
Dianova, Hamburg, 
Germany 
115-165-003 
anti-rabbit IgG TRITC 1:600 
Jackson 
Immunoresearch, 
Dianova, Hamburg, 
Germany 
111-025-003 
anti-mouse IgG DTAF 1:600 
Jackson 
Immunoresearch, 
Dianova, Hamburg, 
Germany 
115-015-072 
anti-rabbit IgG DTAF 1:600 
Jackson 
Immunoresearch, 
Dianova, Hamburg, 
Germany. 
111-015-144 
anti-DEP-1 Mouse / FITC labelled 1:500 
Santa Cruz 
Biotechnology, 
Heidelberg, 
Germany 
sc-21761-
FITC 
Phalloidin TRITC 1 µM 
Sigma Aldrich, 
Deisenhofen, 
Germany 
P1951 
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2.1.4. Cell Lines and Media 
COGA-1, COGA-2, COGA-3 and COGA-12 cell lines were kindly provided by 
Dr. L.A. Huber (Research Institute of Molecular Pathology, Vienna, Austria). LT 97, a 
human colon adenoma cell line, was a kind gift from Prof. Brigitte Marian (Institute for 
Cancer Research, University of Vienna, Austria). All other cell lines were obtained from 
DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, 
Braunschweig, Germany). Unless otherwise stated, all cell culture vessels (flasks, dishes 
and freezing tubes) were purchased from Greiner bio-one (Cellstar, Frickenhausen, 
Germany) whereas all cell culture media (RPMI, DMEM and Trypsin) were purchased 
from PAA Laboratories, (Cölbe, Germany). Fetal Bovine Serum (FBS) was purchased 
from Biochrom, Berlin, Germany. 
2.1.5. Plasmids and Primers 
The plasmids pNRTIS 33 (DEP-1 WT) and pNRTIS 33 (DEP-1 C1239S) were kindly 
provided by Enrico Jandt (Jandt, Denner et al. 2003). The vector pNRTIS 21 was 
provided by Tencho Tenev (Tenev, Bohmer et al. 2000). The plasmid pSUPER.retro.puro 
was purchased from Oligoengine. The necessary oligonucleotides for shRNA constructs 
were purchased from Jena Biosciences, Jena, Germany. 
 
441 (s) 
5’-gat ccc c GGGCCAGATCCTGTGCGCA ttc aag aga 
TGCGCACAGGATCTGGCCCttt ttg gaa a-3’ 
441 (as) 
5’-agc ttt tcc aaa aa GGGCCAGATCCTGTGCGCA tct ctt 
gaa TGCGCACAGGATCTGGCCC ggg-3’ 
1151 (s) 
5’-gat ccc c TACAACATCAACCCGTATC ttc aag aga 
GATACGGGTTGATGTTGTA ttt ttg gaa a-3’ 
1151 (as) 
5’-agc ttt tcc aaa aa TACAACATCAACCCGTATC tct ctt gaa 
GATACGGGTTGATGTTGTA ggg-3’ 
1524 (s) 
5’-gat ccc c CGAGTCGTCATCTAACTAT ttc aag aga 
ATAGTTAGATGACGACTCG ttt ttg gaa a-3’ 
1524 (as) 
5’-agc ttt tcc aaa aa CGAGTCGTCATCTAACTAT tct ctt gaa 
ATAGTTAGATGACGACTCG ggg-3’ 
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2348 (s) 
5’-gat ccc c ATTCCAGCAACGCAACACA ttc aag aga 
TGTGTTGCGTTGCTGGAAT ttt ttg gaa a-3’ 
2348 (as) 
5’-agc ttt tcc aaa aa ATTCCAGCAACGCAACACA tct ctt gaa 
TGTGTTGCGTTGCTGGAAT ggg-3’ 
Non-targeting 
control (s) 
5’-gat ccc c AATTCTCCGAACGTGTCACGT ttc aag aga 
ACGTGACACGTTCGGAGAATT ttt ttg gaa a-3’ 
Non-targeting 
control (as) 
5’-agc ttt tcc aaa aa AATTCTCCGAACGTGTCACGT tct ctt 
gaa ACGTGACACGTTCGGAGAATT  ggg-3’ 
 
2.2. Methods 
2.2.1. Cell Culture 
All the cells were cultured either in RPMI or in DMEM, supplemented with 10% FBS. 
For routine passage, they were cultured in 75 cm2 flasks in an incubator (Thermo 
Electron Corporation, Langenselbold, Germany) maintained at 37oC, 5% CO2 and 95% 
humidity. The cells were allowed to become 80% confluent before they were split. For 
splitting, the media was removed and the cell layer was washed twice with a solution of 
Trypsin-EDTA. Usually, a splitting ratio of 1:10 or 1:20 was used. Freezings: Cells were 
frozen with the usual culture medium containing 10% DMSO. They were aliquoted into 
special freezing tubes (Cellstar, Frickenhausen, Germany) and allowed to freeze in a 
polystyrene container at -80oC. Then, they were stored in liquid nitrogen. For thawing, 
the cells were removed from the liquid nitrogen, quickly thawn at 37oC and spun down 
(to remove DMSO). The cell pellet was then mixed with fresh growth medium and new 
cultures were initiated. 
 
The adenoma cells, LT 97 (Richter, Jurek et al. 2002) was cultivated in a specialized 
mixture of media containing 400 ml of MCDB Basal Medium (without glutamine) with 
NaHCO3 (Biochrom, Berlin, Germany) and 100 ml of L-15 Leibovitz medium 
(Biochrom, Berlin, Germany). A number of supplements were added including 2 mM 
Glutamine, 2% FBS, Insulin-Transferrin-Selenium-mixture (Gibco, Invitrogen, 
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Karlsruhe, Germany, Cat. No. 41400-045), 0.2 nM Triiodothyronine, 1 µg/ml 
Hydrocortisone, 30 ng/ml Epidermal Growth Factor (Calbiochem, Schwalbach, 
Germany). For splitting, a solution of PBS with 5 mM EDTA was used and splitting was 
carried out as follows: after removal of media, the cells were incubated with PBS/EDTA 
for 5-7 min at 37oC. The PBS/EDTA was then removed and cells were incubated for 
another 3-4 min at 37oC. The cells were now readily detached with a bit of mechanical 
agitation. After mixing with growth media, the suspension was used for further passaging 
or seeded for experiments. 
2.2.2. Cloning 
The cDNAs corresponding to DEP-1 WT or CS were sub-cloned from pNRTIS 33 into 
pNRTIS 21. Briefly, the vector pNRTIS 21 was first digested with EcoRI followed by 
dephosphorylation of the ends with Calf Intestinal Phosphatase (CIP, Sigma-Aldrich, 
Deisenhofen, Germany). The cDNA insert was excised from parental plasmids also with 
EcoRI. Ligation was performed with dephosphorylated vector and insert (ratio of 4:1) 
overnight at 12oC. The ligation mixture was transformed into competent XL1Blue 
bacteria and positive clones were screened by making mini preparations of plasmids 
(Qiagen, Hilden, Germany). 
Digestion with restriction enzymes 
pNRTIS 21 (conc. 1 µg/µl) 5 µl 
EcoRI  (20 U/µl) 2 µl 
Buffer (10 x) 5 µl 
Water 38 µl 
Total 50 µl 
The reaction mixture was incubated at 37oC for two hours. The enzyme was inactivated 
at 65oC with 20 min incubation time. 
Dephosphorylation of vector 
30 µl of the digested vector was mixed with 3 µl of 10 x CIP buffer and 1 µl CIP. It was 
carried out for two hours at 37oC after which it was inactivated with 0.5% SDS and 5 mM 
EDTA at 65oC for 30 min. DNA was then precipitated with 0.3 M of sodium acetate, 1 µl 
of Linear Acrylamide [LAA was kindly provided by Dr. Lucho Karagyozov and prepared 
(Gaillard and Strauss 1990) with a stock conc. - 10µg/µl] mixed with an equal volume of 
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isopropanol. It was spun down and washed with 70% ethanol and the pellet was 
resuspended in TE buffer. 
Digestion with Restriction enzymes to excise insert 
The plasmids harboring either DEP-1 WT or CS in pNRTIS 33 were also digested as 
described above with EcoRI. 
Ligation 
40 ng of dephosphorylated vector was mixed with 10 ng of insert in a volume of 20 µl. 
1 µl of DNA ligase (3U/µl) and 2 µl of 10 x ligase buffers with 10 mM ATP were then 
added and incubated overnight at 12oC. 
Transformation 
80 µl of competent E.Coli cells (XL1Blue) was mixed with 20 µl of 5 x KCM buffer 
along with 10 µl of ligation mixture. The sample was kept on ice for 15 min after which it 
was heat-shocked at 42oC for 2 min and brought back to ice. 1.0 ml of Luria Broth 
medium (without antibiotics) was added and incubated at 37oC. Half of the 
transformation mixture was used for plating on Luria Broth plates containing ampicillin 
(100 µg/ml) and the resistant colonies were allowed to grow overnight at 37oC. 
Minipreparations of plasmids 
The resistant colonies were inoculated in 3.0 ml Luria Broth medium each, allowed to 
grow overnight and plasmids were extracted using a Qiaprep Spin Miniprep Kit (Qiagen, 
Hilden, Germany) as described by the manufacturer. 
Checking the clones 
The clones were analysed to check whether they have the insert in the right orientation by 
performing a double digestion with Hind III (cuts at 3’ end of the insert) and EcoRV (cuts 
in the vector pNRTIS 21). The digested fragments were electrophoresed on 1% agarose 
gels and positive clones were detected. 
2.2.3. Transient Transfections – HEK 293 cells 
Transient transfections to analyse expression were carried out in HEK 293 cells using 
calcium phosphate. In brief, HEK 293 cells were routinely cultured in DMEM/F-12 
medium supplemented with 10% FBS. For transfections, cells were trypsinized and 3.5 x 
105 cells/2.0 ml/well were seeded in 6 well plates. A specialized mixture of transfection 
medium containing one part of DMEM/F-12 and two parts of DMEM, both 
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supplemented with 10% FBS were used for this purpose. 24 hours later, DNA 
precipitates were made by mixing 96 µl of pre-mix (8.6 ml of H2O and 1 ml of 2.5 M 
CaCl2), 4 µg of plasmid DNA and 100 µl of BBS buffer and incubated for 20 min at RT. 
The precipitates were then added in drops to the cells, gently shaken and incubated at 3% 
CO2 incubator overnight. The next day, fresh media was replaced and the cells were put 
back to the normal 5% CO2 incubator. It was incubated for additional 24 hours after 
which the cells were lysed. 
2.2.4. Generation of Stable Cell Lines 
SW 480 cells were transfected using Lipofectamine 2000 (Invitrogen, Karlsruhe, 
Germany). The ratio between DNA and Lipofectamine 2000 used was 1:4. The plasmids 
pNRTIS 21 with either DEP-1 WT or DEP-1 CS inserts were first linearized with Bst 
Z171 in order to ease integration into the genomic DNA. Two days after transfection, the 
cells were selected with the antibiotic G418 (PAA Laboratories, Cölbe, Germany) at a 
concentration of 200 µg/ml. Selection was carried out for a period of two weeks. The 
resistant pools were then trypsinized and diluted in a 96 well plate (1 cell/100µl/well) for 
clonal selection. All these steps were carried out in the presence of 150 ng/ml of 
Anhydrotetracycline (Sigma Aldrich, Deisenhofen, Germany) in order to suppress DEP-1 
expression. Those wells that harbored single clones (arising from single cells) were then 
trypsinized and further expanded and analysed for their expression in western blots. 
2.2.5. Cell Sorting - MACS 
Magnetic Assisted Cell Sorting (Milltenyi Biotech, Bergisch Gladbach, Germany) was 
performed to enrich the DEP-1 expressing cells. At first, the cells were cultured without 
Atc for four days completely relieving the suppression. The cells were then mildly 
trypsinized by quickly washing the monolayer of cells twice with a solution of Trypsin / 
EDTA followed by very short incubation (usually around 1 min) at 37oC. The cells were 
readily detached with a bit of mechanical agitation and were suspended in 5.0 ml of fresh 
media with serum. The serum will inhibit the trypsin and the cells were then pelleted by 
centrifuging at 1,000 rpm for 3 min. The cells were blocked by suspending the pellet in 
PBS containing 10% FBS and incubating them at RT for 10 min. Anti-DEP-1 antibody 
(2µg/500µl) in MACS buffer was added and incubated for additional 30 min at RT 
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followed by washing thrice with MACS buffer. The secondary antibody coupled to 
magnetic beads was then added (20µl antibody + 80 µl MACS buffer) and incubated for 
15 min at 4oC. The cells were washed thrice again in the same buffer (5 min each). 
Meanwhile, the MACS column is placed in the magnetic field of MACS separator and is 
equilibrated by washing thrice with 500 µl of MACS buffer. The samples were then 
loaded onto the column. Unbound cells were removed by washing the column thrice with 
500 µl of the same buffer. The column was then separated from the magnetic field and 
the bound cells were eluted with the plunger provided. 
2.2.6. Phosphatase Assay - pNpp assay 
Para-nitrophenylphosphate (pNpp) was used as the substrate for this assay. The assay is 
based on the cleavage of the phosphate group from pNpp (due to the enzyme activity of 
the phosphatase) turning into nitrophenol (yellow colour substance). This can be 
quantified by measuring the absorbance at 405 nm. The assay was started by mixing of 
pNpp substrate (10 mM), buffer and sample to a total volume of 50 µl. The mixture was 
incubated for 30 min at RT. The reaction was terminated by addition of 100 µl of 1 M 
NaOH after which absorbance was measured at 405 nm. 
2.2.7. Proliferation Assay 
2.2.7.1. Cell counter 
100,000 cells/2.0ml/well were seeded in a 6 well plate. On alternative days, they were 
trypsinized and counted in a Casy-1 cell counter (Schärfe Systems, Reutlingen, 
Germany). Assays were always performed in triplicates. 
2.2.7.2. DAPI assay 
The assay is based on the ability of 4', 6-Diamidino-2-phenylindole (DAPI) to bind to 
DNA which will then fluoresce. The assay was usually carried out in 96 well plates. 
8,000 cells/100 µl/well were seeded and were treated wherever necessary. On the 
respective days, cells were first fixed with methanol (100 µl/well for 5 min). Following 
the removal of methanol, the plate was just left open for 15 min at RT in order to remove 
the residual moisture. A 20 µM solution of DAPI (100 µl/well) in PBS was then added, 
followed by incubation at 37oC for at least 30 min (formation of DNA-DAPI complexes). 
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The plate was then measured in a fluorescent plate reader (TECAN Spectrafluor GmbH, 
Crailsheim, Germany) using the following parameters: Ex/Em - 360/465, Gain - 60, 
Reading mode - bottom and multiple readings per well. 
2.2.8. Migration Assay 
2.2.8.1. Wound healing assay 
A sterile 6 well plate was taken and the bottom side of each well was marked to position 
the wound and five random fields were also marked to aid in quantification towards the 
end of the assay. 200,000 cells/2.0ml/well were seeded in 6 well plates, allowed to grow 
to confluence, and starved overnight. The cell layer was wounded by scratching with a 
sterile 1.0 ml pipette tip. The wound was created in such a way that it coincided with the 
marked place at the bottom.  Detached cells were removed by washing three times with 
serum-free medium. Medium containing 10% fetal bovine serum (or other motogens) was 
added. The plates were now examined under a microscope at all the five marked places 
using an ocular with grids and the positions were noted. It was incubated at 37oC for 24 
h. The plates were then examined exactly at the same positions by aligning the ocular 
with grids to the wound. The numbers of migrated cells at all these five fields were 
counted. 
2.2.8.2. Transwell assay 
The assay was carried out in a modified 12 well plate which contains an insert with a 
basal membrane of defined pore size of 8 µM (12 mm well chambers; Transwell Costar 
Corp., Cambridge, MA). The membrane was first coated with a 50 µg/ml collagen type I 
solution (Sigma-Aldrich, Deisenhofen, Germany, Cat. No. C9791) by incubating for one 
hour at 37oC followed by washing thrice with PBS. Starved cells (50,000 cells/500 µl) 
were seeded on top of the collagen-coated membrane, and cells migrating to the bottom 
side (towards stimulus) were scored after 6 hours by staining with 0.5% crystal violet in 
20% methanol for 5 min. followed by washing thrice with PBS. The cells on the top of 
the membrane (non-migrated) were removed using a cotton swab. The membrane was 
gently excised using a scalpel from the attached insert and mounted on a glass slide with 
DePeX mounting solution. The cells on the bottom side were then counted using a 
microscope. Five different fields randomly chosen were counted and quantified. 
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2.2.9. Adhesion Assay 
Adhesion assays were carried out in two different ways. The first method is based on the 
rate at which the cells attach to the substratum, whereas the second one scores the rate at 
which the cells can detach. In the first method, 96 well plates were coated with 50 µg/ml 
collagen type I (Sigma-Aldrich, Deisenhofen, Germany, Cat. No. C9791) at 4oC 
overnight and then washed twice with PBS. Cells were suspended at a density of 3x105 
cells/ml in serum-free medium and kept in suspension for 30 min, after which 100 µl cell 
suspension was added per well. Adhesion was allowed for different time points and was 
stopped by removal of the medium with non-adhered cells. The adhered cells were then 
stained with 0.5% crystal violet in 20% methanol for 5 min. The wells were washed twice 
with PBS, and the dye was solubilized in 0.1 M sodium citrate (100 µl per well) and 
measured at 570 nm. In the second method, cells were plated in 24 well plates in 
quadruplicates at a density of 1x105 cells/well. Cells were allowed to adhere by 
incubating them at 37oC for one day and then gently washed initially with 500 µl of Ca2+ 
and Mg2+ free PBS followed by incubating again with a solution of PBS or with a 
solution of Accutase (PAA Laboratories, Cölbe, Germany). Detached cells were removed 
by aspirating them along with the medium. The remaining attached cells were scored by 
fixing and staining with methanol and crystal violet as described above. 
2.2.10. Immunofluorescence and Phalloidin Staining 
Cells were plated on collagen-coated coverslips in 24 well plates (10,000 cells/ml/well) 
followed by washing with PBS. They were fixed with 4% paraformaldehyde in PBS (pH 
7.0-7.4) by incubating for 10 min at RT followed by washing thrice with PBS. The cells 
were then permeabilized with 0.2% Triton X -100 in PBS at RT for 4 min followed by 
blocking with 1.5% BSA in PBS. Phalloidin or primary antibodies were dissolved at the 
desired concentrations (phalloidin - 1 µM, vinculin - 1:500 or phospho-paxillin - 1:100) 
and the coverslips were incubated either for one hour at RT or overnight at 4oC. They 
were then washed thrice with 1.5% BSA/PBS (20 min each). Corresponding Cy3 or 
TRITC labelled secondary antibodies with a dilution of 1:600 were then added and the 
coverslips incubated for one hour at RT, then washed thrice with PBS. The nuclei were 
stained with DAPI (2 µg/ml in PBS) by incubating the coverslips at RT for 5 min. The 
coverslips were finally washed thrice with PBS and then mounted on glass slides with 
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mounting solution (Immumount). The slides were dried overnight at RT (dark conditions) 
before examination under a microscope. Pictures were taken with a Zeiss AxioCam HRC 
digital camera system, mounted on a Zeiss Axioplan2 microscope, and the AxioVision 
3.1 software. The following filter sets were used for examination of the slides. 
Channel Filter set numbers Excitation 
Beam 
splitter Emission Cat. No. 
Red Filter set 15 BP 546/12 FT 580 LP 590 488015-0000-000 
Green Filter set 9 BP 450-490 FT 510 LP 515 488009-0000-000 
Blue Filter set 1 BP 365/12 FT 395 LP 397 488001-0000-000 
2.2.11. Apoptosis Assay 
A Cell Death Detection ELISA kit (Roche Diagnostics, Mannheim, Germany, 
Cat. No. 1774425) was employed. The assay is based on a quantitative sandwich-enzyme 
immunoassay principle using mouse monoclonal antibodies directed against DNA and 
histones which allows determining the mono- and oligonucleosomal fraction in the 
sample. In brief, 10,000 cells/well in a 24 well plate (sometimes higher cell numbers 
were used but the lysates were diluted before analysis) were seeded and allowed to settle 
overnight. The next day, the cells were treated with different concentrations of 
staurosporine for 4 hours. They were then lysed in the lysis buffer (provided in the kit) at 
RT for 30 min and then centrifuged at 200 x g for 10 min. Cell lysates corresponding to 1 
x 103 cells were transferred to the provided streptavidin coated microtitre plate. A 
mixture of biotin-labeled histone antibodies and peroxidase-conjugated anti DNA 
antibodies was added and the plates were incubated at RT for further two hours. The 
unbound antibodies were removed by washing thrice with the incubation buffer provided. 
The bound peroxidase was determined photometrically at 405 nm with ABTS as 
substrate. Since the assay is quite sensitive, it is essential to have equal inputs for all the 
samples under investigation. For this purpose, similar amounts of cells were seeded in 
parallel on the first day of the experiment. They were then lysed and protein amounts 
were estimated by performing either BCA assay (BCA Protein Assay Kit, Perbio Science, 
Bonn, Germany, Cat. No. 23235) as described by the manufacturer or by immunoblotting 
the lysates against vinculin antibody. The obtained data were then used to normalize the 
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data of the apoptosis ELISA. Apoptosis was also detected by monitoring the cleavage of 
poly (ADP-Ribose) polymerase (PARP-1), using an antibody that detects both the 
cleaved (89 kDa) and uncleaved (116 kDa) forms in immunoblotting. 
2.2.12. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) 
A single step RT-PCR reaction was performed in order to detect the presence of DEP-1 
mRNA in the cell populations under study. Briefly, 2 x 106 cells were seeded in 6.0 cm. 
dishes and allowed to settle overnight. Total RNA was isolated using RNeasy kit 
(Qiagen, Hilden, Germany). 1 µg of the total RNA was used to perform a single step RT-
PCR using the One Step RT-PCR kit (Qiagen, Hilden, Germany, Cat. No. 210212) under 
the following conditions and the resulting products were analysed in 1% agarose gel 
electrophoresis. 
Cycle 1 (1x): cDNA synthesis 
 Step 1:  50 oC  30 min. 
Cycle 2 (1x):  Initial Denaturation 
 Step 1:  95 oC  15 min. 
Cycle 3 (35x):  Amplification 
 Step 1:  95 oC  30 sec. 
 Step 2:  54 oC  60 sec. 
 Step 3:  72 oC  45 sec. 
Cycle 4 (1x): Final Extension 
 Step 1:  72 oC  5 min. 
Cycle 5 (1x): Pause 
 Step 1:  4 oC   infinite 
Forward primer: 5’-CCTGGTTATTGTGACTGTGGAGG-3’ 
Reverse primer: 5’-TCTGGACCGAAAGTTTGACACG-3’ 
2.2.13. Cell lysis, Immunoprecipitation and Blotting 
Cells were usually grown either in 6 well plates or in 6.0 cm dishes to 70% - 80% 
confluence. Wherever necessary, starvation was always performed overnight in serum 
free medium. Stimulations were usually done with 10% FBS (unless otherwise specified) 
for the indicated time periods. For preparing cell extracts, cells were washed with ice-
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cold PBS, followed by lysing with lysis buffer (300 µl/well in a 6-well plate or 500 µl/6.0 
cm. dish). The cells were then scraped off and centrifuged at 14,000 rpm at 4oC for 15 
min. The supernatant was either subjected to immunoprecipitation (IP) or to western 
blotting. IP of DEP-1 was performed by mixing lysates with mouse monoclonal anti-
DEP-1 antibody (0.5-1.0 µg/sample) and incubating them at 4oC for one hour in a rotary 
wheel. 20 µl of protein A-sepharose bead suspension per sample was then added and 
incubated for another hour. The beads were then washed thrice with HNGT buffer, boiled 
in 30 µl of 2 x sample buffer and finally subjected to electrophoresis. 
 
For western blotting, usually 10% of cell lysates were subjected to polyacrylamide gel 
electrophoresis and thus separated. The percentage of the gel casted was dependent on the 
size of the protein of interest. The gel was then transferred to PVDF membrane 
(Millipore, Eschborn, Germany) by a Semidry Transfer Cell System (Millipore). The 
membranes were blocked with NET-G-T solution, either for one hour at RT or at 4oC 
overnight. They were then probed with primary antibody (specified dilution) either for 
one hour at RT or overnight at 4oC followed by washing thrice with NET-G-T. The 
appropriate secondary antibody (1:10,000) coupled to horse-radish peroxidase was then 
added and incubated at RT for another hour. They were finally washed thrice with NET-
G-T and the signals were detected with chemiluminescent reagents [Western lightening, 
Chemiluminiscent Reagent Plus (Cat. No. NEL104, NEL 105) or SuperSignal West Dura 
Extended Duration Substrate (Cat. No. 34075), Perkin Elmer, Rodgau Jügesheim, 
Germany] by exposing them to X-ray films (CL-XPosure Film, Perbio Science, Bonn, 
Germany, Cat. No. 34090). To reprobe the same membrane with another antibody, the 
blots were first stripped by incubating them with stripping buffer at 56oC for 20-30 min 
followed by three washes with NET-G-T and detection with another antibody as 
described. 
2.2.14. Density Dependent Upregulation 
In order to determine the density dependent upregulation, HT 29 cells were seeded at 
different densities either in 6.0 cm or in 10.0 cm dishes (cell numbers are given in the 
table below). The following day, the cells were lysed and IP of DEP-1 was performed as 
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described before. Loading controls were performed by immunoblotting of lysate samples 
with anti-vinculin antibodies. 
Confluence 
(x 104 cells/cm2) 
Diameter of 
the dish 
No. of cells 
seeded 
1 10 cm 6 x 105 
2.5 10 cm 15 x 105 
5 10 cm 30 x 105 
10 6 cm 20 x 105 
25 6 cm 50 x 105 
75 6 cm 150 x 105 
2.2.15. GTPase Pull Downs 
The binding domains of small GTPase effectors were cloned in pGEX vectors 
(Pharmacia, Amersham Biosciences, Freiburg, Germany) and were kindly provided by 
Dr. Ignacio Rubio. The pGEX vectors offer several advantages including the presence of 
a tac promoter which allows chemically inducible, high-level expression. Moreover, the 
target proteins can be expressed as a fusion protein with Glutathione-S-Transferase 
(GST) tag which allows easy purification through the GST purification module. The 
cDNA for Rhotekin (the part that binds to active Rho) was used to pull down active Rho. 
Similarly the Rac binding domain of PAK (Rac effector) is used to pull down active 
fractions of Rac. 
2.2.15.1. Preparation of the binding domain 
The pGEX plasmids harboring the cDNA for the binding domains were transformed into 
the E.coli strains BL21-DE3. In brief, 50 ml of overnight culture was inoculated into 
500 ml Luria Broth containing ampicillin. When the culture had reached an OD600nm of 
0.7, it was induced with 0.1 mM IPTG (isopropyl-beta-D-thiogalactopyranoside) and 
incubated at 37oC for additional 5 hours. The bacterial cells were then pelleted and 
resuspended in approximately 8.0 ml of TBN150 with protease inhibitors. The bacteria 
were lysed by freezing and thawing thrice and by incubation with 5 mg of lysozyme for 
20 min at RT. 280 µl of 500 mM EDTA and 350 µl of 10% Triton X-100 were then 
added and incubated at RT for further 20 min, after which it was centrifuged at 30,000 
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rpm at 4oC for 30 min. The supernatant was mixed with 1.0 ml of Glutathione Sepharose 
(GSH) beads pre-equilibrated with TBN 150 and incubated in a rotary wheel at 4oC for 
one hour. Washing was initially done twice with 10.0 ml of TBN 150 containing 1% 
Triton X-100 followed by washing twice again with EQM buffer. The binding domains 
were finally eluted from the bound GSH beads with 10.0 ml of EQL buffer. The eluate 
was finally concentrated (Amicon Ultra, Millipore, Eschborn, Germany, Cat. No. 
UFC801008), dialysed against PBS overnight and frozen in aliquots at -80oC. 
2.2.15.2. Pull downs 
In brief, 500,000 cells/5.0ml/6.0 cm dishes were seeded and allowed to grow for 2-3 
days. Starvation was done overnight after which the cells were stimulated for the 
indicated time periods. Lysis buffer “C” was used to lyse the cells for performing pull 
down of active Rho / Rac GTPases. Generally, cells were lysed in 1.0 ml of ice cold lysis 
buffer containing the corresponding binding domains (25 µg/ml) and GDP (100 µM) and 
centrifuged at 14,000 rpm at 4oC for 15 min. The supernatants were then mixed with 
40 µl of GSH-sepharose beads pre-equilibrated with lysis buffer. It was incubated in a 
rotary wheel for 30 min at 4oC. The beads were washed twice with the same lysis buffer 
and eluted with 30 µl of 2 x gel loading buffer as described for immunoprecipitation. 
2.2.16. Half-life Determination 
Pulse chase method: HEK 293 cells were transiently transfected with cDNA encoding 
DEP-1 WT using calcium phosphate. Cells were washed twice with PBS after which they 
were starved. Starvation was carried out using a special DMEM medium devoid of L-
glutamine, sodium pyruvate, L-methionine and L-cysteine (Gibco, Invitrogen, Karlsruhe, 
Germany, Cat. No. 21013-024). This medium was supplemented with 1 mM pyruvate 
and 2 mM glutamate and thus cells were starved only for cysteine and methionine. 
Starvation was carried out at 37oC for one hour. The cells were then pulsed for 3 hours 
with 200 µCi/ml of 35S (Redivue PRO-MIX Cell Labelling Mix, Hartmann Analytik, 
Braunschweig, Germany, Cat. No. AGQ0080) and contains both L-[35S] methionine and 
L-[35S] cysteine with a specific activity of 37 TBq/mmol (1000 Ci/mmol). Three hours 
later, the radioactive medium was collected, and the cells were washed with PBS 
followed by replacing with fresh, non-radioactive medium (referred to as “chase”). For 
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chasing, the same media supplemented not only with 1 mM pyruvate and 2 mM 
glutamate but also supplemented with 0.2 mM cysteine and 0.1 mM methionine was 
used. Thereafter, at the specified time points, the cells were washed with PBS and lysed 
in 300 µl of ice-cold lysis buffer. IP was performed with anti-DEP-1 antibody and the 
immunoprecipitates were separated with 7.5% polyacrylamide gel. The gel was first 
stained with Coomassie followed by soaking in Intensify A and then Intensify B (Du 
Pont, Perkin Elmer, Rodgau Jügesheim, Germany) for 45 min each. The gel was finally 
dried and the resulting fluorographic signals were detected by exposure to X-ray film 
with an intensifying screen for a week at -80oC. The resulting images were scanned and 
densitometric analyses were performed with NIH image software. 
2.2.17. shRNA Cloning 
The pSuper.retro.puro vector (Oligoengine, Seattle, USA) was double digested with 
Hind III and Bgl II and the ends were dephosphorylated as described before and purified 
through a low melting agarose gel (S.N.A.P Gel Purification Kit, Invitrogen, Karlsruhe, 
Germany, Cat. No. K1999-25). The 64-mer oligos were annealed as described by the 
manufacturer. In brief, the oligos were dissolved in water to a concentration of 3 mg/ml. 
An annealing mixture containing 1 µl of each oligo, 10 µl of 5 x annealing buffer 
(100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4 and 2 mM magnesium acetate) 
and 38 µl of water were prepared. It was incubated at 95oC for 4 min and cooled down 
slowly to 25oC. The annealed oligos were then precipitated with sodium acetate and 
isopropanol, and dissolved in TE buffer. They were phosphorylated with polynucleotide 
kinase (PNK) (Roche Diagnostics, Mannheim, Germany) in the presence of PNK buffer 
containing 1 mM ATP by incubating them at 37oC for 30 min. The enzyme was then heat 
inactivated by incubation at 70oC for 10 min. The annealed, phosphorylated oligos were 
then ligated with digested vector using DNA ligase as described before except that 
ligation was carried out for one hour at RT. The ligated mixture was transformed into 
competent E.Coli XL1Blue cells. Plasmids were extracted and double digested with 
EcoRI and Hind III to check for the inserts. 
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2.2.18. Retroviral Infection 
Phoenix-Ampho cell lines were used for the generation of helper free amphotropic 
retroviruses. Phoenix is based on the 293T cell line which is engineered to harbor three 
essential retroviral genes - group-specific antigen (gag), polymerase (pol) and envelope 
(env). Briefly, phoenix cells were transfected with the shRNA constructs (construct 441 
and the non-targeting control) using calcium phosphate. After transfecting, the cells were 
moved to a Safety Level 2 (S2) incubator. In parallel, the target cells (HT 29) were also 
seeded for infection (2 x 105 cells/well/24 well plate).) 24 h after the transfected cells 
became confluent, viruses were collected (along with the medium). The medium was 
either centrifuged or filtered (0.45 µM) in order to remove any swimming cells. The 
resulting viral supernatants were now used to infect the target cells (HT 29) along with 
polybrene (10 µg/ml). Medium was changed after 4-6 h of incubation as polybrene is 
toxic for the cells. The next day, a similar second round of infection was performed to 
attain the maximum efficiency of infection. The cells were then brought back to Safety 
Level 1 (S1) incubator and two days later, they were selected with the antibiotic 
puromycin (2 µg/ml). The resistant cell pools were further expanded and checked for 
their suppression. 
2.2.19. Phospho RTK Array 
This technique allows to simultaneously identifying the relative levels of phosphorylation 
of 42 different RTKs. An array of antibodies to 42 RTKs, spotted on a nitrocellulose 
membrane was purchased from R & D Laboratories (Wiesbaden, Germany, Cat. No. 
ARY001). Probing of the membranes was done according to the protocol of the 
manufacturer. In brief, sub-confluent dishes of cells were starved overnight followed by 
stimulation with FBS for 15 min. The cells were lysed in lysis buffer (1% NP-40, 20 mM 
Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium 
orthovanadate, 200 KIE/ml Aprotinin and 10 µg/ml Leupeptin) and placed in a rotary 
wheel at 4oC for 30 min. The mixture was then centrifuged, and the supernatant was 
collected. Equal amounts of supernatant (around 70% of the cell lysates) were applied on 
blocked membranes and incubated overnight at 4oC. The membranes were washed thrice 
(10 min each) in the wash buffer provided. Anti phospho-tyrosine antibody (dilution of 
1:2000) coupled to HRP was added, and incubated for additional two hours. The arrays 
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were finally washed thrice followed by exposing them to chemiluminiscent reagents and 
the resulting signals were scored on films. 
2.2.20. Treatment with Different Nutrient Components 
A freeze dried polyphenol extract from a mixture of table apples (designated AE) was 
kindly provided by Dr. F. Will (Research Institute Geisenheim, Germany). For cell 
treatments, the lyophilisate was freshly dissolved in medium and sterile filtered. A green 
tea extract (GT) was kindly provided by Kampffmeyer Food Service GmbH (Hamburg, 
Germany). Subconfluent cultures of colon cells (HT 29, CaCo2 and LT 97) were either 
left untreated or were treated for 72 h with 2 mM sodium butyrate, apple polyphenol 
extract (AE) at a concentration equivalent to 25 µM phloridzin or green tea (GT) at a 
concentration equivalent to 20 µM epigallocatechine-3-gallate. The cells were lysed and 
IP was performed with anti-DEP-1 antibody as described earlier. Lysate aliquots were 
analysed for actin levels as input control. In addition, LT 97 cells were also treated with 
different concentrations of apple polyphenol extract (concentrations equivalent to 0, 1, 
2.5, 15 or 25 µM phloridzin) for 72 h and DEP-1 expression was again determined by 
immunoprecipitation. 
2.2.21. Real Time PCR 
This technique allows monitoring the relative mRNA levels of genes. Subconfluent 
LT 97 cells were treated as described above and total RNA was extracted with RNeasy 
kit (Qiagen, Hilden, Germany). The RNA concentration was measured using 
spectrophotometer (ND-1000, Nanodrop, Peqlab Biotechnology, Erlangen, Germany). 
2 µg of RNA was used to synthesize cDNA using Superscript First-Strand Synthesis 
System for RT-PCR (Invitrogen, Karlsruhe, Germany, Cat. No. 11904-018) as instructed 
by the manufacturer. The cDNA was subjected to real-time-polymerase chain reaction 
using an iCycler and iQ SYBR Green Supermix (BioRad, Munich, Germany, Cat. No. 
170-8884) detection as instructed by the manufacturer using the following conditions. 
Values were normalized to glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) -
mRNA detected in the same samples. 
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Conditions for Real Time PCR: 
Cycle 1: (1x) Initial denaturation 
 Step 1:   95.0ºC 2 min. 
 
Cycle 2: (40x) Amplification 
 Step 1:   95.0ºC 35 sec. 
 Step 2:   60.0ºC 30 sec. 
 Step 3:   72.0ºC 40 sec. 
 
Cycle 3: (1x) Final Extension 
 Step 1:   72.0ºC 10 min. 
 
Cycle 4: (80x) Denaturation (melting curve analysis) 
 Step 1:   55.0ºC 10 sec. 
 
Cycle 5: (1x) Pause 
 Step 1:    4.0ºC infinite 
 
For human DEP-1:  Forward primer: 5’-TCGTTCGTGACTACATGAAGCA-3’ 
Reverse primer: 5’-CCCCAGCACTGCAATGC-3’ 
For human GAPDH:  Forward primer: 5’-CCCATGTTCGTCATGGGTGT-3’ 
   Reverse primer: 5’-TGGTCATGAGTCCTCCACGATA-3’ 
 
Animal experiments were performed elsewhere and the RNA samples were kindly 
provided by Dr. Stefan W. Barth (Karlsruhe, Germany). Briefly, rats were fed with apple 
juice. Water was used as the control. One group of animals was also injected with the 
carcinogen DMH or sodium chloride as the control. The mucosa was scraped, and total 
RNA was isolated from these tissues. cDNA synthesis and Real Time PCR were done as 
before, except that rat-specific primers were used. Primer sequences for the rat genes and 
conditions for Real Time PCR were kindly provided by Dr. Kai Kappert, Cancer Centre, 
Karolinska, Stockholm, Sweden. Hypoxanthine-guanine phosphoribosyl transferase 
(HPRT) was used to normalize the values instead of GAPDH. 
 
For rat DEP-1: Forward primer: 5’-TTTTGAAGCCAGCCATGGA-3’ 
Reverse primer: 5’-GTGGAGGTTGGCCAGCT-3’ 
For rat HPRT:  Forward primer: 5’-CTCATGGACTGATTATGGACAGGAC-3’ 
   Reverse primer: 5’-GCAGGTCAGCAAAGAACTTATAGCC-3’ 
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3. Results 
3.1. Characterisation of Density Enhanced 
Phosphatase-1 (DEP-1) 
3.1.1. Analysis of Endogenous DEP-1 Levels in Colon Epithelial Cell 
Lines 
Genetic analysis has shown allelic loss of the DEP-1 encoding gene PTPRJ in cases of 
human colon cancer. However, little is known about DEP-1 protein expression in colon 
cancer cells. We therefore analysed a panel of colon epithelial cell lines (including one 
adenoma cell line, LT 97) for DEP-1 protein expression. Cells from one confluent 75 cm2 
flask each were subjected to immunoprecipitation (IP) with anti DEP-1 antibody, 
followed by immunoblotting. As shown in Fig. 3.1a, expression in the analysed cell lines 
varies from relatively high levels in LT 97 adenoma cells and HT 29, DLD-1, HCT-16, 
COGA-1 and COGA-12 colon carcinoma cells, to relatively low levels in LOVO, Colo-
320, COGA-2 and COGA-3 cells, and no detectable DEP-1 protein expression in SW 480 
cells. Interestingly, the relatively abundant DEP-1 expression in the adenoma cell line LT 
97 may reflect its resemblance to normal tissue. Overall, DEP-1 expression is rather 
heterogeneous, and low levels of DEP-1 are not a uniform feature of colon cancer cells. 
       
      Fig. 3.1a 
Fig. 3.1a Expression of DEP-1 in different colon adenoma or carcinoma cell lines. 
All cell lines were grown to confluence, and lysates each from a 75 cm2 flask were 
subjected to DEP-1 immunoprecipitation and immunoblotting. Lysate aliquots were 
subjected to immunoblotting for β-actin to compare inputs. 
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We then performed RT-PCR to know whether the cell line with no detectable protein 
expression, SW 480, also lacked DEP-1 at the level of mRNA. Fig. 3.1b shows the 
presence of mRNA for DEP-1 in this cell line SW 480. Nevertheless, this particular cell 
line SW 480 (as it lacks DEP-1 protein) was chosen for further studies. Re-expression of 
DEP-1 in these cells should reveal the functional consequences of DEP-1 expression. 
 
  Fig. 3.1b 
Fig. 3.1b Detection of mRNA in the colon cancer cell lines. 
2 x 106 cells were seeded in 6 well plates and lysed. Total RNA was extracted and then 
cDNA was synthesized. RT-PCR was then performed to detect the presence of DEP-1 
mRNA. 
3.1.2. Density Dependent Upregulation 
DEP-1 has been named “Density-Enhanced Phosphatase” based on its upregulation in 
dense cultures of human embryonic lung fibroblasts (WI-38) and foreskin fibroblasts 
(AG1518) (Ostman, Yang et al. 1994). It was unknown whether the density-dependent 
upregulation also applied to colon epithelial cells. 
 
Fig. 3.2 
Fig. 3.2 Density dependent upregulation of DEP-1 protein in HT 29. 
Cells were seeded at different densities (see Methods) and were lysed the following day. 
Immunoprecipitations were performed to detect the presence of DEP-1. Loading controls 
were performed by immunoblotting an equivalent amount of lysates against vinculin. 
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The density dependent upregulation of DEP-1 was therefore tested in the cell line HT 29. 
Cells were seeded at different densities (as described in Methods) and lysed the following 
day.From Fig. 3.2, it is clear that the level of this protein increases upon increase in cell 
density or as cells approach confluence 
3.1.3. Half-life Determination 
Half-life is one of the characteristic properties and determines the stability of any protein. 
Since there was a difference in DEP-1 levels between the sparse and dense cells, we 
speculated whether changes in half-life might contribute to the observed differences in 
protein levels. Also it is advantageous to know the half-life of the protein, when working 
with short interfering RNA (siRNA) molecules. The siRNA molecules target only 
mRNA, whereas the protein already present should be degraded in order to see any 
downregulation at the protein level. Therefore we were interested in determining the half-
life of DEP-1 and the pulse-chase labelling technique was used for this purpose. Cells 
were radioactively pulsed with a 35S-labelled mixture of cysteine and methionine for 3 h 
followed by chasing for different time points. Initially, this approach was attempted with 
endogenous DEP-1 in HT 29 cells. Due to relatively low labelling of DEP-1 and high 
background, this system was not successful. Therefore, transiently transfected HEK 293 
cells were used instead. From Fig. 3.3, it is clear that the half-life of DEP-1 in these cells 
is around 12 - 13 hours. 
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Fig. 3.3 Half-life determination of DEP-1. 
HEK 293 cells were transiently transfected with a cDNA encoding the DEP-1 WT. The 
cells were starved in Cys/Met free medium for one hour after which they were pulsed 
with a medium containing 35S labeled Cys/Met for three h. Thereafter, the radioactive 
medium was replaced with non-radioactive medium with all the supplements (“chase”). 
Cells were then lysed at the indicated time points. Lysates were subjected to IP and 
separated in a SDS-PAGE. The levels of remaining radioactive DEP-1 at each time point 
were detected by fluorography. The total DEP-1 protein present at the beginning of the 
chasing time point (zero hour) was considered as 100% and the graph was plotted 
accordingly. 
This shows that DEP-1 is a relatively stable protein as the half-life is considerably long. 
This experiment was performed with transiently transfected cells under subconfluent 
conditions. However, from this experiment we cannot draw any conclusion about its half-
life in sparse and dense cells. 
3.2. Characterisation of DEP-1 WT/CS Re-Expressing 
Cell Lines 
3.2.1. Cloning of DEP-1 WT / C1239S in pNRTIS 21 and Generation of 
Stable Cell Lines 
As the initial screening revealed a cell line (SW 480) negative for DEP-1 protein 
expression, we then aimed to re-express either DEP-1 WT or the catalytically inactive 
C1239S variant in these cells and then to analyse the resulting phenotypes. Previous work 
in fibroblast cell lines in our laboratory employed DEP-1 constructs in the tetracycline-
regulatable vector pNRTIS 33. For the experiments described here, we subcloned the 
cDNA for DEP-1 WT or CS from the vector pNRTIS 33 into pNRTIS 21. Both these 
vectors possess a tetracycline regulated promoter which allows turning off the gene of 
interest by just adding anhydrotetracycline (Atc) to the growth media. The vector 
pNRTIS 33 is tricistronic and contains the genes for the tetracycline-repressed 
transactivator (tTA), the gene of interest (DEP-1) and the neomycin resistance gene, all 
under the tTA-responsive promoter. Thus, positive cell clones can only be selected in the 
induced or expressed state. This may lead to failure of the selection of cell clones with 
phenotypes “adapted” to DEP-1 expression. pNRTIS 21 is bicistronic for tTA and the 
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gene of interest (i.e., DEP-1), whereas the neomycin expression cassette is under a 
separate SV-40 promoter. This allows the screening of clones in the absence of any target 
gene expression and hence was preferred. The sub-cloning was carried out successfully 
(see Methods), and the resulting constructs (shown in Appendix) were stably transfected 
into SW 480. Fig. 3.4a shows the generation of stable, inducible DEP-1 WT or CS re-
expression. As expected, the target gene is completely repressed in the presence of Atc 
and expressed without any Atc. Fig. 3.4b shows the phosphatase assay of the lysates of 
resulting clones. Significant activity was detected only when DEP-1 WT is expressed. 
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Fig. 3.4 Expression of DEP-1 in SW 480 cells stably transfected with DEP-1 WT and 
CS variants. 
Fig. 3.4a Stably transfected clones (both WT and CS) were seeded with and without Atc 
(150 ng/ml) and grown for four days. The cells were then lysed (in the absence of sodium 
orthovanadate) and the lysates were immunoblotted against DEP-1 to detect its 
expression levels. Detection of total Erk½ was used as a loading control. 
Fig. 3.4b 5% of the same lysates were used for the pNpp assay to detect the phosphatase 
activity of both these WT and CS clones. 
Thus, both the wild type and catalytically inactive forms of DEP-1 can be stably and 
inducibly re-expressed in the cell line SW 480. Moreover, considerable phosphatase 
activity was detected in lysates only when the wild type is expressed. 
3.2.2. Cell Sorting 
In general, DEP-1 expression was induced in these clones by culturing the cells without 
Atc for four days. However, some cells (particularly in later passages) failed to induce 
DEP-1 expression upon removal of Atc, as was evident from immunostaining (Fig. 3.5). 
Hence, we decided to enrich those cells that do re-express DEP-1 after induction. For this 
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purpose, we employed a simple technique called MACS (Magnetic Assisted Cell 
Sorting). When indicated, the assays described below were performed after MACS 
enrichment for DEP-1 expressing cells. If no purification is indicated, the assays were 
performed without prior enrichment but earlier passages were utilized. 
 
Fig. 3.5 
Fig. 3.5 Separation of DEP-1 expressing from the non-expressing cells. 
SW 480 cells expressing the DEP-1 WT were cultured in the absence of Atc for four days 
for complete induction. Cells were then trypsinized and sorted using MACS (see Methods 
for details). Immunostaining was performed with FITC labelled anti DEP-1 antibody 
(green channel). Nuclei were stained with DAPI (blue channel). Both the cells before 
purification (left panel) and after purification (middle and right panel) are shown. DEP-1 
expressing cells in the mixed cultures (left panel) are indicated by white arrows. After 
MACS purification homogenous cultures of DEP-1 expressing (right panel) or non-
expressing (middle panel) were obtained. 
Thus, pure and homogenous cultures of either DEP-1 expressing and non-expressing cells 
can be obtained after sorting with MACS. 
3.2.3. Proliferation 
For thyroid, pancreas and glioma cell lines, DEP-1 re- or over-expression has been shown 
to lead to growth inhibition. For fibroblasts, controversial results have been obtained. 
NIH 3T3 clones did not exhibit reduced growth upon induction of DEP-1 expression 
using the pNRTIS 33 system (Jandt, Denner et al. 2003). In order to know whether the re-
expression of DEP-1 confers some growth disadvantage to the colon carcinoma cells, 
proliferation assays were performed. With the derived SW 480 clones, cell proliferation 
in presence of wild-type DEP-1 was clearly reduced as compared to cells with suppressed 
DEP-1 expression (Fig. 3.6a). Inducible expression of the catalytically inactive DEP-1 
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CS variant had however, no effect on proliferation (Fig. 3.6b), establishing that DEP-1 
PTP activity is required for the observed anti-proliferative effect. In the case of DEP-1 
WT, proliferation data with prior enrichment of DEP-1 expressing cells is also shown 
revealing an even more dramatic growth inhibition (Fig. 3.6c). 
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Fig. 3.6c 
Fig. 3.6 DEP-1 WT inhibits proliferation of colon cancer cells. 
Fig. 3.6a SW 480 clones of DEP-1 WT were seeded in a 6 well plate (100,000 
cells/2.0ml/well). They were grown with (designated “off”) and without Atc (designated 
“on”) for the respective days after which they were trypsinized and counted using a cell 
counter. Assays were always performed in triplicates (mean values + s.d., are shown). 
Fig. 3.6b Assays were carried out as described above except that clones of SW 480 
expressing  DEP-1 CS variants were used. 
Fig. 3.6c Proliferation assay (as described above) of the same DEP-1 WT variant, but 
only DEP-1 expressing cells after sorting with MACS was analysed. 
Taken together, DEP-1 is anti-proliferative for the analysed colon carcinoma cells and 
this effect depends on its catalytic activity. 
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3.2.4. Migration 
DEP-1 is a transmembrane phosphatase with eight fibronectin repeats at the extracellular 
side. Such motifs suggest its possible participation in cell-matrix adhesion / migration 
and related signaling mechanisms. Probably in relation to this, effects of DEP-1 on the 
migration and adhesion of cells have been shown in other cell types. In order to explore 
similar functions of DEP-1 in the colon epithelial cells, we subjected the DEP-1 re-
expressing SW 480 cells to two different types of cell migration assays. 
3.2.4.1. Wound healing assays 
Wounding assays were performed in the presence of fetal bovine serum (FBS). The re-
expression of DEP-1 wild-type led to a clear reduction in cell migration (Fig. 3.7). 
Fig. 3.7a shows examples for the microscopic observation of the cell migration in 
SW 480 cells expressing DEP-1 WT. Pictures were made immediately after wounding 
(0 h) and also at the completion of the assay (after 24 h). These assays clearly revealed 
that the expression of DEP-1 strongly inhibits cellular migration. Five random fields were 
also quantified and the results are shown in Fig. 3.7b. Inhibition of cell migration was 
highly significant. In contrast, the DEP-1 CS mutant had no effect on cell migration 
(Fig. 3.7c). Inhibition of cell migration, thus, also depends on DEP-1 PTP activity. 
         
Fig. 3.7a 
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Fig. 3.7b     Fig. 3.7c 
Fig. 3.7 DEP-1 WT inhibits migration of colon cancer cells in wound healing assays. 
Fig. 3.7a Early passages of DEP-1 wild-type-expressing cells in the induced (on) or 
repressed (off) state were seeded in 6 well plates, allowed to grow to confluence and 
starved overnight. The cell layer was wounded by scratching with a sterile 1.0 ml pipette 
tip. Medium containing 10% fetal bovine serum was added and the plates were incubated 
for further 24 h. 
Fig. 3.7b Quantification of five different positions in three wounding experiments (mean 
values+ s.d., ***P<0.001 by t-test). 
Fig. 3.7c Same experiment as in 3.7a and 3.7b, but using DEP-1 CS-expressing cells. 
Only the quantification is shown. 
Thus, the expression of DEP-1 WT in SW 480 clearly inhibited migration in wound 
healing assays. 
3.2.4.2. Transwell assays 
Since wounding assays were performed over a period of 24 h, cell proliferation may 
contribute to repopulation of the wound. To exclude the effects of proliferation, we 
therefore also conducted a different type of migration assay with the modified Boyden 
chamber system. These assays were scored after 6 h, excluding a contribution of 
proliferation to the observed inhibiton of migration. Consistent with the results in the 
wounding assays, wild-type DEP-1 re-expression significantly reduced migration towards 
FBS (Fig. 3.8a), whereas DEP-1 CS apparently had no effect on it (Fig. 3.8b). 
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Fig. 3.8a     Fig. 3.8b 
Fig. 3.8 DEP-1 WT, but not CS inhibits migration of colon cancer cells in transwell 
assays. 
 Fig. 3.8a Early passages of DEP-1 wild-type-expressing cells in the induced (on) or 
repressed (off) state were seeded on top of a collagen-coated membrane with 8 µM pore-
size and cells migrating to the bottom side (media containing 10% FBS) were scored 
after 6 h by staining with crystal violet and counting in the microscope. Five different 
fields randomly chosen were counted and quantified (mean values+s.d., **P<0.01 by t-
test). 
Fig. 3.8b Same experiment as in Fig. 3.8a except that DEP-1 CS-expressing cells were 
used. 
Since re-expression of DEP-1 inhibits migration significantly in wound healing as well as 
transwell assays, the anti-migratory role of DEP-1 is firmly established. 
3.2.4.3. Effect of various motogens 
In order to explore whether the anti-migratory effect of DEP-1 depends on the motogen, 
it is mandatory to know the responsiveness of this cell line (SW 480) towards a range of 
motogens. Hence, several common motogens including lysosphosphatidic acid (LPA), 
sphingosine-1-phosphate (S1P), Stromal Cell Derived Factor - 1 alpha (SDF-1α) and 
Hepatocyte Growth Factor (HGF) were tested in wounding assays and their migratory 
potential was scored. As depicted in Fig. 3.9, LPA at a concentration of 10 µM stimulated 
migration nearly as efficient as FBS whereas the other potential motogens did not reveal 
any migratory response. 
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Fig. 3.9 
Fig. 3.9 Effects of various motogens on the migration of SW 480 cells. 
The parental cells SW 480 were seeded in a 6 well plate and allowed to grow to 
confluence. Wounding assays were performed as described in Fig 3.7a. Following 
scratching, the cells were stimulated with various motogens at the indicated 
concentrations. 24 h later their migratory response was scored. 
Thus, LPA can also be employed as a motogen in these SW 480 cell lines which will 
further shed more light on the anti-migratory role of DEP-1. 
LPA as a motogen for cellular migration 
Since LPA at a concentration of 10 µM stimulated cell migration in the SW 480 cell line, 
transwell migration assays were performed to determine the effect of DEP-1 WT or CS 
expression on LPA stimulated migration. When stimulated with 10 µM LPA, the re-
expression of DEP-1 WT profoundly inhibited migration (Fig. 3.10a) whereas the CS 
mutant had no effect (Fig. 3.10b). 
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 Fig. 3.10a     Fig. 3.10b 
Fig. 3.10 DEP-1 WT inhibits also migration stimulated by LPA. 
Fig. 3.10a Transwell assays were carried out as described in Fig. 3.8a except that 10 µM 
LPA in RPMI was used as motogen (mean values+s.d., ***P<0.001). 
Fig. 3.10b Similar assays as in Fig. 3.10a except that DEP-1 CS expressing clones were 
used. 
HGF as a motogen for cellular migration 
Hepatocyte Growth Factor (HGF), popularly referred to as “scatter factor”, is an 
established motogen in several cellular systems. Even though HGF did induce migration 
in these cell lines under investigation, the extent of migration induced was less than that 
induced by FBS or LPA (not shown). When HGF (50 ng/ml) was used as a motogen in 
wound healing assays, the re-expression of DEP-1 again significantly inhibited the 
migration (Fig. 3.11). 
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Fig. 3.11 
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Fig. 3.11 DEP-1 WT inhibits migration stimulated by HGF. 
Early passages of SW480 cells expressing the DEP-1 WT in the induced (on) or 
repressed (off) state were seeded in 6 well plate and wound healing assays were 
performed as described earlier in Fig. 3.7a. 50 ng/ml of HGF was used as motogen and 
24 h later, five randomly chosen fields were counted and quantified (mean values +s.d., 
**P<0.01). 
In conclusion, DEP-1 inhibits the migration of cells, not only stimulated by FBS but also 
the one stimulated by LPA and HGF. This effect depends on its catalytical activity. 
3.2.5. Adhesion 
The effect of DEP-1 in cell migration could possibly be linked to altered adhesion of the 
cells to the extracellular matrix. For NIH 3T3 fibroblasts and PAE cells, enhanced 
adhesion as a consequence of DEP-1 expression has been shown (Jandt, Denner et al. 
2003). In order to test this hypothesis, adhesion assays were carried out in two different 
ways. With the first method, we checked whether the cells re-expressing DEP-1 can 
attach faster than their non-expressing counterparts. As shown in Fig. 3.12a, there was no 
difference in the adhesion rate of the cells towards the extracellular matrix. With the 
second method, we scored the detachment rate of cells from the substratum either by 
simply washing off the cells with Ca2+ and Mg2+ free PBS alone, or in combination with a 
mild proteolytic treatment using Accutase. Consistent with the first method, again there 
was no difference in the detachment rate of the cells either by PBS alone (not shown) or 
in combination with Accutase (Fig. 3.12b). 
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Fig. 3.12 DEP-1 WT does not play any role in cell-matrix adhesion. 
Fig. 3.12a Early passages of SW 480 cells expressing DEP-1 WT were grown either in 
the presence or absence of Atc for four days. They were trypsinized and kept in 
suspension for 30 min. The cells were then seeded in collagen coated 96 well plates. At 
the indicated time points, non-adhered cells were removed and the adhered cells were 
quantified by staining with crystal violet as described in Methods. The maximum 
attachment of DEP-1 WT non-expressing cells reached after 4 h was considered as 
100%. 
Fig. 3.12b SW 480 cells expressing DEP-1 WT were grown without Atc for four days and 
were purified using MACS. The resulting DEP-1 expressing and non-expressing cells 
were seeded in 24 well plates (without and with Atc respectively) and allowed to grow for 
additional two days. After that, the cells were washed once with PBS followed by 
detaching them with Accutase. At the indicated time points, detached cells were washed 
away and the remaining adherent cells were scored as describe above. Cells that were 
attached to the substratum before the beginning of the assay (at time - 0 min) were 
considered as 100%.  
Thus, the re-expression of DEP-1 does not play any role in adhesion at least in the cell 
lines investigated. 
3.2.6. Immunostaining 
The cells re-expressing DEP-1 WT, when viewed under the microscope were larger and 
exhibited a more flattened morphology than their non-expressing counterparts. In 
addition, DEP-1 mediated cytoskeletal changes were proposed in the case of fibroblasts 
(Kellie, Craggs et al. 2004). To evaluate possible cytoskeletal rearrangements in the 
DEP-1 expressing SW 480 colon epithelial cells, we stained the cells with fluorescently 
labelled phalloidin which stains the filamentous actin. 
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       Fig. 3.13 
Fig. 3.13 Effect of DEP-1 expression on actin cytoskeleton. 
Phalloidin staining of SW 480 cells either expressing (on) or non-expressing (off) wild 
type DEP-1. Cells were seeded on collagen coated coverslips and staining was carried 
out as described in the Methods. Cells were stained with anti DEP-1 antibodies followed 
by DTAF-labelled anti mouse-IgG (green channel), TRITC-labelled phalloidin for 
staining of actin (red channel), and DAPI to visualize nuclei (blue channel). Upper 
panel: Cells that do not express DEP-1 (off).  Lower panel: Cells expressing wild-type 
DEP-1 (on). 
From Fig. 3.13, it is clear that the DEP-1 re-expressing cells (on) exhibit a different 
distribution of filamentous actin, typically characterized by cortical actin bundles in 
proximity to the cell periphery. On the other hand, there was no such organized actin 
bundles when DEP-1 is not expressed (off). Fig. 3.14 shows a magnified image clearly 
illustrating the bundling of filamentous actin due to re-expression of DEP-1 in SW 480 
cells. 
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   Fig. 3.14 
Fig. 3.14 A magnified view of SW 480 cells expressing DEP-1 WT and stained with 
phalloidin. 
Same cells as described in Fig. 3.13, but a magnified image of only DEP-1 WT 
expressing cells stained with phalloidin is shown. This clearly reveals the presence of 
peripheral actin bundles (white arrows). 
Given the migratory phenotype and the striking cytoskeletal changes, we expected also a 
possible differential distribution of the molecules involved in focal adhesion or focal 
complexes. There are several molecules in these focal complexes that are critical for 
migration. Molecules such as vinculin, talin, paxillin, p120 catenin, α-actinin as well as 
focal adhesion kinase (FAK) are either directly or indirectly connected to the actin 
cytoskeleton. In brief, following integrin engagement to the extracellular matrix, c-Src is 
activated and simultaneously focal adhesion kinase (FAK) is also recruited. This results 
in the phosphorylation of paxillin which can then activate the small GTPase Rac. The 
interplay between these above mentioned molecules is important in deciding the 
migratory phenotype of the cell. Hence immunostaining was performed for a few of them 
such as vinculin and paxillin. Since DEP-1 expressing cells exhibited 
hyperphosphorylation of paxillin (as revealed in immunoblotting - see below), we have 
also stained the cells for phospho-paxillin. As shown in Fig. 3.15, in the case of DEP-1 
WT re-expressing cells, the molecules involved in focal adhesion were strongly 
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concentrated only at certain regions of the membrane. But in their non-expressing 
counterparts, at least vinculin and paxillin were distributed throughout the membrane. 
 
Fig. 3.15 
Fig. 3.15 Effect of DEP-1 expression on distribution of vinculin, paxillin and phospho 
paxillin.  
SW 480 cells expressing DEP-1 WT were purified through MACS and seeded on collagen 
coated coverslips. Staining was carried out with antibodies directed against vinculin (top 
panel), paxillin (middle panel) or phospho paxillin (lower panel). This was followed by 
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the addition of either rabbit or mouse secondary antibody (cy 3 labelled) which was 
visualized using the red channel. Nuclei were stained with DAPI (blue channel). Left 
panel: Cells that do not express DEP-1 (off).  Right panel: Cells expressing wild-type 
DEP-1 (on). Clustering of the molecules is indicated with white arrows. 
Taken together, the re-expression of DEP-1 led to strong re-arrangements of actin 
cytoskeleton, associated with clustering and presumably activation of focal adhesion 
complexes, indicated by presence of phospho-paxillin. 
3.2.7. Apoptosis Assay 
DEP-1 has been proposed as a tumor suppressor protein. One known function of some 
tumor suppressors is to sensitize the cells towards apoptosis. In a very recent siRNA 
screen, the effects of depletion of kinase and phosphatase expression on apoptosis 
induced by cytotoxic drugs such as cisplatin, taxol and etoposide were analysed. In this 
screen using HeLa cells, DEP-1 was scored as an apoptosis-promoting protein 
(MacKeigan, Murphy et al. 2005). We therefore wondered whether re-expression of 
DEP-1 in colon epithelial cells can also have a role in apoptosis regulation. Apoptosis 
was induced using staurosporine, and ELISA based assays were performed. From Fig. 
3.16a, it is clear that the re-expression of DEP-1 WT rendered the cells more apoptotic 
whereas the catalytically inactive DEP-1 mutant had no effect (Fig. 3.16b). 
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Fig. 3.16 DEP-1 WT sensitizes the cells towards apoptosis. 
Fig. 3.16a DEP-1 WT expressing SW 480 cells were cultured in the absence of Atc for 
four days and purified with MACS. DEP-1 non-expressing and expressing cells were then 
seeded in 24 well plates and treated with the indicated concentrations of staurosporine 
for four h. They were then lysed and lysates corresponding to 1 x 103 cells were used for 
and apoptosis detecting ELISA (see Methods). The color development was measured at 
405 nm. Apoptosis induction by 1 µM Staurosporine in the DEP-1 expressing cells was 
considered as 100%. 
Fig. 3.16b SW 480 cells expressing DEP-1 CS were used and similar assays were carried 
out as described in Fig. 3.16a. 
These experiments show that the sensitization of the cells towards apoptosis also depends 
on its catalytical activity as only in wild type expressing cells apoptosis is promoted. It 
seems therefore likely, that one or more DEP-1 targets in the SW 480 cells have an anti-
apoptotic function. 
3.3. Signaling Mechanisms Evoked by Re-Expression of 
DEP-1 in SW 480 Cells 
3.3.1. Phosphorylation Status of Paxillin, FAK and PLCγ – Molecules 
Involved in Migration 
Since there was a strong inhibition of migration which is also associated with changes in 
the distribution of focal adhesion molecules, the phosphorylation status of proteins 
involved in focal adhesion proteins was analysed. As shown in Fig. 3.17a, the cells re-
expressing DEP-1 WT exhibited a strong hyperphosphorylation of paxillin at Tyr118. In 
sharp contrast, DEP-1 re-expression led to nearly complete dephosphorylation of PLCγ at 
Tyr783. In the case of Focal Adhesion Kinase (FAK), site specific hyperphosphorylation 
was detected at Tyr408, Tyr861 and Tyr925 whereas other sites (Tyr566 and Tyr567) failed to 
reveal any significant changes (Fig. 3.17b). Analysis of the phosphorylation status of c-
Src kinase revealed a small increase of phospho-tyrosine in the activation loop (Tyr418) 
whereas no significant dephosphorylation at the inhibitory site (Tyr529) was evident 
(Fig. 3.17c). It should be noted that in all the cases, even though the cells were stimulated 
with FBS, all described changes evoked by DEP-1 re-expression were also evident in 
unstimulated cells. Moreover, none of these changes were revealed in cells expressing the 
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catalytically inactive DEP-1 CS variant, indicating the importance of its phosphatase 
activity.
 
Fig. 3.17a 
 
Fig. 3.17b 
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Fig. 3.17c 
Fig. 3.17 Expression of DEP-1 WT causes hyperphosphorylation of paxillin, of some 
phospho-tyrosyl sites in FAK and a complete dephosphorylation of PLCγ. 
Fig. 3.17a DEP-1 WT or CS expressing SW 480 cells were cultured either in the presence 
or absence of Atc (as indicated) and DEP-1 expressing cells were enriched using MACS. 
500,000 cells/6.0 cm dishes were seeded and allowed to grow for 2-3 days. Cells were 
starved overnight, followed by stimulation with 10% FBS for the indicated time points 
after which they were lysed. Lysates were analysed for their DEP-1 expression. Loading 
controls were performed by immunoblotting against vinculin. Lysates were also probed 
to detect phospho-paxillin and phosphor-PLCγ with corresponding antibodies. The same 
membrane was stripped and immunoblotted to detect the total levels of paxillin and PLCγ 
species. 
Fig. 3.17b The same lysates were used to detect site-specific phosphorylation of FAK. 
Site specific antibodies that recognize different tyrosyl phosphorylated species of FAK 
were employed. The total levels of FAK were also detected using an antibody that detects 
FAK irrespective of its phosphorylation status. 
Fig 3.17c Same lysates were probed to detect the phosphorylation status of c-Src. Both 
activating Tyr418 and inhibitory Tyr529 tyrosine residues were detected using antibodies 
which specifically recognize the corresponding phosphorylated sites. Total c-Src levels 
were also detected. 
Thus, the re-expression of DEP-1 leads to hyperphosphorylation of paxillin and some 
tyrosyl sites in FAK, and is associated with complete dephosphorylation of PLC γ. These 
changes may be due to the elevated Src activity. 
  Results 
 76
3.3.2. Phosphorylation Status of Erk and Akt – Molecules Involved in 
Proliferation and Survival 
Since DEP-1 is anti-proliferative and pro-apoptotic in the SW 480 cells, the activation 
status of two signaling molecules which are often actively involved in these processes - 
Erk (proliferation) and Akt (apoptotis) were analysed. As shown in Fig. 3.18, the re-
expression of DEP-1 WT caused hypophosphorylation of Akt (independent of 
stimulation). Even though phosphorylation of Erk is inducible with FBS, there was no 
significant difference between phospho-Erk levels in the DEP-1 expressing cells and their 
non-expressing counterparts. These results were also validated with cells expressing the 
DEP-1 CS mutant, and again no changes were observed. 
 
Fig. 3.18 
Fig. 3.18 Expression of DEP-1 causes decreased phosphorylation of Akt. 
Lysates were prepared as described in Fig. 3.17a. They were probed to detect the 
phosphorylation status of Akt and Erk. Loading controls were performed by detecting 
total Erk1/2 and Akt levels after stripping of the same membrane. 
Thus, the re-expression of DEP-1 is associated with hypophosphorylation of Akt whereas 
phospho-Erk levels, induced as a result of serum stimulation were not affected. 
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3.3.3. Effect of DEP-1 on Signaling Induced by Various Cellular Stimuli 
In order to understand the effect of DEP-1 on different pathways, it is essential to know 
which factors can induce phosphorylation cascades (potential motogens or mitogens) in 
SW 480 cells. Hence a range of factors (EGF, HGF and LPA) were screened and the 
phosphorylation status of Erk was initially used to score the cellular signaling response. 
As is evident from Fig. 3.19, Hepatocyte Growth Factor (HGF) can induce similar levels 
of Erk phosphorylation as FBS, followed by Lysophosphatidic Acid (LPA), whereas 
Epidermal Growth Factor (EGF) didn’t induce any phosphorylation. Thus, EGF is 
potentially not a relevant stimulus of SW 480 cells and was not further investigated. In 
contrast, HGF appears as a potentially important factor in this cell line. 
 
Fig. 3.19 
Fig. 3.19 Effect of different factors on Erk1/2 activation in SW 480 cells. 
The parental SW 480 cells were seeded in 6 well plates, starved overnight and stimulated 
with the indicated factors for 5 and 15 min. The cells were then lysed and immunoblotted 
with phospho-Erk antibody. Loading controls were performed by detecting total Erk 
levels. Unstimulated cells were shown in the first lane as a control for stimulation. 
Starting from these observations, the effects of DEP-1 expression on LPA and HGF-
induced signaling were analysed more closely. 
3.3.3.1. Lysophosphatidic acid (LPA) 
DEP-1 expressing and non-expressing cells were starved overnight and stimulated with 
10 µM LPA for the indicated time points. As is evident from Fig. 3.20, LPA induced a 
similar level of Erk phosphorylation as FBS. Hyper-phosphorylation of paxillin, hypo-
phosphorylation of Akt was also observed and again both these effects were independent 
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of LPA stimulation. Phosphorylation of Erk following LPA stimulation was again not 
affected due to the re-expression of wild type DEP-1. 
   
Fig. 3.20 
Fig. 3.20 Effect of DEP-1 expression on LPA-induced signaling in SW 480 cells. 
The experiment was performed as described in Fig. 3.17a except that 10 µM LPA was 
used for stimulation. Lysates were probed to detect levels of phosphorylated Akt, Erk and 
paxillin. Controls were shown by reprobing the membrane with antibodies which detect 
total levels of Erk / Akt. 
Thus, the effect of DEP-1 expression upon stimulation with LPA mirrors, the one upon 
FBS stimulation in these cells. 
3.3.3.2. Hepatocyte Growth Factor (HGF) 
HGF stimulation led to phosphorylation of its receptor HGFR (c-Met) which was easily 
detectable at the level of cell lysates. Expression of DEP-1 WT led to a complete 
dephosphorylation of the receptor at Tyr1234, 1235, 1236 as detected with the phospho-
tyrosine antibodies directed against these residues. Also, receptor levels appeared reduced 
upon DEP-1 re-expression (Fig. 3.21). Paxillin hyper-phosphorylation and Akt hypo-
phosphorylation in the presence of DEP-1 were again observed independent of 
stimulation (similar to FBS and LPA stimulation – compare Fig. 3.17, Fig. 3.18 and 
Fig. 3.20). In contrast, the effect on the phosphorylation status of Erk was very different. 
Phosphorylation of Erk was completely undetectable in the case of DEP-1 WT expressing 
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cells after HGF stimulation. Consistent with FBS stimulation, the expression of the CS 
mutant hardly revealed any changes in the phosphorylation status of all these proteins 
following HGF stimulation emphasizing again the essential role of the phosphatase 
activity of DEP-1 (not shown). 
 
Fig. 3.21 
Fig. 3.21 DEP-1 WT expression leads to dephosphorylation of HGFR (c-Met). 
The experiment was performed as described in Fig. 17 except that 50 ng/ml of HGF was 
used for stimulations. The phosphorylation status of HGFR and of some signaling 
proteins (paxillin, Akt and Erk) were also analysed. Control blots were performed after 
stripping the same membrane to detect the total levels of paxillin, Akt and Erk. 
Thus, re-expression of DEP-1 WT in SW 480 cells upon HGF stimulation can antagonize 
not only its receptor (HGFR) but also their downstream effectors (Akt, Erk). 
3.3.4. Pull-downs of the Small GTPases Rho and Rac 
Since DEP-1 expressing cells showed a hypo-migratory phenotype associated with 
cortical stress fibre formation, we speculated whether this could be mediated via small 
GTPases such as Rho or Rac. We performed pull downs to see the active fraction of Rho 
or Rac (GTP bound forms) against the total Rho and Rac. As shown in Fig. 3.22, there 
was no obvious difference in the activation status of Rac, which was constitutively high, 
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due to the re-expression of DEP-1 WT. However, there was a small difference in the 
activation state of Rho when DEP-1 WT was expressed (again independent of 
stimulation) which could be related to the observed changes in actin cytoskeleton. 
 
Fig. 3.22 
Fig. 3.22 Re-expression of the DEP-1 WT causes activation of the small GTPase Rho 
but not Rac. 
SW 480 cells expressing the DEP-1 WT were purified through MACS and seeded as 
described in Fig. 3.17a. They were either left unstimulated or stimulated for 5 min with 
10% FBS. Cells were then lysed in the presence of corresponding binding domains and 
GSH beads were used to pull down the active fractions of Rho / Rac as described in 
Methods. Lysate aliquots were subjected to immunoblotting to detect the total levels of 
Rho or Rac and to confirm DEP-1 expression. 
Thus, the observed changes in migration and actin cytoskeleton of the DEP-1 re-
expressing cells may be due to the upregulation of Rho GTPases. 
3.4. shRNA Mediated Suppression of DEP-1 
The re-expression of DEP-1 WT showed an anti-proliferative, anti-migratory and pro-
apoptotic phenotype accompanied by several changes in the signaling molecules. This 
approach may, however, lead to over-interpretation of some effects, due to 
supraphysiological levels of DEP-1. Knockdown of endogenous DEP-1 expression is a 
complementing approach. We therefore wondered, whether some of the phenotypes could 
be recapitulated by suppressing endogenous DEP-1. This should greatly facilitate to 
understand the physiological relevance of DEP-1 in colon cells. DEP-1 suppression in a 
suitable cell line was carried out using a shRNA construct that produces a 64 nucleotide 
(nt) short hairpin RNA (shRNA) which upon processing targets the endogenous DEP-1 
mRNA. 
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3.4.1. Testing of shRNA Constructs in Transient Transfections in HEK 
293 Cells 
In an initial screen using the search-programs at the websites of the siRNA companies 
Dharmacon and Oligoengine, three sequences were selected - 1151, 1524 and 2348. 
(Numbers correspond to the position of the starting nucleotide in DEP-1 mRNA). 
Another published sequence (441) for DEP-1 suppression (Lampugnani, Zanetti et al. 
2003) was additionally included. All these sequences were successfully cloned into 
pSUPER.retro.puro in order to facilitate retrovirus mediated infection of the target cells. 
As shown in Fig. 3.23, in transient transfections, all the four constructs had an inhibitory 
effect on DEP-1 expression when compared to the vector controls, albeit with different 
efficiencies. 
 
Fig. 3.23 
Fig. 3.23 shRNA mediated suppression of DEP-1 – testing of different shRNA 
constructs. 
HEK 293 cells were transiently co-transfected with DEP-1 WT construct and different 
shRNA constructs (numbered according to the first nucleotide in the targeted sequence of 
the mRNA) or a non-targeting control. 4 days after transfection, cells were lysed and 
lysates were immunoblotted to detect the remaining DEP-1 levels. Loading controls were 
performed by immunoblotting of lysates against β-actin. 
Thus, all the four designed constructs showed some level of suppression against their 
non-targeting controls. However, only one of them, construct 441 turned out to be useful 
in our further studies. 
3.4.2. Stable Suppression of Endogenous DEP-1 in HT 29 Cells 
Since the extent of suppression was very efficient with the construct 441, this construct 
was used for creating stably suppressed cell lines. Moreover, the construct was based on a 
retroviral system; hence we chose to use the retroviral transduction for achieving better 
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efficiency and stability in these cell pools. Retroviruses were produced by transfection of 
a packaging cell line (Phoenix). As target cells, we chose the HT 29 cell line. These cells 
contain significant levels of DEP-1 (see Fig. 3.1a) and revealed intact density-dependent 
regulation (see Fig. 3.2). The HT 29 cells were infected with the produced retroviruses, 
thus facilitating stable integration of the shRNA construct into the genome. Since the 
extent of suppression was not satisfactory after one round of retroviral infection, a similar 
second round of infection was performed. From Fig. 3.24, it is clear that DEP-1 can be 
stably suppressed using such an approach, whereas the control cell line which contains 
the non-targeting sequence had unaltered DEP-1 expression. 
 
Fig. 3.24 
Fig. 3.24 Suppression of endogenous DEP-1 in HT 29 cells by shRNA. 
Construct 441 (s) and the non-targeting control (nt) were used to produce the retrovirus 
from the phoenix packaging cell line. Stable cell pools of HT 29 were generated after 
retroviral transduction with the resulting virus. IP of lysates were performed and the 
efficiency of DEP-1 protein suppression is shown by immunoblotting. Loading controls 
were performed by immunoblotting of lysates for total Erk1/2 levels. 
Thus, using the construct 441, endogenous DEP-1 can be stably and efficiently 
suppressed in HT 29 cell line. 
3.4.3. Proliferation Assay 
Since the re-expression of DEP-1 WT reduced the proliferation of the SW 480 cells, it 
was obvious to speculate that the suppression of DEP-1 might result in a growth 
advantage. Proliferation assays were carried out using a fluorescent nuclear dye DAPI, 
which binds the DNA. As shown in Fig. 3.25, it is clear that the HT 29 cells with 
suppressed DEP-1 expression had a growth advantage compared to corresponding control 
cells, particularly under conditions of reduced serum (2% FBS), confirming the 
antiproliferative function of this PTP. 
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Fig. 3.25 
Fig. 3.25 Enhanced proliferation of HT 29 cells upon suppression of endogenous 
DEP-1 by shRNA. 
HT 29 cell pools with downregulated DEP-1 expression (s) or a corresponding control 
pool (nt) were analysed for cell growth. 8,000 cells/well in 96 well plates were seeded at 
different concentrations of fetal bovine serum (2% or 10%, as indicated). On the 
corresponding days, cells were fixed with methanol followed by staining with a nuclear 
dye 4',6-Diamidino-2-phenylindole-2HCl (DAPI). The fluorescence emitted by the bound 
DAPI was taken as a measure of the cell amounts. 
These data show that upon suppression of endogenous DEP-1 in HT 29, the cells acquire 
a growth advantage emphasizing the anti-proliferative effect of DEP-1. 
3.4.4. Immunoblot Analysis of Phospho-protein Molecules 
The re-expression of DEP-1 had revealed both hypo- and hyper-phosphorylation of 
various phospho-proteins involved in signaling. Hence, we wanted to know whether the 
suppression of DEP-1 can also affect on the same molecules. Various signaling 
molecules were, however, not affected by DEP-1 suppression. These include the 
phospho-paxillin, FAK and Erk (not shown). We cannot say at this point whether this 
discrepancy to the data in DEP-1 re-expressing SW 480 cells is due to the different 
cellular backgrounds or an issue of DEP-1 levels. However, an effect was reproducibly 
seen on Akt phosphorylation upon DEP-1 suppression. From Fig. 3.26, it is clear that the 
serum-stimulated phosphorylation of Akt is elevated in the cell lines with suppressed 
DEP-1 expression when compared to their non-targeting controls. 
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Fig. 3.26 
Fig. 3.26 Hyper-phosphorylation of Akt upon suppression of DEP-1. 
HT 29 cell pools with downregulated DEP-1 expression (s) or a corresponding control 
pool (nt) were seeded in 6.0 cm dishes. Cells were starved overnight and stimulated with 
10% FBS for the indicated time points. Lysates were probed to detect the 
phosphorylation status of Akt. Total Akt levels in the same samples were also detected. 
The membrane was also probed with DEP-1 antibody to detect the extent of suppression 
and loading controls were shown with vinculin. 
Thus, suppression of endogenous DEP-1 in HT 29 leads to hyper-phosphorylation of Akt 
in contrast to hypo-phosphorylation of Akt upon re-expression of DEP-1 in SW 480. 
3.4.5. RTK Array Analysis 
Since the phosphorylation of Akt is reduced in DEP-1 re-expressing cell lines and an 
inverse effect was observed upon DEP-1 suppression, we were interested in identifying 
the upstream kinase (potentially some RTK) that signals to Akt phosphorylation and may 
be the target of DEP-1. Hence we employed a RTK array (R&D) that allows the 
simultaneous detection of the phosphorylation status of 42 different RTKs. The cells 
from the DEP-1 suppressed and non-targeted cells were either left unstimulated or were 
stimulated with FBS for 15 min. They were then lysed and analysed with the RTK array. 
As shown in Fig. 3.27, a few RTKs including insulin receptor (box 2 coded in red) and 
insulin-like growth factor-1-receptor (IGF-1R, box 3 coded in pink) were hyper-
phosphorylated due to stimulation with 10% FBS. There was obviously no elevated 
phosphorylation of any RTK in the cells with suppressed DEP-1. Surprisingly, HGFR 
(box-1 shown in blue) was hyper-phosphorylated in the non-targeting pools irrespective 
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of stimulation. Interestingly in the same experiment, robust Akt hyper-phosphorylation 
was seen in cells with suppressed DEP-1 expression. Another HT 29 cell line, where 
DEP-1 WT was over-expressed, was also analysed, but again no obvious changes were 
observed (not shown). 
 
Fig. 3.27 
Fig. 3.27 RTK array analysis of the DEP-1 suppressed (s) and non-targeting (nt) pools. 
HT 29 cell pools with downregulated DEP-1 expression (HT 29 - s) or a corresponding 
non-targeting control pool (HT 29 - nt) were seeded in 6.0 cm dishes. Cells were starved 
overnight and were either left unstimulated (top panel) or stimulated with 10% FBS for 
15 min (lower panel). Lysates were probed with an antibody array as described by the 
manufacturer. The resulting chemiluminiscent signals were scored on X-ray films. Box 
number 1 coded blue denotes phosphorylation of HGFR. Box number 2 coded red and 
box number 3 coded pink denotes the phosphorylation of insulin receptor and insulin-like 
growth factor-1- receptor respectively. 
These data reveals that the analysed RTKs are not the prime targets of DEP-1 upstream 
of Akt under the conditions analysed. 
3.5. Tumor Suppressor DEP-1 and its Relation to 
Nutrient Components 
The colon is constantly exposed to nutrients. Epidemiological studies have shown that 
colorectal cancer incidence could be significantly modulated by dietary intake of 
flavonoids as part of fruits and vegetables (Terry, Giovannucci et al. 2001). Apples are a 
significant part of the Western diet, and they are a major source of flavonoids. Various 
flavonoid compounds have been found to possess a range of cancer preventive activities 
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including prevention of oxidative DNA damage, inhibition of carcinogen activation, 
induction of carcinogen detoxifying systems, interaction with cellular signaling pathways 
and modulation of gene expression controlling proliferation, differentiation and apoptosis 
of cancer cells (Barth, Fahndrich et al. 2005). Another important nutrient of dietary origin 
is butyrate. Human colonic bacteria ferment oligo- and polysaccharides to short chain 
fatty acids (SCFA), mainly acetate, propionate and butyrate. Butyrate has been suggested 
to play a central role in reducing cancer risks by regulating differentiation, inducing 
apoptosis and inhibiting growth of tumor cells in vitro (Hague and Paraskeva 1995). Tea 
is one of the most popular beverages consumed worldwide. Interest in the beneficial 
effects of green tea has led to investigations on activities by its main catechin - 
epigallocatechin-3-gallate (EGCG). This antioxidative compound could contribute to 
cancer chemoprevention by acting antigenotoxic (Glei and Pool-Zobel 2006). 
3.5.1. Upregulation of DEP-1 by Different Nutrient Components 
We speculated that some of the beneficial effects of certain nutrients towards colorectal 
cancer might be mediated through DEP-1 upregulation. We tested different nutrient 
components such as a polyphenol extract from apple juice (AE), butyrate (But) and an 
extract from green tea (GT) for their effects on DEP-1 levles in colon epithelial cell lines.  
From Fig. 3.28a, it is clear that in the case of HT 29 and CaCo2 cells, DEP-1 expression 
can be upregulated, upon 72 h treatment with butyrate or green tea, whereas AE had no 
effect on DEP-1 levels in these cells. We also tested an adenoma cell line LT 97. In these 
cells all the nutrients tested upregulated DEP-1 expression (Fig. 3.28a). One of the 
nutrients AE was also tested in different concentrations which again showed a clear dose-
dependent upregulation of DEP-1 expression (Fig. 3.28b). 
    
  Fig. 3.28a 
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Fig. 3.28b 
Fig. 3.28 Upregulation of DEP-1 expression by nutrient components in colon epithelial 
cells. 
Fig. 3.28a Subconfluent cultures of HT 29, CaCo2 and LT 97 cells were left untreated 
(control, C), or were treated for 72 h with 2 mM sodium butyrate (But), 25 µM phloridzin 
equivalents of apple polyphenol extract (AE) or 20 µM epigallocatechine-3-gallate 
equivalents of Green Tea (GT). The cells were lysed and IP was performed to detect 
DEP-1 expression. Lysate aliquots were analysed for actin levels as input control. The 
shown experiment is representative of four with consistent results. Numbers under the 
lanes indicate relative amounts determined by densitometry of the DEP-1 signal.  
Fig. 3.28b Subconfluent cultures of LT 97 adenoma cells were treated with apple 
polyphenol extract (concentrations equivalent to 0, 1, 2.5, 15 or 25 µM phloridzin), for 
72 h and DEP-1 expression was determined by IP. The resulting blots were scanned, 
normalized to vinculin levels and a densitometric plot is shown. 
These data reveal that DEP-1 expression can be upregulated in all the cell lines analysed 
by most of the tested nutrient components. Furthermore, polyphenol extract from apple 
can upregulate DEP-1 expression in a dose-dependent manner. The anti-proliferative 
effects of these nutrients (Pool-Zobel, Selvaraju et al. 2005; Shimizu, Deguchi et al. 
2005; Veeriah, Kautenburger et al. 2006) could be linked to DEP-1 upregulation. 
However, this may not be the only mechanism, as the nutrient treatment of the DEP-1 
depleted HT 29 cells also exhibited growth inhibition (not shown). 
3.5.2. Induction of DEP-1 Occurs at the Transcriptional Level 
Western blot analysis revealed the upregulation of DEP-1 by treatment with different 
nutrient components in LT 97 cells. In order to know whether the upregulation of DEP-1 
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was at the transcriptional or at the translational level, mRNA quantification of DEP-1 
using Real Time PCR was performed. We observed an induction of DEP-1 mRNA in LT 
97 adenoma cells by all the three tested nutrient components to a similar extent as 
observed at the protein level (Fig. 3.29). 
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Fig. 3.29 
Fig. 3.29 Upregulation of DEP-1 mRNA upon treatment with protective nutrients. 
Subconfluent cultures were treated for 72 h as described in Fig. 3.28a Total RNA was 
extracted and subjected to real-time reverse transcriptase - polymerase chain reaction. 
Values were normalized to glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) mRNA 
detected in the same samples and were expressed relative to results for untreated cells 
(100%) (mean + s.d., n=3). 
Since the extent of upregulation obtained at the mRNA level correlates with the level of 
upregulation obtained at protein levels, we can conclude that upregulation of DEP-1 by 
these nutrient components is mainly transcriptional. 
3.5.3. No Detectable Effect of Apple Juice on DEP-1 Transcript Levels In 
Vivo 
Upon treatment with apple extract, DEP-1 is upregulated in adenoma cells but not in 
carcinoma cells. Since adenoma mirrors more closely the normal tissue, we wondered if 
an effect of apple could also be scored in vivo. We therefore tested whether intake of 
apple juice (AJ) can upregulate DEP-1 expression in the colonic mucosa of rats. Rats 
were fed either with apple juice (treatment) or water (control). One subgroup of animals 
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was also injected intraperitoneally either with a carcinogen di-methyl hydrazine (DMH) 
or sodium chloride (NaCl) as the control. All these animal experiments were performed at 
the Institute of Nutritional Physiology, Karlsruhe and the RNA from the colonic mucosa 
was kindly provided by Dr. S. W. Barth. As shown in Fig. 3.30, the mRNA levels of 
DEP-1 in these experimental animals varied strongly. The data failed to reveal any 
significant upregulation of DEP-1 mRNA. 
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Fig. 3.30 
Fig. 3.30 Apple juice drinking animals does not exhibit significant DEP-1 upregulation 
in their colonic mucosa. 
Rats were fed either with apple juice (AJ) or water. Two sub-groups of animals were also 
injected intraperitoneally either with the carcinogen (DMH) or sodium chloride (NaCl) 
as control. The colonic mucosa of the animals was scraped off and total RNA was 
isolated and kindly provided by Dr. S. W. Barth. cDNA was synthesized from these RNA 
samples, and finally subjected to real time PCR to detect the mRNA level of DEP-1 (see 
Methods). Four animals in each group were used for these studies. 
3.5.4. Induction of Apoptosis by Apple Polyphenol Extract in HT 29 
In the literature (Hague and Paraskeva 1995; Wenzel, Kuntz et al. 2000), it has been 
suggested that various nutrients including butyrate and other flavonoids may also exert 
their beneficial effects by inducing apoptosis of colon carcinoma cells. As has been 
shown by others, the apple polyphenol extract has a cytostatic activity on HT 29 cells 
(Veeriah, Kautenburger et al. 2006) but the mechanistic basis for the cytostatic effect has 
been yet unknown. Apoptosis induction would be a possibility. Hence, we were curious 
to know whether the polyphenol extract of the apple juice (AE) can induce apoptosis. 
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Apoptosis was scored by the cleavage of poly (ADP-ribose) polymerase (PARP), which 
in HT 29 cells can be easily detected with an antibody. The antibody employed detects 
both the uncleaved (116 kDa) and cleaved (89 kDa) forms of PARP. As shown in Fig. 
3.31, treatment of the HT 29 cells with AE can induce apoptosis in a dose and time 
dependent manner. 
 
  
Fig. 3.31 
Fig. 3.31 Induction of apoptosis by apple polyphenol extract (AE). 
Sub-confluent HT 29 cells were either treated with apple polyphenol extract (AE) at 
concentrations equivalent to 0, 15, 30 and 45 µM phloridzin (Ph eq) or treated with 2 
mM butyrate (But) or 1 µM staurosporine (ST) and checked for apoptosis induction. At 
the indicated time points (24 h, 48 h and 72 h) cells were lysed and lysates were 
immunoblotted to detect the cleavage of PARP. Apoptosis assay was performed both in 
the presence and in the absence of serum. 
These data reveal that the polyphenol extract from apples can induce apoptosis in HT 29 
cells and may at least be in part responsible for the observed cytostatic effect. 
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4. Discussion 
Protein tyrosine phosphatases are key regulators of protein tyrosine phosphorylation. 
They have been implicated in a range of physiological processes, de-regulation of which 
can lead to various diseases including cancer. One of the transmembrane phosphatases, 
DEP-1 (Density Enhanced Phosphatase-1), has been proposed as a tumor suppressor in 
the case of glioma, mammary, pancreas and thyroid carcinomas. It has been mapped 
down to the colon cancer susceptibility locus (Scc 1) in mice (Ruivenkamp, van Wezel et 
al. 2002). Recently, it has been reported that loss of heterozygosity (LOH) on 11p11, in 
the region containing PTPRJ, is an early event in colon carcinogenesis (Luo, Shen et al. 
2006). These and other data suggest DEP-1 as a candidate tumor suppressor for colon 
carcinogenesis. Nevertheless, the physiological role of DEP-1 in colon cells has largely 
remained ill-defined. Here we show that Density Enhanced Phosphatase-1 (DEP-1) 
negatively regulates proliferation and migration in colon cancer cells, and is associated 
with distinct cytoskeletal changes. Moreover, DEP-1 also exhibits a pro-apoptotic 
function and sensitizes the cells towards apoptosis. Furthermore, we were able to partly 
dissect the signaling mechanism of DEP-1 in these colon cancer cells. 
4.1. Model System: Cell lines with inducible DEP-1 
expression and shRNA mediated suppression 
4.1.1. Inducible DEP-1 (WT or CS) expression 
One approach to analyse the physiological role of any protein is to over-express or re-
express the protein of interest in appropriate cellular backgrounds. Stable cell clones can 
be achieved either with constitutive expression or having the expression in an inducible 
manner. Constitutive over-expression has several disadvantages. First of all, if the protein 
is lethal or harmful for the viability of the host cells, it may be impossible to cultivate 
them. Moreover, the continuous presence of the protein can make the cell to adapt to 
certain phenotypes which may not be physiological. Hence, we decided to create stable 
cell clones with inducible DEP-1 expression. The particular cellular background is 
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another aspect for such studies. The analysis of endogenous DEP-1 expression (at protein 
level) in a set of colon cancer cell lines revealed the expression to be variable (Fig. 3.1a). 
Interestingly, the relatively abundant DEP-1 expression in the adenoma cell line LT 97 
may reflect that this cell line resembles more closely the normal colon epithelium than 
cancer cells. The genetic constitution of the cell lines with respect to the possible absence 
of one allele of PTPRJ is not known. Abundant expression in some colon cancer cell 
lines such as HT 29 suggests, however, that these cell lines probably possess both alleles 
and, therefore, have unaltered DEP-1 levels. One of the cell lines, SW 480, had no 
detectable DEP-1 protein expression. However, RT-PCR analysis revealed the presence 
of DEP-1 mRNA in this cell line (Fig. 3.1b). This indicates the presence of at least one 
functional DEP-1 allele, despite the protein level being very low. It should be pointed 
out, that the RT-PCR analysis did not allow concluding on the mRNA levels. They may 
also be very low. Because of the absence of DEP-1 in SW 480, this cell line was chosen 
for our re-expression studies. To achieve inducible re-expression, the vector pNRTIS 21 
was the preferred choice. The use of this vector has several advantages: The vector is 
based on a bi-cistronic system and has the gene of interest and the tetracycline-repressed 
transactivator (tTA) under the tTA-responsive promoter. The neomycin resistance gene is 
under a separate SV-40 promoter. This setup enables to select for resistant clones in the 
absence of any target gene expression. The expression of DEP-1 can be simply turned 
“off” or “on” either by just adding or removing anhydrotetracycline in the growth media 
respectively (popularly referred to as “Tet off” system), allowing a simple and stringent 
way of controlling gene expression. We have also employed both DEP-1 WT and a 
catalytically inactive mutant of DEP-1 (C1239S) in which the active site cysteine is 
mutated to a serine residue. This helped to differentiate the need for an active 
phosphatase against possible other effects of protein expression such as a potential 
scaffolding function. Using this inducible, bi-cistronic vector system, we have 
conditionally re-expressed the DEP-1 WT or CS variant into the DEP-1 negative cell line 
SW 480 (Fig. 3.4a). Moreover, when lysates were subjected to phosphatase assay, the 
DEP-1 WT expressing cells showed four-fold increased activity than their non-expressing 
counterparts. The catalytically inactive variant did not exhibit any activity in either of the 
expressing or non-expressing states (Fig. 3.4b). Once successful clones were established, 
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the cells were routinely cultured with Atc, devoid of any target gene expression. This 
prevents the cell from adapting to any phenotype due to the exogenous DNA. Whenever 
necessary, DEP-1 expression was easily induced by just culturing the cells in the absence 
of Atc for 3 - 4 days. This approach also overcomes the problem of clonal variation as the 
same clone is analyzed in both the expressing and non-expressing states for their 
resulting phenotypes. 
 
Even though we created stable cell lines with inducible expression, induction of DEP-1 
was gradually reduced in later passages (Fig. 3.5). There are several possible 
explanations for this phenomenon. Although the cultures were strictly maintained in the 
repressed state, a minimal level of foreign gene expression occurs from the vector 
pNRTIS 21. This is required to express a basal level of tTA which is needed to initiate 
transcription upon removal of Atc. DEP-1 is anti-proliferative (see Fig. 3.6) and hence 
the cultures which express low level of DEP-1 will have a growth disadvantage. This 
may have led to overgrowth of cells which have lost DEP-1 expression. However, the cell 
lines engineered to express the catalytically inactive DEP-1 CS variant, which had no 
growth differences, also gradually lost induction. Cellular background is another issue to 
be considered here. Segregation of cells with respect to DEP-1 expression may occur by 
silencing of the inducible promoter, a phenomenon frequently seen in cancer cells (Prof. 
Jürgen Behrens, personal communication). 
4.1.2. shRNA mediated suppression 
Another approach to study the physiological relevance of a protein is to knock out the 
corresponding gene or to suppress its expression in those cells that normally harbors it 
and to directly compare the biological outcomes with the results of re-expression. 
Previously, antisense oligonucleotides were used for this purpose which will bind to the 
target mRNA thereby blocking translation. In recent years, the suppression of protein 
expression by the use of small interfering RNAs (siRNAs) has been successfully 
employed for this purpose. Here we have used a shRNA which upon processing will 
produce a short 21 nucleotide (nt) siRNA. This will target the corresponding DEP-1 
mRNA transcript thereby bringing down the protein levels. In order to have efficient and 
  Discussion 
 94
stable integration of the shRNA vector into the host genome, a retroviral based 
transduction approach was employed. A non-targeting vector which contains sequences 
that do not target any of the known coding sequences was also included to exclude any 
irrelevant effects. The HT 29 cell line was chosen for this purpose as this cell line had 
relatively high levels of endogenous DEP-1 (Fig. 3.1a) and also revealed intact density 
dependent upregulation (Fig. 3.2). We have designed four shRNA constructs (see 
Methods) targeting different regions of the mRNA transcript. Initially, all these four 
constructs were tested in transient transfections by co-transfecting DEP-1 WT and 
shRNA constructs in HEK 293 cells. Since the pulse-chase experiment revealed the half-
life of DEP-1 to be approximately around 13 hours (Fig. 3.3), the transfected cells were 
lysed 96 hours after transfections to allow for sufficient downregulation of the existing 
DEP-1 protein. All the four constructs showed some level of suppression (Fig. 3.23) and 
one of them was successfully employed for generating a stably suppressed HT 29 cell 
line. Even though the retroviral mediated transduction protocol was followed, it should be 
noted that different cell lines have different levels of susceptibility to the retroviral 
infection. With a single round of infection, only a weak suppression was achieved. But 
when two rounds of retroviral infections were performed, approximately 70-80% of 
endogenous DEP-1 was efficiently and stably suppressed (Fig. 3.24). Using these two 
cellular models (re-expression and suppression) we further investigated the role of DEP-1 
in relation to its role in the colon epithelial cells. 
4.2. Phenotypes of DEP-1 re-expression in colon cancer 
cells 
4.2.1. DEP-1 negatively regulates proliferation 
DEP-1 has been named “Density-Enhanced Phosphatase” as the levels of this 
phosphatase increase upon an increase in cell density. One of the first publications 
describing the cloning of DEP-1 also showed that at least in human embryonic fibroblasts 
(WI-38) and foreskin fibroblasts (AG1518), DEP-1 levels increase as cells approach 
confluence with respect to both the protein levels as well as the phosphatase activity. 
These data led the authors to propose that DEP-1 can participate in contact mediated 
  Discussion 
 95
growth arrest (Ostman, Yang et al. 1994). In support of this, contact inhibition of VEGF-
induced proliferation in endothelial cells has been shown to be mediated through DEP-1 
by antagonizing VEGFR signaling (Lampugnani, Zanetti et al. 2003). Moreover, several 
studies have indicated that DEP-1 can antagonize signaling of several growth factor 
receptors including PDGFR, EGFR, VEGFR and HGFR in various cell lines. DEP-1 has 
also been shown to decrease proliferation in case of glioma (Massa, Barbieri et al. 2004), 
breast (Keane, Lowrey et al. 1996), thyroid (Iuliano, Trapasso et al. 2003), and pancreatic 
cancer models (Trapasso, Yendamuri et al. 2004). However, in the case of NIH 3T3 
fibroblasts, controversial results have been obtained. Previous work in our lab has shown 
that inducible expression of DEP-1 had no effect on proliferation (Jandt, Denner et al. 
2003). Another group has shown that DEP-1 can inhibit proliferation under similar 
conditions (Kellie, Craggs et al. 2004). Recently, a bivalent form of a monoclonal 
antibody against CD 148 (i.e., DEP-1) has been shown to inhibit endothelial cell growth, 
thereby negatively regulating angiogenesis (Takahashi, Takahashi et al. 2006). Consistent 
with most of the above findings, the re-expression of DEP-1 severely inhibited 
proliferation also in colon cancer cells (Fig. 3.6a). A more robust effect was seen when 
the proliferation assay was performed after DEP-1 expressing cells were enriched with 
the help of MACS (Fig. 3.6c). The re-expression of the catalytically inactive variant 
however did not have any effect on proliferation (Fig. 3.6b). These findings suggest that 
the intact catalytically active DEP-1 is necessary for exerting growth inhibition. To 
complement this hypothesis we also subjected the DEP-1 suppressed HT 29 cell lines to 
proliferation assays. Using this approach, we were able to show that the suppression of 
endogenous DEP-1 in HT 29 cells resulted in a growth advantage when compared to cells 
expressing non-targeting control siRNA and the effect was even more pronounced under 
conditions of reduced serum (Fig. 3.25). Taken together, these data clearly reveal the 
anti-proliferative effect of DEP-1 in colon epithelial cells. 
 
Generally, the proliferative ability of any cell is correlated with the phosphorylation 
status of Erk. In case of thyroid cells, the expression of DEP-1 WT has been correlated 
with decreased Erk phosphorylation (Trapasso, Iuliano et al. 2000; Iuliano, Trapasso et 
al. 2003). Similar observations have also been reported in the case of fibroblasts 
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following PDGF stimulation (Jandt, Denner et al. 2003; Kellie, Craggs et al. 2004). Also 
in T cells, CD 148 (i.e., DEP-1) expression has been shown to downregulate Erk 
phosphorylation following stimulation with an anti-TCR monoclonal antibody (Baker, 
Majeti et al. 2001). In glioma cells, DEP-1 has been proposed to directly interact with and 
dephosphorylate Erk following bFGF stimulation (Massa, Barbieri et al. 2004). In 
contrast, DEP-1 re-expressing colon cells did not reveal any difference in Erk 
phosphorylation following serum stimulation for 30 min (Fig. 3.18). When stimulated 
with specific growth factors specific effects became apparent. In case of stimulation with 
LPA again no difference in Erk phosphorylation was observed (Fig. 3.20). However, 
when the cells were stimulated with HGF, a complete inhibiton of Erk phosphorylation, 
associated with dephosphorylation of HGFR was observed (Fig. 3.21). This antagonizing 
effect of DEP-1 on HGFR signaling may, under certain conditions, contribute to the 
observed anti-proliferative effect. Clearly, our data are not compatible with a direct effect 
of DEP-1 on Erk1/2 activity. Also, since DEP-1 inhibits growth in the presence of FBS 
and in the absence of any clear effect on serum stimulated Erk1/2 activities, the 
contribution of this pathway to growth inhibition is not clear. It should be noted that 
Erk1/2 activity has not been analysed under conditions of the continuous presence of 
FBS. 
4.2.2. DEP-1 promotes apoptosis 
Tumor suppressors such as p53, retinoblastoma protein or PTEN have been extensively 
studied and their tumor suppressive effect has been linked to reduced cell survival or 
enhanced apoptosis. Since DEP-1 is a putative tumor suppressor, we wondered whether 
re-expression of DEP-1 might play a role in apoptosis regulation of the cell. It has been 
described in the case of pancreatic carcinoma cells that the expression of DEP-1 disrupts 
the cell cycle and leads to apoptosis (Trapasso, Yendamuri et al. 2004). Moreover, a 
“sensitized” RNAi screen of all human kinase and phosphatase genes has revealed 
PTPRJ, the gene encoding DEP-1 as encoding a cell death promoting phosphatase in the 
presence of apoptosis-inducing cytotoxic compounds (MacKeigan, Murphy et al. 2005). 
Consistent with these findings, we showed that the re-expression of DEP-1 WT can 
sensitize the colon cancer cells to staurosporine-induced apoptosis in a dose-dependent 
  Discussion 
 97
manner (Fig. 3.16a). The need for an active phosphatase was confirmed since the re-
expression of the catalytically inactive variant failed to induce any apoptosis (Fig. 3.16b). 
 
Similar as the phosphorylation status of Erk is correlated with cell proliferation, the 
survival or apoptosis rate is frequently regulated by Akt phosphorylation. Even though 
the apoptotic index of DEP-1 expressing cells has been scored in the case of pancreatic 
cancer cell lines, no correlation has been made with Akt phosphorylation. However, in 
the case of fibroblasts, Akt phosphorylation was shown to be suppressed in DEP-1 
expressing cells following PDGF stimulation (Kellie, Craggs et al. 2004). In contrast, in 
endothelial cells, stimulation of CD 148 activity with a bivalent antibody did not seem to 
affect Akt phosphorylation (Takahashi, Takahashi et al. 2006). In our studies in the 
DEP-1 re-expressing SW 480 cells, in contrast to Erk phosphorylation, Akt 
phosphorylation was consistently downregulated (Fig. 3.18, Fig. 3.20 and Fig. 3.21). It 
should be noted that these cells exhibited a high level of the basal Akt phosphorylation. 
Furthermore, HT 29 cells with downregulated DEP-1 expression exhibited hyper-
phosphorylation of Akt following serum stimulation (Fig. 3.26). Thus, taking together the 
re-expression and suppression studies, we were able to show consistent effects on Akt 
phosphorylation. These results clearly suggest a physiological relevance of the negative 
regulation of Akt phosphorylation by DEP-1 expression, which may relate to regulating 
apoptosis. Akt cannot be a direct target for DEP-1 as it is phosphorylated only on serine 
and threonine residues. DEP-1 being a transmembrane phosphatase, it is easy to speculate 
the involvement of certain RTKs regulating Akt phosphorylation as targets for DEP-1. 
However, our RTK array analysis failed to reveal downregulation of any of the 42 RTKs 
spotted onto the membrane (Fig. 3.27). Hence, we hypothesize the involvement of RTKs 
that are not included in the array, or other cytoplasmic tyrosine kinases as targets of 
DEP-1 mediating Akt phosphorylation. 
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4.2.3. DEP-1 negatively regulates migration with associated changes in 
actin cytoskeleton and focal adhesion molecules 
4.2.3.1. DEP-1 negatively regulates migration 
Density Enhanced Phosphatase (DEP-1) is a large transmembrane phosphatase with eight 
extracellular fibronectin repeats. The presence of these motifs has often been implicated 
in either mediating cell-cell contacts or cell matrix adhesion and migration. Similar 
transmembrane phosphatases such as those of the LAR-PTP family including LAR-PTP, 
PTPσ and PTPδ have been shown to affect migration in different cellular models (Serra-
Pages, Kedersha et al. 1995; Elchebly, Wagner et al. 1999). One of the closest relatives of 
DEP-1, GLEPP1 (PTPRO) and its mouse ortholog PTPφ have been shown to induce 
rapid dephosphorylation of molecules involved in focal adhesions (Pixley, Lee et al. 
2001). Moreover, previous data from our lab have indicated that inducible expression of 
DEP-1 inhibits the migration of fibroblasts (Jandt, Denner et al. 2003). Consistent with 
these findings, we were able to show that DEP-1 negatively regulates migration also in 
colon cancer cells. In wound healing assays, DEP-1 WT inhibited the migration by as 
much as 60% (Fig. 3.7). Since these assays were performed over a period of 24 hours, we 
cannot rule out that the inhibition of migration could have been partly due to the lack of 
proliferation of the DEP-1 re-expressing cells. Hence, we went on further to confirm our 
findings with a modified Boyden Chamber Assay (transwell assay) which was performed 
only for a period of six hours. Again the re-expression of DEP-1 inhibited the migration 
around 50% in these colon cancer cells (Fig. 3.8). Moreover, DEP-1 inhibited the 
migration induced not only with FBS but also the migration induced with LPA 
(Fig. 3.10). Even though the scatter factor HGF is a well established motogen for several 
cellular systems, HGF induced migration only weakly in the cell lines under 
investigation. Nevertheless, in wounding assays, cells migrated when stimulated with 
HGF. Again the re-expression of DEP-1 inhibited migration (Fig. 3.11). Since FBS, LPA 
and HGF induce migration by activating different receptor classes, this observation 
suggests the existence of common cellular targets downstream of these receptors that are 
affected by DEP-1 expression. Similar to proliferation, the re-expression of only the 
DEP-1 WT strongly inhibited migration whereas the C1239S mutant had no effect on 
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migration. This reveals that DEP-1 does not merely act as a scaffold. It rather mediates its 
effects by dephosphorylating yet unidentified substrates. 
4.2.3.2. DEP-1 induces cytoskeletal changes 
The migration of the cell is always associated with dynamic changes in their actin 
cytoskeleton. Migration involves actin remodeling at both the cell front and rear. Since 
the re-expression of DEP-1 strongly inhibited migration; it was interesting to see the 
associated cytoskeletal changes. In the case of fibroblasts, DEP-1 expressing cells had 
fewer actin containing microfilament bundles and a reduced density of vinculin and 
paxillin-containing adhesion plaques (Kellie, Craggs et al. 2004). These authors 
attributed these altered cytoskeletal changes to defective focal adhesion turnover, with a 
lack of activation of FAK. In contrast, staining of DEP-1 re-expressing colon cancer cells 
with phalloidin which binds filamentous actin revealed abundant cortical actin bundles 
lining the cell periphery. A uniform pattern of bundled actin can be seen beneath the cell 
membrane which is clearly absent in DEP-1 non-expressing cells (Fig. 3.13, Fig. 3.14). 
Moreover, staining of the cells with phospho-paxillin or vinculin revealed a characteristic 
re-distribution of these focal adhesion molecules (Fig. 3.15). In the case of DEP-1 re-
expressing cells, these molecules are concentrated on certain regions of the membrane 
which may be the point of contacts or focal adhesions of the cell membrane towards the 
surrounding matrix. In the case of their non-expressing counterparts, vinculin and 
phospho-paxillin are not restricted to certain regions of the membrane. Instead they are 
distributed throughout the cell periphery. 
 
Usually, migration involves the formation of small and broad lamellipodia or thin and 
long filopodia. These processes are initiated by the action of the small GTPases Rac and 
Cdc 42 respectively. Another small GTPase, namely Rho, is often implicated in the 
formation of stress fibres. Therefore, we explored the activation state of Rac and Rho in 
DEP-1 re-expressing cells. The pull down of the active fraction of small GTPases Rac 
failed to reveal any differences between DEP-1 expressing and non-expressing cells. In 
contrast, Rho pull down revealed a small upregulation of active Rho in DEP-1 expressing 
cells (Fig. 3.22). Due to technical difficulties, thereafter pull down of active Rho failed, 
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and so these effects were neither sufficiently confirmed nor could the analysis be 
performed for extended time periods. Still, the potential involvement of Rho is interesting 
and warrants further investigation. Rho mediates stress fibre formation and has been 
linked to both promoting and inhibiting migration. Some recent literature has indicated 
that Rho GTPase may play a role in inhibiting migration by antagonizing the action of 
Rac GTPase (Ohta, Hartwig et al. 2006). Potentially, activation of Rho in the DEP-1 
expressing SW 480 cells could lead to the formation of stress fibres resulting in inhibition 
of migration. However, the involvement of other small GTPases or other signaling 
pathways cannot be ruled out. Local activation of Rho and Rac can be another possibility 
as well. One future prospect is to dissect the local activation of Rho (and Rac) either only 
at the leading or trailing edges. Taken together, DEP-1 re-expressing cells exhibit a 
distinct actin cytoskeleton associated with inhibition of migration. Actin reorganization 
could be mediated by the small GTPase Rho. 
4.2.3.3. DEP-1 causes hyper-phosphorylation of paxillin and FAK with a 
complete dephosphorylation of PLC γ 
As cellular migration involves a continuous formation and disassembly (turn over) of 
focal adhesion complexes, it is worthwhile to have a closer look at the molecules 
involved. Most of these molecules are regulated by tyrosyl phosphorylation. PLC γ has 
already a well established role in cellular migration by binding to various RTKs. Upon 
activation of the RTKs, PLC γ has been reported to be directly phosphorylated by the 
corresponding RTKs and thus being activated. Activated PLC γ hydrolyzes phospho-
inositide-(4,5)-bisphosphoate (PIP2) to diacyl glycerol (DAG) and inositol-triphosphate 
(IP3) releasing gelsolin (an actin binding protein) from PIP2. PIP2 is usually present in the 
membrane in the absence of stimulation. The released gelsolin then severs established 
actin filaments while cofilin and profilin will nucleate it, resulting in enhanced migration 
of the cells (Wells and Grandis 2003). Analysis of the tyrosyl phosphorylation of PLC γ 
at pTyr783 in DEP-1 expressing cells revealed a complete dephosphorylation irrespective 
of stimulation (Fig. 3.17a). Absence of the tyrosyl phosphorylation on PLC γ correlates 
well with the anti-migratory role of DEP-1. 
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c-Src kinase is a non-receptor tyrosine kinase that has long been known to be involved in 
cell-substratum adhesion. Knock out of c-Src affects the adhesive properties of the cells 
(Kaplan, Swedlow et al. 1995). The activity of c-Src is regulated by the phosphorylation 
status of two tyrosine sites: Tyr529 and Tyr418. The carboxy-terminal Tyr529, after its 
phosphorylation (usually by c-Src kinase abbreviated as Csk), interacts with the c-Src 
SH2 domain. As a consequence of this intramolecular binding, c-Src remains in an 
inactive conformation and does not exert any tyrosine kinase activity (Yeatman 2004). 
Several tyrosine phosphatases such as PTPα and PTP1B can activate c-Src by 
dephosphorylating phospho-tyrosine 529 (Zheng, Wang et al. 1992; Bjorge, Jakymiw et 
al. 2000), thereby counteracting the activity of Csk. Conversely, dephosphorylation of the 
second regulatory site of c-Src, Tyr418, leads to inhibition of c-Src tyrosine kinase 
activity. Src mediated phosphorylation of paxillin and FAK has also been proposed to 
increase the adhesion and to inhibit the migration of cells. Moreover, r-PTPη, the rat 
homolog of DEP-1 has been shown to directly interact with and to dephosphorylate the c-
Src inhibitory tyrosine residue (Tyr529) both in vitro and in intact cells (Pera, Iuliano et al. 
2005). Our results also show a slight decrease in phosphorylation of the inhibitory 
tyrosine residue (Tyr529) associated with an increased phosphorylation at the 
autophosphorylation site (Tyr418) in the case of DEP-1 expressing cells (Fig. 3.17c). This 
finding indicates that c-Src activity may be elevated upon DEP-1 re-expression. 
However, Src activity assays directly showing c-Src activation were not performed. 
 
Focal Adhesion Kinase (FAK) is an intracellular tyrosine kinase and has been initially 
identified as a substrate of the viral Src oncoprotein. It has been found as a highly tyrosyl 
phosphorylated protein that localizes to integrin-enriched cell adhesion sites (Mitra, 
Hanson et al. 2005). FAK contains six tyrosyl phosphorylation sites. Tyr397 is the 
autophosphorylation site and has been shown to be phosphorylated in response to a 
variety of growth factors and integrin activation. All the other sites have been proposed to 
be phosphorylated by activated c-Src. The kinase domain has two phospho-tyrosines 
(Tyr576 and Tyr577) both of which are not affected due to the re-expression of DEP-1 in 
these colon cells (Fig. 3.17b). This may indicate that the kinase activity of FAK is not 
altered due to re-expression of DEP-1, although again, this has not been directly tested. 
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However, other phospho-tyrosines of FAK (Tyr407, Tyr861 and Tyr925) showed hyper-
phosphorylation in DEP-1 re-expressing cells (Fig. 3.17b). The activation of c-Src as 
demonstrated by the hyper-phosphorylation at Tyr418 may account for the site-specific 
hyper-phosphorylation of FAK. The tyrosine residue at 861 has been implicated in 
binding to p130cas (Lim, Han et al. 2004) which then binds to the adaptor protein Crk II 
resulting potentially in the activation of the small GTPase Rac (Cary, Han et al. 1998; 
Klemke, Leng et al. 1998). However, we did not observe any Rac activation in the DEP-1 
re-expressing cells and hence the role of the phosphorylation of FAK at Tyr861 in this 
context is not clear. Tyr925 of FAK is also hyper-phosphorylated in DEP-1 re-expressing 
cells. It has been shown that Tyr925 of FAK binds to GRB2 adaptor protein and feeds to 
the Ras/MAPK cascade. Subsequently, Erk phosphorylation of MLCK can modulate 
focal contact dynamics resulting in enhanced motility of the cells. Even though FAK925 
was hyper-phosphorylated, no difference in the phosphorylation status of Erk was 
observed in these DEP-1 expressing cells which may explain the hypo-migratory 
phenotype of these cells. Moreover, consistent with our findings (Fig. 3.17a and 
Fig. 3.17b), restoration of r-PTPη in thyroid cells led to enhanced tyrosyl phosphorylation 
of FAK and paxillin (Pera, Iuliano et al. 2005). 
 
Paxillin is another focal adhesion protein that mediates the signals from the extracellular 
matrix to actin cytoskeleton and is regulated by two tyrosyl phosphorylation sites (Tyr31 
andTyr118) (Turner 2000). Some groups have reported paxillin to be phosphorylated by 
active c-Src, whereas others claim that Tyr118 is a principal phosphorylation site for 
activated FAK (Bellis, Miller et al. 1995). Various studies, including knock out studies 
indicate paxillin as a positive effector of cell migration. Similar to FAK, activated 
paxillin has also been proposed to bind to the adaptor protein Crk leading to the 
recruitment of Rac GEF (Dock 180) resulting in Rac activation (Schaller and Parsons 
1995). Phosphorylated paxillin has also been shown to locally suppress RhoA activity by 
activating p190RhoGAP thereby playing a role in membrane spreading (Tsubouchi, 
Sakakura et al. 2002). All these reports implicate paxillin as a positive regulator of 
cellular migration. However, since there was no change in total Rac activation in DEP-1 
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re-expressing SW 480 cells, these well established pathways may not play any role in the 
migratory phenotype of these cells. 
 
In contrast to the above quoted reports that the activation of FAK or paxillin promotes 
cell migration, a recent study in HeLa cells showed that the siRNA mediated knock-down 
of either FAK or paxillin resulted in enhanced migration on collagen coated plates (Yano, 
Mazaki et al. 2004). In a previous study, the same authors have shown that paxillinα and 
p130cas exert opposing effects and that paxillin can act as a negative regulator of cellular 
migration (Yano, Uchida et al. 2000). Local down regulation of Rac by paxillin and FAK 
was suggested as a mechanism for the anti-migratory phenotype (Schaller 2004). Again, 
local effects on Rac cannot be excluded based on our biochemical data. In conclusion, the 
signaling pathway analysis in the DEP-1 re-expressing cells is not easily interpretable in 
the light of the current knowledge on regulation of cell migration. More data, notably on 
local signaling events are required for a better understanding. 
 
Another possibility to identify the critical steps in the anti-migratory action of DEP-1 is 
to analyse the cells with down regulated DEP-1 expression for the phosphorylation status 
of these discussed focal adhesion molecules. However, no significant differences in the 
phosphorylation status of either paxillin or FAK were observed. These results can be 
interpretated at least in two ways. One issue concerns the general morphology of the cells 
used for the re-expression (SW 480), or suppression (HT 29) studies. SW 480 cells are 
larger, spindle shaped and has a very short doubling time. On the other hand, HT 29 cells 
are much smaller in size and usually grow in clumps or islands. Hence these cells may 
employ different molecules or mechanisms for their cell matrix interactions, mediating 
adhesion and migration. One possibility to overcome this problem may be to employ 
DEP-1 suppression in CaCo2 cells, as the morphology of these cells resembles more 
closely to SW 480. A second issue can be linked to the levels of DEP-1 expression. 
During re-expression of DEP-1 in SW 480 cells, supraphysiological levels may be 
attained. As a result, DEP-1 is forced to dephosphorylate non-physiological substrates 
which may be responsible for these observed hyper-phosphorylation of paxillin and FAK. 
However, the alternative may also hold true. Since the siRNA mediated suppression was 
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not 100%, the remaining small amounts of DEP-1 may still be sufficient to perform its 
physiological role. Surely re-expression or suppression in additional cell lines will shed 
more light on the physiological targets of DEP-1 in cytoskeletal regulation. 
4.2.4. Re-expression of DEP-1 antagonizes c-Met 
HGF, popularly referred to as “scatter factor” acts by inducing phosphorylation of the 
RTK, c-Met (HGFR). In the case of starved cells, HGFR phosphorylation cannot be seen 
in both DEP-1 expressing and non-expressing cells. However after stimulation, 
phosphorylation was visible only in the case of DEP-1 non-expressing cells (Fig. 3.21). It 
should also be noted that the receptor levels (HGFR) appeared somewhat less in the case 
of DEP-1 expressing cells. After HGF stimulation, phosphorylation was not only 
indetectable for its receptor (HGFR), but also a complete blockade of downstream 
signaling events, notably the HGF-stimulated phosphorylation of Erk was observed. HGF 
is a so called “scatter factor” as the signaling by this molecule causes the cells to scatter 
or to migrate. HGF is also a potent mitogen as it has been shown to enhance proliferation 
and migration in HT 29 cells (Dignass, Lynch-Devaney et al. 1994). HGFR has also been 
shown to regulate the anti-apoptotic protein bcl-x(L) thereby inhibiting apoptosis 
(Kitamura, Kondo et al. 2000). Being an established motogen, it is no wonder that the 
HGF induced migration is believed to play an important role in the context of cancer 
metastasis. A recent study has shown that HGF inhibitors can block HGF-induced 
invasion of cancer cells (Parr and Jiang 2006). Hence antagonizing the action of this 
receptor HGFR may be very important in the context of tumor suppression. An initial 
substrate trapping approach (using the DA mutants) of DEP-1 in breast tumor cell lines 
revealed the possibility of HGFR as a substrate for DEP-1. The authors went on to show 
that DEP-1 can be immunoprecipitated with HGFR in over-expression studies using HEK 
293 cells (Palka, Park et al. 2003). Consistent with their findings, re-expression of DEP-1 
in colon cancer cells also inhibited HGFR signaling. At this point, special emphasis has 
to be laid on Erk phosphorylation. Following LPA or serum stimulation, no obvious 
difference in the phosphorylation status of Erk was observed (Fig. 3.18 and Fig. 3.20). In 
contrast, phosphorylation of Erk was completely undetectable following HGF stimulation 
(Fig. 3.21). This shows that DEP-1 can specifically antagonize the signals emanating 
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from this receptor (HGFR) which may be an important aspect of its tumor-suppressive 
activity. 
4.2.5. DEP-1 does not play a role in cellular adhesion 
Cellular migration requires a series of repetitive and integrated processes to produce 
coordinated cellular movements. It involves a constant turn-over of adhesion complexes 
in which it initiates the formation of new adhesion complexes at the cell front and has to 
dismantle them again at the cell rear. One possibility for the observed inhibition of 
cellular migration could be an enhanced adhesion of the cells to the matrix components. 
Moreover, various phosphatases such as PTPα, PTP1B, and PTP-PEST have been 
reported to alter the adhesive properties of the cell (Burridge, Sastry et al. 2006). The role 
of DEP-1 in relation to adhesion has been studied in the case of fibroblasts. Previous data 
from our group indicated that DEP-1 acts as a positive effector of cell-substrate adhesion 
(Jandt, Denner et al. 2003). In contrast, another group has shown that DEP-1 negatively 
regulates cell-substratum interactions, whereas enhancing cell-cell adhesion (Kellie, 
Craggs et al. 2004). In the case of malignant thyroid cells, the expression of DEP-1 has 
been implicated in enhanced cell-substratum adhesion (Pera, Iuliano et al. 2005) and this 
effect has been attributed to the dephosphorylation of the c-Src inhibitory tyrosine residue 
(Tyr529). Moreover, during trypsinization of the DEP-1 expressing and non-expressing 
cells for our experiments, it always appeared that the DEP-1 expressing cells had a 
tendency to attach stronger to the substratum than their non-expressing counterparts. In 
contrast, the experimental results indicated that the re-expression of DEP-1 did not affect 
cell-matrix adhesion (Fig. 3.12). To assess possible changes, we have employed two 
different methods: the first one measured the rate at which the cell attached to the 
substratum, and the second one scored the detachment rate of the cell from the 
substratum. Perhaps, in this analysed SW 480 cell line, DEP-1 may not play any role in 
cell-matrix adhesion or the assays which we performed were not sensitive enough to 
score some subtle differences. 
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4.2.6. Lessons from Knock-out mice 
There are currently two published reports on Ptprj knock out mice which have revealed 
contradictory findings. The initial report showed that knocking out Ptprj in mice resulted 
in embryonic lethality (Takahashi, Takahashi et al. 2003). These authors have replaced 
Ptprj with a mutant allele CD148ΔCyGFP, an enzymatically inactive DEP-1-GFP (Green 
Fluorescent Protein). The mutant allele also possessed the extracellular domain of Ptprj 
whereas the cytoplasmic part was replaced in-frame with a cDNA encoding the GFP. 
Mice bearing such a mutation died at mid-gestation due to vascularization failure with 
disorganized vascular structures and cardiac defects. In contrast, recently obtained viable 
Ptprj knock out mice have been created by targeting the exons 3, 4 and 5 of Ptprj, 
resulting in its complete deletion (Trapasso, Drusco et al. 2006). Analyses of these mice 
have revealed that Ptprj is dispensable for growth and development. Moreover, Ptprj 
gene inactivation did not predispose the mice to spontaneous tumorigenesis. One 
possibility for the controversial findings could be that, in the initial knock out mice, the 
extracellular domain of Ptprj is still present and only the cytoplasmic domain is replaced 
by GFP. This suggests that the extracellular domain of Ptprj might act as a functional 
ligand able to block a pathway responsible for the correct assembly of endothelial cells in 
the generation of normal vessels resulting in the lethal phenotype. 
 
Given the existing body of evidence suggesting a tumor suppressive role of DEP-1 in 
different cancers including our own results, it is quite surprising that no spontaneous 
tumorigenesis was detectable in the Ptprj-/- mice. Since most of these previous data were 
obtained in established carcinoma cells (likely to have more than one genetic lesion) the 
effect of DEP-1 may depend on the status of other genes. It is possible that Ptprj loss co-
operates with additional genetic lesions in cancerogenesis. One possibility to test this 
hypothesis is by crossing these viable KO mice with other genetically modified tumor 
prone mice. This approach has recently uncovered a tumor-suppressive capacity of PTP 
1B (Dube, Bourdeau et al. 2005). 
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4.3. Upregulation of DEP-1 by protective nutrients 
4.3.1. Apple polyphenols upregulate DEP-1 and induce apoptosis 
Normal epithelial cells in the colon are constantly exposed to dietary components and 
their fermentation products. The incidence of colon cancer has often been correlated with 
the lifestyle and particularly to food intake. Intake of refined grain, red meat, processed 
meat and alcohol has been correlated with increased risk of colorectal cancer incidence. 
On the other hand, consumption of whole grain, raw and cooked vegetables, citrus and 
other fruits, green tea and red wine has been shown to reduce the risk of cancer incidence 
(Levi, Pasche et al. 1999). However, the underlying mechanisms are only partially 
characterized. Apples are a widely consumed, rich source of phytochemicals and 
epidemiological studies have linked the consumption of apples with the reduced risk of 
some cancers, cardiovascular disease, asthma and diabetes (Aprikian, Busserolles et al. 
2002; Liu and Sun 2003). Apples have been found to have very strong antioxidant 
activity, inhibiting cancer cell proliferation, decreasing lipid oxidation and lowering 
cholesterol levels (Boyer and Liu 2004). Many of the beneficial effects of apple intake 
are believed to be caused by apple polyphenols, including quercetin, catechin, phloridzin 
and chlorogenic acid, all of which are strong antioxidants (Lu and Foo 1997). In cell 
culture studies, these flavonoids have been implicated in a range of processes including 
inhibition of cancer cell proliferation, induction of apoptosis, prevention of oxidative 
DNA damage and induction of carcinogen detoxifying enzymes. Furthermore, three 
independent groups have shown that apple intake by rats has a strong antiproliferative 
effect on carcinogen-induced lesions in the colon epithelium (Barth, Fahndrich et al. 
2005; Gosse, Guyot et al. 2005; Graziani, D'Argenio et al. 2005). Using cDNA 
microarrays, a recent study has shown that an apple polyphenol extract induces several 
genes involved in drug metabolism thereby modulating the toxicological defense of 
various carcinogens against colon cancer cells (Veeriah, Kautenburger et al. 2006). In 
accordance with the upregulation of several beneficial genes by the apple polyphenol 
extract, the expression of DEP-1 is also upregulated upon treatment, at least in the tested 
adenoma cell line LT 97 (Fig. 3.28a). Our findings are consistent with the data obtained 
in a custom-designed expression array (Veeriah et al., unpublished data). While two 
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tested carcinoma cell lines failed to reveal any upregulation of DEP-1 expression, the 
adenoma cell line even exhibited a dose-dependent upregulation of DEP-1 with apple 
polyphenol extract (Fig. 3.28b). We further investigated whether this upregulation of 
DEP-1 can also be seen in vivo. In a study to assess the chemopreventive properties of 
apple juice, rats were fed either with the apple juice or water as the control. One group of 
rats was also injected with the carcinogen DMH, whereas the control group received only 
sodium chloride (see Methods and Results for more details). Analysis of the RNA 
samples from apple juice drinking animals revealed only a slight trend but failed to show 
any significant upregulation (Fig. 3.30). This result could have been caused by different 
reasons. Either DEP-1 may not be significantly upregulated under in vivo conditions. 
Alternatively, and more likely, the negative result might be attributed to the sample 
preparation. In the rats, only the luminal parts of colon epithelial cells are exposed to the 
apple juice. DEP-1 regulation may occur only in certain components, such as epithelium 
in the crypts. RNA had been obtained by scraping off the mucosa for the analysis. This 
preparation may very well contain underlying cells or tissues that were not exposed to the 
apple juices, thereby changes in expression may have remained undetected. A solution to 
this problem could be the microdissection of tissue before expression analysis. 
 
Dietary flavonoids and polyphenols have been shown not only to inhibit proliferation of 
cancer cells (cytostatic effect) but also to promote apoptosis in colon cancer cells 
(Wenzel, Kuntz et al. 2000). Hence, we wondered whether the complex apple polyphenol 
extract could do so. In accordance with the published literature, we can clearly show that 
the flavonoids present in the apple extract can also induce apoptosis in a dose- and time-
dependent manner as depicted by the PARP cleavage (Fig. 3.31). Thus, from our studies 
it could be suggested that the apple polyphenols exert their beneficial effects not only by 
upregulating the tumor suppressor DEP-1, but also by inducing apoptosis. 
4.3.2. Upregulation of DEP-1 by butyrate and green tea components 
The beneficial effects of short chain fatty acids are also well established, in particular for 
butyrate. Butyrate is a non-specific inhibitor of histone deacetylases, thereby regulating 
transcription (Hassig, Tong et al. 1997). Butyrate is known for its anti-proliferative 
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activity on colon cancer cells in which it also induces apoptosis, whereas it acts as a 
survival factor and a nutrient in non-transformed cells as well (Pool-Zobel, Selvaraju et 
al. 2005). Butyrate has earlier been shown to enhance DEP-1 expression and to induce 
differentiation in mammary carcinoma cell lines such as ZR75 and SKBr-3 (Keane, 
Lowrey et al. 1996). Consistent with the effect on mammary carcinoma lines, butyrate 
also upregulated DEP-1 expression in all the colon cancer cells tested, albeit to a different 
extent (Fig. 3.28a). Thus, in addition to apple polyphenols, butyrate as a fermentation 
product may also mediate an anti-proliferative effect by elevated DEP-1. 
 
Epigallocatechine-3-gallate (EGCG), a major component of green tea, and related 
constituents have various anticancer effects, including a marked antioxidant potential 
(Ames, Gold et al. 1995), induction of apoptosis (Weinreb, Mandel et al. 2003) and 
likewise inhibition of proliferation of human colon cancer cells (Shimizu, Deguchi et al. 
2005). Similar to butyrate, treatment with green tea resulted again in upregulation of 
DEP-1 expression in all the cell lines analysed. Thus, green tea may also exert a 
protective role with respect to colon carcinogenesis by upregulating DEP-1 expression.  
 
The induction of DEP-1 by the various dietary components cannot be attributed to 
increases in cell density, as all components either inhibited cell growth (butyrate and 
apple polyphenols) or had little influence on cell proliferation (green tea). We were also 
interested in understanding whether the upregulation of DEP-1 expression is either 
transcriptional or related to altered protein stability. Analysis of the mRNA from the 
adenoma cell line LT 97 treated with all three tested nutrient components revealed an 
upregulation of DEP-1 mRNA to a similar extent as observed at the protein level. This 
finding suggests that transcriptional regulation is, at least in part, the underlying 
mechanism of DEP-1 induction and is in line with current concepts of protective nutrient 
activity. Transcriptional regulation of the detoxifying enzymes such as Glutathione-S-
Transferases (GSTs) by various dietary components is well established. It often involves 
an antioxidant-responsive response element (ARE) in the promoter of affected genes and 
the transcription factor nuclear factor E2-related factor 2 (Nrf2), which is bound to the 
Kelch-like ECH associated protein 1 (Keap1) in the cytoplasm. Antioxidants may disrupt 
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the Keap–Nrf2 complex, allowing Nrf2 to translocate to the nucleus and mediate 
expression of several GSTs via interaction with the ARE (Pool-Zobel, Veeriah et al. 
2005). Similar transcriptional mechanisms may also hold true for DEP-1 upregulation. 
DEP-1 induction by nutrients may additionally also involve effects at the protein level, 
such as on protein stability. Induction of DEP-1 is, however, not the only mechanism of 
growth inhibition by butyrate or apple polyphenols, as shRNA-mediated depletion of 
DEP-1 did not render HT 29 cells refractory to growth inhibition by these agents. To our 
knowledge, this is the first report where the effects of protective nutrients are attributed to 
the upregulation of a tumor suppressor. This suggests an upregulation of DEP-1 as a 
previously unrecognized aspect of chemoprevention by dietary compounds. 
  Conclusion and Outlook 
5. Conclusion and Outlook 
5.1. Conclusion 
In conclusion, our data support that DEP-1 may be a tumor suppressor protein in 
colon cancer:  
a) The expression of DEP-1 is partially or completely reduced in colon cancer cell 
lines 
b) Its re-expression hinders cell proliferation and furthers cell death. 
c) DEP-1 inhibits cell migration and causes hyper-phosphorylation of paxillin and 
FAK. 
d) DEP-1 impairs activation of the Erk pathway upon stimulation with HGF. 
e) DEP-1 is also upregulated upon treatment with various protective nutrients and 
thus may form one of the missing links between nutrients and cancer prevention. 
 
Based on our data, we propose the following model for the mode of action of DEP-1. 
(Fig. 5.1). The transmembrane phosphatase DEP-1 can antagonize RTKs by directly 
dephosphorylating them, thereby modulating proliferation and apoptosis. DEP-1, by 
activating c-Src, causes hyper-phosphorylation of paxillin and FAK. Together with 
activating the small GTPase Rho, it induces severe cytoskeletal changes leading to 
inhibition of migration. 
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Fig. 5.1 Proposed model for the tumor suppressive action of DEP-1 in colon epithelial cells 
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5.2. Outlook 
Even though our work has shed some light on the role of DEP-1 in colon epithelial cells, 
it also opens the door for a number of questions. 
¾ Identification of DEP-1 substrates acting upstream of Akt. 
¾ Completing the signaling chains responsible for the anti-migratory phenotype of 
DEP-1: Assay of Src and FAK tyrosine kinase activity, local changes of the small 
GTPases Rac and Rho. 
¾ Follow up on the role of DEP-1 on HGF stimulated Erk downregulation. 
¾ In vivo studies in nude mice: Transplantation of inducible DEP-1 expressing 
SW 480 cells into nude mice and assessing the transformation potential in vivo. 
¾ Refinement of expression analysis in colon epithelial cells (microdissection) 
¾ Identification of relevant polyphenols for DEP-1 upregulation. 
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6.2 Abbreviations 
aa Aminoacids 
ACF Aberrant Crypt Foci 
APC Adenomatous Polyposis Coli 
AE Apple polyphenol Extract 
AJ Apple juice 
aPK Atypical protein kinase 
Asp Aspartate 
Atc Anhydrotetracycline 
But Butyrate 
Cdk Cyclin Dependent Kinase 
COX Cyclo-oxygenase 
CS (C1239S) Cysteine – Serine mutant 
Cy 2 Cyanine 
Cy 3 Indocarbocyanine 
Cys Cysteine 
DA Aspartate – Alanine mutant 
DAPI 4',6-Diamidino-2-phenylindole 
DEP-1 Density Enhanced Phosphatase-1 
DMH 1,2 - dimethyl hydrazine 
DTAF Dichlorotriazinylaminofluorescein 
ECM Extracellular matrix 
EGCG Epigallocatechin-3-gallate 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
Erk Extracellular regulated kinase 
ePK Eukaryotic protein kinase 
FAK Focal Adhesion Kinase 
FBS Fetal Bovine Serum 
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Fig. Figure 
FITC Fluorescein Isothiocyanate 
GAB2 Grb2 Associated Protein 
GAP GTPase Activating Protein 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GDP Guanosinediphosphate 
GEF Guanine nucleotide Exchange Factor 
Grb2 Growth Factor Receptor bound 2 
GSH Glutathione Sepharose 
GST Glutathione-S-Transferase 
GT Green Tea 
GTP Guanosine-triphosphate 
h Hours 
HGF Hepatocyte Growth Factor 
HGFR Hepatocyte Growth Factor Receptor 
HIF-1α Hypoxia Inducible Factor 1 alpha 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HRP Horse radish peroxidase 
IGF-1R Insulin-like Growth Factor -1- Receptor 
IP Immunoprecipitation 
IR Insulin Receptor 
JAK Janus Kinase 
kDa Kilodalton 
KO Knock out 
LB Lysis buffer 
LM PTP Low Molecular Weight Protein Tyrosine Phosphatase 
LOH Loss of Heterozygosity 
LPA Lysophosphatidic acid 
MACS Magnetic Assisted Cell Sorter 
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Met Methionine 
min Minutes 
MAPK Mitogen Activated Protein Kinase 
MEK MAP / Erk kinase 
MKP Map Kinase Phosphatase 
MLCK Myosin Light Chain Kinase 
MMP Matrix Metalloproteinase 
NFkB Nuclear Factor of kappa B Cells 
NRPTP Non-receptor Protein-Tyrosine Phosphatase 
nt Non-targeting control 
PAE Porcine Aortic Endothelial Cells 
PAGE Polyacrylamide gel electrophoresis 
PARP Poly ADP-ribose polymerase 
PDGFR Platelet Derived Growth Factor Receptor 
Ph eq Phloridzin equivalents 
PI3K Phosphoinositide 3 kinase 
PLC Phospholipase C 
PTK Protein tyrosine kinase 
PTP Protein Tyrosine Phosphatase 
PTP 1B Protein Tyrosine Phosphatase 1B 
pTyr Phospho-tyrosine 
Raf Ras Activated Factor 
Ras Rat Sarcoma 
RASGAP Ras GTPase Activating Protein 
ROS Reactive Oxygen Species 
RPTP Receptor like Protein-Tyrosine Phosphatase 
RT Room temperature 
RT-PCR Reverse Transcriptase - Polymerase Chain Reaction 
RTK Receptor Tyrosine Kinase 
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s suppressed 
S1P Sphingosine-1-phosphate 
Scc Susceptibility to Colon Cancer 
SCFA Short chain fatty acids 
SDF 1α Stromal Cell Derived Factor 1 alpha 
sec seconds 
Ser Serine 
SFKs Src Family Kinases 
siRNA Short interfering RNA 
SH Src homology 
shRNA Short hairpin RNA 
SOS Son of Sevenless 
STAT Signal Transducers and Activators of Transcription 
STS Staurosporine 
TCR T cell receptor 
Thr Threonine 
TRITC Tetramethyl Rhodamine Isothiocyanate 
tTA Tetracycline-repressed Transactivator 
Tyr Tyrosine 
VEGF Vascular Endothelial Growth Factor 
WT Wild type 
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6.3. Plasmid Maps and Vector Constructs 
Map of the inducible pNRTIS 21 vector 
pNRTIS 21
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EcoRI
EcoRV
NotI
PspXI
ApaI
BstBI
Bst1107I
SspI
AatII
ZraI
pCMV tet op
IRES
tTA
BGA poly A
f1 ori
pSV40-oriNeo
SV 40 poly A
Col E1
Amp
 
 
Maps of pNRTIS 21 vector harboring the DEP-1 WT and CS variants 
 
pNRTIS21_WT
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BstBI
Bst1107I
SspI
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BGA poly A
f1 ori
pSV40-ori
Neo
SV 40 poly A
Col E1
Amp
pNRTIS21_CS
11087 bps
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4000
6000
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NotI
ApaI
Bsu36I
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XcmI
AatII
ZraI
SanDI
BsrGI
SspI
BstEII
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AccIII
BstBI
EcoRI
EcoRV
NotI
PspXI
ApaI
BstBI
Bst1107I
SspI
AatII
ZraI
pCMV tet op
Dep-1 CS
IREStTA
BGA poly A
f1 ori
pSV40-ori
Neo
SV 40 poly A
Col E1
Amp
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Map of pSUPER-retro-puro vector 
 
pSUPER-retro-puro
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Map of pSUPER-retro-puro vector containing the 64 nt shRNA construct 
(construct 441) 
pSuper-retro-puro-DEP1-441
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6.4. RTK Array 
List of anti-RTK antibodies spotted on the membrane 
 
Transparency overlay used to the identify the corresponding RTK 
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